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 The development of vaccines against infectious diseases has been highly successful.  
However, while effective vaccines have been licensed against many diseases such as smallpox, 
polio, measles, rubella, mumps, varicella, diphtheria, tetanus and pertussis, there are still a 
number of infectious diseases that continue to wreak havoc on public health.  Many attempts have 
been made to create vaccines against intractable pathogens, such as HIV, malaria, and influenza 
A virus (IAV), but the construction of vaccines that induce broadly protective immunity against 
these diseases has proven difficult.  This necessitates further research into conserved epitopes and 
new vaccine approaches. 
 In this study, I investigate the role of a highly conserved epitope of influenza A virus, the 
M2 extracellular domain (M2e), in the viral life cycle; this region has become a major molecular 
target for universal IAV vaccines.  Using in vitro transcomplementation assays with cell lines 
stably expressing M2e mutants, we determined that this region of the M2 protein is tolerable of 
mutations since directed alanine mutagenesis nor deletion of several amino acids attenuated IAV 
replication.  This suggests that this portion of M2e is not required for function and that alternative 
reasons exist for the high conservation.   
 In addition, the use of viral vectors for vaccines was investigated.  Adenovirus (Ad) is a 
highly immunogenic viral vector.  Recombinant Ads that display either the M2e or conserved 
HA2 alpha helix (HA2A) of IAV in hexon hypervariable regions were examined as potential 
universal influenza A vaccines. While these recombinant Ads were successfully created, they 
were not immunogenic in mice.  Induction of effective immune responses by conventional 
vaccination methods is uncertain, especially for pathogens such as malaria and HIV.  As an 
alternative to relying on an individuals’ immune system to mount a protective response,  adeno-
associated virus (AAV) was used to express previously characterized human broadly neutralizing 
monoclonal antibodies to the Plasmodium falciparum circumsporozoite protein (CSP) as a 
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transgene.  This ‘vectored immunoprophylaxis’ (VIP) approach allowed for rapid and high 
sustained expression of monoclonal antibodies to CSP that were capable of protecting mice from 
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Each year, epidemics of influenza caused by either influenza A (IAV) or B viruses 
circulate through the human population causing significant morbidity and mortality, responsible 
for 3-5 million clinical infections and 250,000 – 500,000 deaths [1, 2].  More than 90% of 
influenza associated deaths occur among adults 65 or older [3].  In the United States, an estimated 
6-20% of the population is infected with influenza each year [4].  The number of deaths that 
occur each year due to this respiratory virus varies considerably depending upon circulating 
strains and vaccine efficacy [3]. Currently, H1N1 and H3N2 of IAV and both strains of influenza 
B viruses are responsible for seasonal outbreaks.   
Seasonal outbreaks in most parts of the world coincide with colder weather.  This is in 
part correlated to an increase in individuals crowding indoors during cold seasons, as the virus 
can be spread by aerosolized droplets from coughing or sneezing, along with the decrease in 
temperature and humidity that allows the virus to survive in the environment for longer periods of 
time [5].  Most seasonal outbreaks are due to antigenic drift of influenza viruses, a process where 
amino acid changes are selected for that enable the virus to escape neutralizing antibodies [6].  
However, periodically, antigenic shift occurs, where gene reassortment involving human, swine 
and/or avian influenza viruses yield in an antigenically distinct virus, usually resulting in the 
introduction of a new hemagglutinin (HA or H) gene into the population [6].  This process 
resulted in the 2009 H1N1 pandemic, where a triple reassortment of avian, swine and human 
viruses created a novel strain of influenza that led to a significant increase in morbidity and 
mortality.   
The recurrences of highly pathogenic strains of influenza have been spread throughout 
history.  A novel zoonotic influenza virus strain emerged with a genotype that resulted from 
genetic reassortment and multiple point mutations in 1918 [7-9].  This resulted in a highly 
transmissible and virulent virus that led to the “Spanish” flu outbreak.  It infected one-third of the 
population worldwide in a year and exhibited a case fatality rate of approximately 10%, killing 40 
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million people [8, 10], marking the deadliest influenza pandemic to date.  In addition to the 
severe death toll, the 1918 H1N1 virus was unique in exacting the greatest toll on young healthy 
adults rather than infants and the elderly, in contrast to seasonal epidemics.  While there are many 
possible explanations as to this age distribution, one suggests that those over 65 could have 
acquired cross-reactive influenza-specific antibodies prior to the 1918 pandemic, leaving those 
between age 15 and 45 more susceptible [9].   
Novel serotypes of influenza continue to arise due to genetic reassortment with existing 
human strains.  In 1957, reassortment between the 1918 H1N1 and an avian strain yielded a novel 
H2N2 [10].  The acquisition of a novel HA and neuraminidase (NA or N) in a naïve population 
led to 40% of people becoming infected with approximately 50% of infections leading to severe 
disease as a result of secondary bacterial pneumonia [11].  Subsequently, in 1968, another 
reassortment occurred between human and avian viruses resulting in an H3N2 strain.  The novel 
H3 allowed for the virus to be effectively transmitted within a population however, preexisting 
immunity to the H3 likely limited morbidity and mortality [10, 12].  H1N1 strains were 
reintroduced into the population in 1977 without causing a major pandemic due to immunity that 
was already developed against both HA and NA [10].  Direct bird to human transmission resulted 
in emergence of another novel influenza strain, an H5N1, in Hong Kong in 1997 [13].  While it 
has a 50% mortality rate, it exhibits poor direct human to human transmission and did not result 
in a pandemic [14].  Currently, most H5N1 infections have been due to direct contact with 
infected domestic poultry.   The first 21st century pandemic emerged in 2009 as a novel H1N1 that 
was a product of a recombination event with swine, avian and human viruses [15].  While H1N1 
viruses have been circulating in the population for decades, the antigenic properties of this strain 
was sufficiently unique that most individuals lacked effective preexisting immunity and were 
susceptible to infection [16, 17].  More recently, an H7N9 avian flu has emerged in southern 
China, infecting approximately 140 people and killing 45.  However, the virus has not achieved 
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effective human to human transmission as 70% of cases have resulted from direct contact with 
infected poultry [18]. 
Pandemic viruses are rare but seasonal epidemics occur yearly.  While an influenza 
vaccine is licensed and updated yearly, it is only effective against homologous strains of 
influenza and provides very little cross-protection from antigenic drift viruses.  This not only 
results in morbidity and mortality but also has a significant economical impact.  It was estimated 
that $87.1 billion are lost annually due to the lack of productivity and medical costs associated 
with influenza illness [4].  Government and private institutions spend a significant amount of 
money on surveillance, basic research and public health education, in addition to the $2-4 billion 
that is spent annually on vaccine production [19].  Thus, while there is a licensed influenza 
vaccine, it does not offer sufficient protection for highly susceptible populations or to the general 
population during years of significant antigenic diversity [20, 21], to prevent the high economic 
cost and public health burden that accrues during seasonal influenza.  An effective cross-
protective vaccine would reduce morbidity, mortality and influenza-associated economic costs.  It 
is particularly important to have a vaccine that offers effective protection to young infants and the 
elderly who are the most susceptible populations to influenza infection and subsequent 
complications [22, 23].  This necessitates more in-depth investigations into basic influenza 
virology, the immune response and host correlates of protection to rationally design a ‘universal’ 
vaccine, capable of inducing effective cross-protective immune responses. 
Influenza virology 
To develop an effective vaccine that is capable of inducing a robust humoral and cellular 
immune response against all influenza virus subtypes, a basic understanding of influenza virology 
is imperative.  Influenza virus is an RNA virus belonging to the Orthomyxoviridae family.  It has 
an 8 segment negative sense RNA genome [24] that is packaged into a primarily spherical lipid-
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envelope (Figure 1A), although elongated filamentous particles are found in influenza strains 
isolated from humans [25-27].  Five genome segments encode for a single viral protein, while 
segments encoding PB1, NA and M have more than one open reading frame leading to multiple 
mRNAs produced by splicing or frame shift [28-30].  Eleven viral proteins have been identified 
thus far in IAV although not all strains produce the PB1-F2 protein [30].   
In humans, influenza is transmitted primarily through aerosolized respiratory droplets 
[31] and infection starts when the HA on the virion surface binds to its receptor, a cell surface 
sialic acid (SA) [32].  Avian influenza viruses preferentially bind SA that is linked to galactose 
via a α2,3 linkage (α2,3 SA) which can be found in the gut whereas human strains bind 
preferentially to α2,6 linked SA (α2,6 SA) found in the respiratory tract [33].  However, influenza 
viruses that infect swine have more diverse receptor specificity by being able to bind either α2,3 
or α2,6 SA [33-35].  The ability to bind different sialyloligosaccharides is important for cross-
species transmission of the virus as viruses with this property are able to infect many different 
hosts and cause more systemic infections [35, 36]. 
Upon receptor binding, influenza is internalized by clathrin-mediated endocytosis [37] 
and acidification of the late endosome triggers conformational changes in HA that produces a 
fusogenic peptide [38]; this results in fusion of the viral membrane with the endosomal membrane 
[39].  Concurrently, the integral ion channel protein, M2, pumps H+ ions into the virion interior 
[40-42].  The acidification of the interior of the virus prompts M1 dissociation from viral 
ribonucleoproteins (RNP).  These RNPs consist of the viral RNA segments, the viral RNA-
dependent RNA polymerase (RdRp) comprised of PB1, PB2 and PA, and the nucleoprotein (NP) 
[43, 44].  Dissociation from M1 allows for the RNPs to be imported into the nucleus via host 
importin complexes and a nuclear localization signal (NLS) located in the NP protein [43, 45].  
Influenza is one of the few RNA-containing viruses that replicate within the nucleus due to the 
requirement for host splicing machinery, 5’ 7-methylguanosine caps from host pre-mRNAs and 
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potentially, to sequester RNA away from pathogen recognition receptors (PRR) that can activate 
the immune response [46].   
Once inside the nucleus, PA, PB1 and PB2 form the RdRp.  While the PB1 protein 
contains the catalytic subunit of the RNA polymerase, allowing for the addition of nucleotides 
during RNA chain elongation [47], it also has endonuclease activity necessary for generation of a 
capped primer.  Replication is initiated upon PB1-mediated cap snatching of 5’ caps from cellular 
mRNA which acts as a primer for viral mRNA synthesis [46].  A polyadenosine tail is added to 
the 3’ end of the genome due to RdRp stuttering and is important for nuclear export, translation 
and mRNA stability.  Positive-sense RNA serves as a template to synthesize negative-sense RNA 
which will be exported from the nucleus upon association with M1 and the viral nuclear export 
protein (NEP/NS2) [46].  These negative-sense RNAs will eventually be incorporated into new 
virions to continue the viral life cycle.  
Inside the nucleus, the M, PB1 and NA mRNA segments are subject to cellular splicing 
by the splice factor SF2/ASF [48].  Splicing is tightly regulated as protein needs to be produced 
from both unspliced and spliced mRNA.  Many control mechanisms for differential splicing exist 
including the rate of nuclear export and access to the splice site.  For example, both M1 and M2 
are synthesized from the M genomic RNA segment by differential splicing.  The three spliced 
mRNA transcripts encoded by the M segment share the same 3’ splice site but have alternative 5’ 
splice sites.  At early times during infection, the strong 5’ splice site on the M segment is used, 
resulting in M3-mRNA [49].  Once a sufficient amount of the RdRp complex has been 
synthesized, the polymerase proteins bind to the 5’ terminal M1-specific sequences in mRNAs, 
blocking access to the 5’ M3-mRNA splice site; this allows for unspliced M1-mRNA to be 
synthesized [50].  As the polymerase complex moves down the mRNA, it blocks the 5’ M1-
mRNA splice site, allowing for the cellular splicing machinery to switch to the weaker 5’ M2-
splice site to create M2-mRNA. However, the splice site for M2 is suboptimal and its recognition 
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depends upon the SF2/ASF splice factor binding to a splice enhancer at the 3’ end of the mRNA 
[48, 50].  This demonstrates the complexity of the viral and cellular interactions necessary for 
influenza virus replication. 
Following splicing, mRNA’s are transported to the cytoplasm where viral membrane 
proteins, HA, NA and M2, are translated by ribosomes bound to the endoplasmic reticulum (ER) 
[46].  These proteins then enter the secretory pathway where, inside the ER, both HA and NA are 
glycosylated, HA is assembled into a trimer and NA and M2 form tetramers.  Cysteine residues 
on HA and M2 are palmitoylated in the cis-Golgi network [51] and M2 uses its ion channel 
activity in the trans-Golgi to stabilize the HA protein and prevent conformational rearrangement 
[52].  From the secretory pathway, HA, NA and M2 are targeted to the host cell membrane.  Both 
HA and NA have signal sequences in their transmembrane domain that target them to lipid rafts 
that are rich in sphingolipids and cholesterol [46].  Most of M2 is selectively excluded from lipid 
rafts and a sorting signal for M2 has not been characterized.  It is suggested that M2 might bind to 
cholesterol which would target it to the periphery of lipid rafts [53, 54].   
Relatively little is known about how viral proteins other than HA and NA are 
incorporated into virions.  Virus budding has been shown to preferentially occur at lipid rafts 
where HA and NA are localized [55, 56].  M1 has been postulated to be recruited into the virion 
by crosslinking the cytoplasmic tails of HA and NA [57, 58].  Experimental evidence 
demonstrates that the cytoplasmic tail of M2 helps to incorporate RNPs [59], either by direct 
binding to NP or through interactions with M1 although the exact packaging mechanism of RNPs 
is also poorly understood.  A fully infectious influenza virion requires a full complement of RNA 
segments and multiple pieces of evidence have demonstrated that the virus selectively packages 
eight different vRNPs into virus particles.  The cytoplasmic tail of M2 has been shown to be 
required for efficient vRNP incorporation of infectious virus particles [60-62].  It is also still 
unknown how M2 is incorporated into the virion since it is excluded from sites of viral budding 
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[56]. Currently it is speculated that binding to M1 [60] may recruit M2 to the periphery of lipid 
rafts where it would be able to bind cholesterol [53, 63, 64] and become incorporated into the 
virion. 
The initiation of budding requires an outward curvature of the plasma membrane and 
experimental evidence suggest that this process is started with HA and NA [65].  These 
glycoproteins are targeted to lipid raft domains and then recruit M1, NP and RNPs [56].  M2 is 
recruited to the site of budding by M1 [64].  In addition to the positive membrane curvature 
asserted by HA, NA and M1 [65, 66], M2 exerts more positive membrane curvature on the neck 
of the budding virion by inserting its amphipathic helix into the membrane,  thus mediating 
membrane scission and release [53].  This hypothesis has not been fully proven. 
The final step in the influenza life cycle is the release of the virion from the site of 
budding.  Influenza virus has to be actively released from the host cell because HA is able to 
anchor the virus to the cell by binding to its sialic acid receptor [46].  Here, the enzymatic activity 
of NA is required to remove the sialic acid from the host cell membrane thus releasing the virus 
[67, 68].  It also cleaves the sialic acid off viral glycoproteins to prevent virus aggregation.  The 
influenza virus is not fully infectious until the immature HA0 that is present on the viral surface is 
cleaved by host proteases into HA1/HA2 [69, 70].  This exposes the binding site on the head of 
HA1 that recognizes SA.  The ability of multiple different types of proteases to cleave HA0 is 
dependent upon the composition of the proteolytic site and determines the pathogenicity of the 
virus [71].  Influenza A viruses with a multibasic cleavage site containing several lysines and/or 
arginines, are more virulent and induce more systemic infections as many different proteases are 
capable of cleaving HA0.  Viruses with a monobasic HA cleavage site are only capable of 





Innate immune response 
Replication of influenza virus does not go unnoticed in the host. After bypassing physical 
barriers to infiltrate the respiratory tract, influenza virus infection is sensed by infected cells, 
usually respiratory epithelial cells, via PRR that include toll like receptors (TLR), retinoic acid 
inducible gene-1 (RIG-I) and the NOD-like receptor family pyrin domain containing 3 (NLRP3) 
[72].  These all recognize different forms of viral RNA.  TLR7 binds single-stranded viral RNA 
whereas TLR3 and RIG-I recognize double-stranded viral RNA [73-75].  Recognition by these 
receptors leads to the production of proinflammatory cytokines and type I interferons (IFNs).  
IFNs have a strong antiviral activity by inhibiting protein synthesis in host cells and limiting virus 
replication.  IFN-β is produced first by signaling through the PRRs and, via a positive feedback 
loop, leads to the expression of IFN-α and more IFN-β [76].  These type I IFNs also induce 
interferon stimulating genes (ISG), such as the myxovirus (MX) gene which encodes the antiviral 
MxA protein, through the JAK/STAT signaling pathway [77, 78] and have been shown to 
stimulate dendritic cells (DCs), a professional antigen-presenting cell (APC), to enhance 
presentation of antigen on CD4+ and CD8+ cells through major histocompatibility complex II 
(MHCII) and MHCI, respectively.  During this process, NLRP3, a component of the 
inflammasome, a cytoplasmic complex associated with immunity to influenza virus, is activated 
by the influenza M2 ion channel activity [79].  This component induces the induction of Th17 
cells and expansion of CD4+ T cells.   
Once the virus reaches the alveoli, alveolar macrophages are activated.  This subset of 
highly effective APC phagocytoses influenza-infected cells [80, 81].  However, while the 
activation of alveolar macrophages do limit viral spread, they produce nitiric oxide synthase 2 
(NOS2) and tumor necrosis factor alpha (TNF-α) which causes immune mediated pathology [82, 
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83]. This highlights the delicate balance that is required of the immune response.  Highly 
pathogenic avian influenza (HPAI) viruses are lethal because they are able to infect blood-derived 
macrophages, leading to the production of large quantities of pro-inflammatory cytokines which 
causes immunopathology [84].    
Natural killer (NK) cells are also an important arm of the innate immune response as they 
are able to recognize infected cells through their cytotoxicity receptor NKp44 and NKp46 which, 
upon binding, will trigger NK cells to lyse the infected cells [85].  A subset of NK cell called 
invariant NKT cells are thought to stimulate the induction of cellular immunity and regulate 
infection induced pathology [86].  
DCs are a major component of the host innate immune system and are situated close to 
the airway epithelium and basal membrane in order to monitor the airway lumen for infection via 
their dendrites.  Upon detection of virus, DCs phagocytize opsonized virions and apoptotic bodies 
released from infected cells.  While these cells can become infected by influenza virus, it does not 
result in viral replication or immune-mediated pathology but instead, the DC migrates to the 
draining lymph node via the lymphatic system and presents influenza viral antigens to CD4+ or 
CD8+ T cells to initiate the adaptive immune response [87].   
While the immune response is capable of sensing influenza virus infection, the virus itself 
expresses proteins that can inhibit the induction of the innate immune response.  In particular, the 
pathways that stimulate type I IFN production are targeted by the NS1 protein which interferes 
with PRR that detect viral RNA [88].  This IFN antagonist also inhibits post-transcriptional 
production of IFN by interfering with mRNA processing factors and export machinery [89-91].  
Finally, NS1 has also been shown to disrupt IFN stimulated genes [88, 92].  These functions of 
NS1 demonstrate how the virus has evolved to evade immune detection and ultimately contribute 
to the pathogenicity of influenza. 
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Adaptive immune response 
The innate immune response is responsible for controlling and containing the viral 
infection until the adaptive immune response can be activated.  This second line of defense 
consists of two main aspects: cellular immunity mediated by T cells and humoral immunity 
through the action of virus-specific antibodies.   
Upon infection with influenza virus, APCs such as DCs, phagocytose or endocytose 
exogenous antigen which is then processed into peptides to be presented on MHCI for cytotoxic 
CD8+ T cells or on MHCII for CD4+ T helper cells (Th).  Importantly, CD4+ Th cells initially 
are considered Th0 cells and can be further developed to promote specific responses: Th1 or Th2 
[93].  Th1 cells stimulate production of IgG2A antibody and are mainly involved in cellular 
immune responses and promoting the proliferation of CD8+ cytotoxic T cells whereas Th2 cells 
stimulate production of IgG1, IgA and IgE antibody production, thus promoting B cell responses 
[94].  In addition to the multiple types of CD4+ T cells, there are regulator T cells (Treg) and 
Th17 cells.  Generally, Treg cells are associated with anti-inflammatory responses while Th17 
induce proinflammatory responses.   It is through the use of these cells, and others that the 
immune response attempts to create a balance of proinflammatory and anti-inflammatory 
responses to kill the invading pathogen but also prevent immune-mediated pathology. 
CD8+ T cells are an important aspect of the cell mediated immune response.  Upon 
recognition of antigenic peptide presented on MHCI, IFN-γ is released which has antiviral 
activity and activates macrophages.  In addition to the release of a potent type II IFN, CD8+ T 
cells have lytic activity mediated by the release of perforin and granzymes A (GrA) and GrB and 
can also kill virally infected cells directly through Fas/FasL interactions, leading to the activation 
of caspases and apoptosis.   
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The other arm of the adaptive immune response is humoral immunity, characterized by 
antibody produced by B cells.  While T cells recognize linear epitopes, B cells recognize antigen 
in its native form.  The principal function of B cells is to make antibodies that are membrane 
bound or secreted.  Antibodies specific for influenza antigens are then used to identify and 
neutralize influenza virions or influenza infected cells.  Most antibody-mediated protection is due 
to secretory IgA (sIgA) and IgG [95].  SIgA is able to be transported across mucosal epithelium 
of the upper respiratory tract and are the first antibody barrier to influenza viruses.  Serum IgA is 
produced rapidly after influenza virus infection and the presence of these antibodies is indicative 
of a recent influenza infection [96, 97].  IgG is able to transude from serum into the respiratory 
tract by diffusion and has been shown to be primarily responsible for protection of the lower 
respiratory tract as it affords long-lived protection [98].  However, not all antibody-mediated 
protection is due to those two types of immunoglobulins.  IgM antibodies are able to initiate 
complement, a biochemical cascade of the innate immune system, to neutralize influenza virus 
and their presence indicates a primary infection as it is the first immunoglobulin expressed by 
mature B cells [99, 100].   
There are multiple different ways that antibody is capable of providing protection against 
a virion.  They can inhibit assembly of progeny virus, prevent uncoating or aggregation of 
virions, destabilize the virion structure or inhibit an important viral function through a signal 
transduction cascade.  For example, upon dimeric IgA binding to a polymeric Ig receptor 
expressed on the basolateral surface of epithelial cells, it becomes transcytosed to the apical 
surface where the poly-Ig receptor is cleaved.  SIgA is then released to prevent infection; this 
mode of intracellular neutralization has been noted in anti-HA IgA antibodies [95].  Antibodies 
specific for the variable globular head of HA are able to bind and prevent attachment of influenza 
to SA receptors on the cell [101-103], thus preventing infection whereas antibodies that bind to 
the more highly conserved stem region of HA prevent the conformational changes necessary for 
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fusion [104-107].  Along with the globular HA head, NA-specific antibodies are in abundance 
and correlate with protective immunity [108].  These antibodies do not neutralize the virus, unlike 
HA but instead inhibit the enzymatic activity of NA that is required for release of the budding 
virus which causes aggregation of virus particles on the infected cell surface [108, 109].  Not all 
antibodies bind directly to the virus but can also coat infected cells to eliminate them through 
ADCC, mediated by recognition of the antibody Fc receptor by NK cells.  Antibody-coated 
infected cells can also be opsonized by macrophages or activate the classical complement 
pathway [100, 110-112] .  It is thought that M2- and NP-specific antibodies function in one of 
these ways as they are both protective but non-neutralizing.   
Once the viral infection is cleared, residual influenza-specific B and T cells are found in 
lymphoid organs and in circulation and comprise the memory immune response.  This population 
is maintained under DC and T cells producing IL-17 and can reactivate quickly upon subsequent 
influenza virus infections [113].  Most human memory responses are against the NP, M1 and PA 
proteins [114-117].  Due to the high conservation of these proteins, the memory response is 
highly cross-reactive between different influenza A subtypes. However, epitopes recognized by 
virus-specific CTL are also under selective pressure and the virus has the capacity to overcome 
functional constraints through compensatory mutations in order to evade T cell immunity.    
Licensed influenza A vaccines 
There are currently two different types of licensed influenza vaccines: an inactivated and 
a live attenuated influenza virus (LAIV).  Both vaccines have a trivalent or a quadrivalent version 
with the trivalent currently being composed of two different IAV strains: an H1N1 and an H3N2 
along with one of the two influenza B strains while the quadrivalent incorporates the same IAV 
strains but also both influenza B strains [118, 119].  These vaccines are updated yearly to 
antigenically match strains that the WHO global surveillance predicts will predominantly 
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circulate in the upcoming flu season [120, 121].  Antibodies are induced against HA and NA in 
which there is documented protective efficacy.   
Inactivated influenza vaccines have been extensively used for decades; the first 
commercial vaccine using whole inactivated influenza virus was approved for use in the United 
States in 1945 [122, 123].  This vaccine consists of purified virus that has been chemically 
inactivated with formalin or β-propiolactone and in most formulations, is also treated with 
detergent to produce soluble forms of the viral surface antigens.  Each of the IAV subtypes are 
adapted to grow in embryonated eggs or are a reassortant containing the HA and NA of strains 
included in the vaccine with the rest of the viral genome from the A/Puerto Rico/8/34 (PR8; 
H1N1) virus [124].  This virus allows for high growth capacity in eggs to increase vaccine 
production.  However, HA and NA can affect the growth characteristics of reassortant viruses 
such that certain combinations are not as well-adapted in eggs [125]. 
While the inactivated vaccine has provided >59% efficacy in the past 12 flu seasons in 
adults 18 to 65 years old [21], there are still some inherent failures.  First, the duration of the 
protective immunity induced by the inactivated vaccine is short, with levels of antibody 
decreasing by 75% over an 8-month period in some patients [126].  Additionally, the 
intramuscular route of injection of this vaccine fails to induce a local mucosal immune response, 
where influenza infection would occur, and also does not induce robust cellular immunity [127-
129].  The inactivated vaccine also exhibits variable efficacy and is unable to protect against 
antigenic shift and drift viruses [120]. 
The development of the LAIV aimed to address several of the issues associated with the 
inactivated vaccines.  While the LAIV is a live virus, delivered by a nasal spray, it has been cold-
adapted such that it can only replicate at 25°C, the approximate temperature of the nasal passage, 
is temperature sensitive and is unable to replicate at 37° or 39°C which are temperatures 
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associated with the lower respiratory tract.  The LAIV virus is further attenuated to contain other 
mutations that prevent it from producing flu-like illness.  For the seasonal vaccines, the HA and 
NA of the influenza strains to be included in the vaccine is reassorted with the internal proteins 
from the master donor attenuated virus (MDV): A/Ann Arbor/6/60 and B/Ann Arbor 1/66.  The 
MDV was initially developed by serial passage at sequentially lower temperatures, leading to the 
acquired cold adapted, temperature sensitive and attenuated phenotypes due to multiple mutations 
in the internal viral proteins [130].  This vaccine exhibits higher efficacy in children as compared 
to the inactivated [118, 131] and intranasal delivery allows for the production of serum IgG and 
mucosal IgA antibody that are associated with protection at mucosal surfaces [132-134].  In 
addition, this vaccine induces a robust cellular immune response that is more cross-protective 
than antibodies and may contribute to protection against clinical symptoms [135].  However, this 
vaccine also has its weaknesses in that it is less effective in adults and is not approved for use in 
people over 50, a subpopulation that is highly susceptible to flu infection and complications [131, 
136].  This necessitates further understanding of the immune correlates of protection in order to 
develop new vaccines capable of offering protection to highly susceptible populations. 
Currently, the gold standard for evaluation of immunogenicity of influenza vaccines is 
the HA serum antibody titer measured by the HA inhibition (HI) assay, with a titer greater than 
40 being considered protective [137, 138].  A dose of 15µg of HA is sufficient to induce this level 
of antibody but only in adults who were previously exposed to an influenza virus of the same 
subtype.  It takes a higher dose of vaccine or multiple doses in elderly or unprimed individuals 
[139, 140].  Flu viruses have evolved since the creation of the HI assay and new influenza 
viruses, such as H5N1 and H7N7, pose a significant public health threat.  In preclinical animal 
studies for H5N1 vaccines, it has been difficult to detect H5 specific HI antibodies, even in 
H5N1-infected humans [141, 142].  While influenza vaccines have been evaluated by the HI 
assay historically, there is an enormous need to develop alternative correlates of protection.  
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Research has been ongoing into the development of new influenza vaccines based upon immunity 
to the M2 extracellular domain (M2e) or conserved proteins, of which protective antibodies are 
not neutralizing.  These antibodies are currently measured by ELISA which does not assess their 
biological protective activity and there is no antibody titer linked to protection for M2 antibodies 
[112, 143, 144].  The LAIV induces mucosal immunity and there are only poor correlates of 
protection associated with mucosal antibody and cellular immunity[145].  Additionally, 
evaluation of vaccines solely by HI titer does not consider CD8+ T cell-mediated protection.  
Attempting to correlate this immunity to protection is much more complex as it would have to 
take into account an individual’s HLA phenotype, immunological status and influenza infection 
and vaccination history [114].   
There are also inherent problems with the current influenza vaccines that impact their 
protective efficacy.  Both inactivated and LAIV are not protective against antigenic drift viruses.  
Five different antigenic sites have been identified in the globular head of HA that determine 
antigenic properties and mutational changes in these sites can alter antigenicity or increase 
receptor binding affinity [146].  Suboptimal match or complete antigenic mismatch of the vaccine 
and circulating strains can affect the efficacy of these vaccines, leading to lower vaccine benefit.  
When the vaccine antigenically matches circulating strains, up to 90% of infections can be 
prevented however, antigen divergence can reduce protection to 30-40% of infections [147, 148].  
In addition, these vaccines are not protective against antigenic shift viruses which are associated 
with pandemics such as the 2009 H1N1 or the 1918 “Spanish” flu.  Finally, the amount of time 
required to create the vaccine is lengthy as most influenza vaccines require embryonated chicken 
eggs for production which necessitates early strain prediction [149].  At times, the predicted strain 
to circulate does not grow well in embryonated eggs such as in the 2003-2004 influenza season 
and vaccine shortage can occur if there are not enough embryos to grow virus or if the virus does 
not grow well [150].  This has been partially solved through the approval of cell-cultured 
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influenza vaccines [125] however, strains to be included in the vaccine are still predicted by the 
WHO.  Further research needs to be conducted in developing more cross-protective, ‘universal’ 
vaccines that are not susceptible to antigenic mismatch and that would provide protection against 
pandemic strains. 
Universal influenza vaccines 
While current seasonal influenza vaccines target the variable HA and NA glycoproteins 
for antibody-mediated protection, there are more highly conserved proteins or regions that could 
be targeted to induce cross-protective immune responses; two such candidates are M2 and HA2 
stalk region.   
M2e 
The M2 ion channel protein has become a main target for vaccine induced immunity in 
universal vaccines.  It is a highly conserved single pass type III transmembrane protein that forms 
homotetramers on the surface of the virion and is translated from a spliced variant of the mRNA 
coding for M1, thus restricting its sequence diversity [29, 151-153].  The transmembrane domain 
of M2 acts as a pH gated ion channel protein that is essential for release of the viral genome 
during viral entry by acidifying the virion interior after endocytosis [40, 154, 155].  The 54 amino 
acid cytoplasmic tail has also been shown to be important for incorporation of viral RNPs into 
infectious viral particles by interacting with M1 [59, 60, 64] whereas the 24 amino acid N-
terminal extracellular domain does not have a known function.  However, the M2e is highly 
conserved within a species but not across species [156].  While only about 16-20 molecules of 
M2 are incorporated into each virion, it is expressed abundantly at the apical plasma membrane of 
infected cells [153]. 
Despite being a weak immunogen [157], M2 is an attractive target for a universal vaccine 
based upon its high conservation.  Naturally, antibodies against M2e are not induced, most likely 
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due to the immunodominant HA and NA but are protective in vivo from influenza challenge [144, 
158].  In vitro, M2e antibodies reduce the size of influenza virus plaques, potentially due to 
blocking late stage replication, interactions with other viral proteins, or interfering with assembly 
and budding at the plasma membrane [144, 159].  Passive immunization with these antibodies in 
mice results in reduced viral lung titers and protection from mortality from IAV challenge but 
mice still become infected, exhibiting weight loss associated with morbidity [158, 160].  
However, there is no known mechanism for M2e-mediated antibody protection.  One study 
suggests that antibodies bound to M2e on the viral surface are recognized and the virion is 
removed by opsonophagocytosis by macrophages or NK cells [112, 161].  Several studies have 
shown that non-neutralizing anti-influenza humoral immunity is dependent on 
opsonophagocytosis of influenza virions by macrophages [100, 110, 162] with IgG2A isotypes 
being known to interact efficiently with complement and Fc receptors [110, 163-165].  Other 
studies have demonstrated that M2e based immunity is complement dependent or rely on an 
ADCC mechanism [112].  Depletion experiments using clodronate liposomes have shown the 
importance of DC and macrophages [143]. However, each study on the mechanism of M2e-
antibody mediated protection uses a different form of M2e, either conjugated to an adjuvant, in a 
vector or as a pure protein, and thus the different ways of introducing the epitope may be 
affecting the type and quality of immune response that is generated and the mechanism of 
protection.  Due to this, there is no true correlate of protection for these antibodies despite it being 
suggested that the induction of IgG1 and IgG2a antibodies provide the most protection [166-168]. 
Since the observation of the protective capacity of M2e antibodies, many investigators 
have attempted to provide cross-protective immunity by creating vaccines based upon M2.  
Slepushkin et al was the first to describe cross-protection by vaccinating mice with the full length 
M2 protein, purified from a baculovirus insect-cell expression system, in combination with 
incomplete Freunds adjuvant (IFA) [169].  Vaccinated mice demonstrated reduced morbidity, 
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mortality and viral titers in the lungs.   Initially, the entire M2 protein was utilized for vaccination 
purposes but this immune response was further tailored to focus solely on the M2e.  The first 24 
amino acids of M2e are highly conserved across both IAV groups with 17 of these amino acids 
conserved at a rate of over 94% and 100% conservation occurs in the first nine amino acids [168, 
170].  Along with this conservation, the M2e was described to be the most immunologically 
relevant portion of the protein [169, 171] and subsequent immunization of M2e conjugated to 
carrier proteins such as glutathione-S-transferase (GST) [171], human papilloma virus (HPV) L 
protein [172], keyhole limpet hemocyanin (KLH) [173], bacterial outer membrane complex [174] 
and other various carrier molecules provided homologous and heterologous protection [112, 167, 
175-178].  It was also found that antibodies induced by vaccination with just M2e resulted in 
equivalent antibody titers to that of vaccination with full length M2 and the induction of IgG 
antibody was shown to be protective [167, 169, 171].  Several investigators have created a 
hepatitis B core (HBc) –M2e fusion protein which resulted in aggregates of highly immunogenic 
VLPs that induced long lasting protection against heterosubtypic lethal IAV infection after 
intraperitonal (i.p.) or intranasal (i.n.) administration [156, 174, 179].  This protective efficacy 
was further enhanced by adding adjuvant leading to lower morbidity among mice.   
To further enhance the immunogenicity of M2e, several strategies were utilized to 
present multiple copies of the M2e to the immune system.  B cells require cross-linkage of 
immunoglobulin (Ig) receptors for activation of intracellular signaling events that lead to the 
maturation of antibody-secreting cells [180].  Four tandem copies of M2e was fused to flagellin, a 
TLR5 ligand [181] or to a GST fusion protein bearing multiple M2e copies [182].  The high M2e 
epitope density in a single recombinant protein molecule resulted in enhanced M2e-specific 
humoral responses, leading to higher survival rates in infected animals.  Ernst et al used a 
liposomal based M2e vaccine where M2e was fused to a proprietary hydrophobic protein domain 
and was incorporated into the membrane of small unilamellar liposomes of 100nm in diameter 
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[178].  Three different M2e sequences were incorporated that represented potentially pandemic 
strains: an H1N1, H5N1 and H9N2.  As the M2e is conserved within but not across species, this 
approach would be protective against potentially HPAIV viruses.  This vaccine candidate 
stimulated the production of M2e specific IgG1 antibodies and mice were protected against 
various influenza strains [178].   
While chemical and genetic conjugation of M2e have been used frequently to create an 
M2-based universal vaccine, there was some indication that these approaches may not present the 
epitope in its native tetrameric form.  Antibodies induced by vaccination with M2e HBc 
conjugates were able to recognize M2 peptide but did not bind efficiently to M2 on virus particles 
[112] suggesting that despite M2e being the immunologically relevant portion of the protein, 
vaccination with whole WT M2 would be advantageous since it would likely retain its 
membrane-anchored native conformation.  Vaccination with M2 VLPs, without the use of 
adjuvants, induced antibodies that recognized M2 on the cell surface and virus particles and 
provided protection from lethal challenges of different subtypes [183].  By mimicking the 
quarternary structure of M2e, oligomer specific antibodies were induced [184].  This was 
achieved by using M2e bound to a modified version of a leucine zipper from yeast transcription 
factor GCN4 (M2e-tGCN4).  I.P. and i.n. vaccination resulted in high titer antibody that 
recognized M2e on the surface of virus infected cells or in an M2 expressing cell line, suggesting 
that M2e-tGCN4 chimeric proteins adopted the WT M2e structure. These immunized mice were 
100% protected from a lethal dose of IAV [184].  A consensus M2e sequence has also been 
linked to the rotavirus fragment NSP498-135 that exists as a coiled-coil and is known to form 
tetramers in aqueous solution.  This fusion vaccine induced an accelerated, augmented and more 
broadly protective antibody response when compared to M2e peptides and resulted in a 
significant decrease in lung viral titer [185].   It was subsequently found that M2-specific 
monoclonal antibodies that preferentially bound to M2 multimeric but not monomeric forms were 
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more protective, independent of NK-cell mediated effector functions [186], reinforcing the need 
for multimeric antigen presentation.  
Many approaches have demonstrated the cross-protective efficacy of M2-based vaccines.  
However, while these vaccines protect against mortality, there is still a significant amount of 
morbidity observed as M2 antibodies are not neutralizing and do not prevent infection.  DNA and 
viral vector vaccines have been used as a prime-boost regimen to improve not only humoral but 
also cellular immune responses [187, 188].  While the cellular immune response does not inhibit 
initial infection, it does aid in influenza clearance and replication suppression, working 
collaboratively with the humoral response [110, 112].  M2 contains T cell epitopes against which 
a cellular immune response can be elicited.  Adenovirus (Ad) is a popular virus vector that has the 
potential to prime all aspects of the immune response to induce a far greater cell-mediated 
response without the use of adjuvants. Tompkins et al investigated the DNA/Ad vectored prime-
boost approach by using a full-length consensus M2-DNA to prime the immune response 
followed by a boost with recombinant Ad (rAd) expressing M2 that was able to enhance cross-
reactive antibody responses and induce a T cell response which conferred broad protection 
against lethal IAV challenge [173]. Subsequently, this approach was refined to include another 
conserved antigen, NP, in the rAd boost for a greater induction of heterosubtypic immunity [189, 
190].  Results demonstrated that DNA prime-rAd boost with NP and M2 was protective against a 
lethal challenge with an H5N1 and induced a greater protective immune response than the LAIV 
which fails to induce detectable antibody to M2e [188].  More recently, rAd expressing M2e in a 
variable region of hexon, the most abundant capsid protein, and NP as a transgene demonstrated 
the induction of a robust M2e-specific antibody response that could be boosted upon a second 
dose and a CD8+ T cell response against NP that reduced morbidity and was completely 
protective in outbred mice [189].  These studies show the immunogenicity and protective capacity 
not only of prime-boost approaches but of viral-vectored M2e vaccines.   
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Most M2e vaccines have been tested via intramuscular (i.m.) or i.p. injection but i.n. 
immunization has provided better protection despite the induction of lower levels of serum IgG 
specific for native M2 [166].  I.n. vaccination induces local airway associated immunity that 
involves IgA and M2e-specific B and T cells [191]. Immunity in the upper respiratory tract may 
operate more effectively against influenza infection as the virus replicates in respiratory epithelia.  
Unfortunately, there are no correlates of protection for mucosal-based immunity or M2e 
immunity and the mechanism of protection by vaccination of M2e is still not understood, thus 
necessitating further research into this area. 
While vaccines based upon the induction of M2e-immunity demonstrate cross-protective 
properties, there are still many issues that need to be addressed before an M2 universal vaccine 
can be licensed.  Natural infection or current influenza vaccines rarely induce M2 immunity and it 
is not known, if used on a global scale, if escape viruses would emerge [157].  No escape viruses 
were isolated after 11 passages of influenza viruses through M2e immunized immunocompetent 
mice, suggesting that the likelihood of emergence of a fit M2e escape virus is low but this still 
remains a possibility [192].  The level of protection conferred by current inactivated vaccines 
upon antigen match to circulating strains has not been achieved by M2 vaccines[193].  This is 
compounded by the lack of a clear mechanism and correlate of protection for M2 vaccines.  
Additionally, a major goal of vaccines is to neutralize the pathogen and completely prevent 
infection.  However, this cannot be achieved by M2 universal vaccines as it is infection 
permissive and only serves to reduce disease symptoms and overall mortality [158, 160]; this is a 
realistic goal for a pandemic vaccine but would not be a suitable replacement for seasonal 
vaccines.  Currently, it is highly unlikely that an M2 universal vaccine will be licensed as a 
‘stand-alone’ vaccine given the current research but it would be suitable as an adjunct to current 
vaccines in order to provide increased cross-protection in case of an unanticipated emergence of a 
major drift variant or a new subtype.  The addition of an M2e peptide enhanced cross-protection 
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in mice when immunized i.p. with an aluminum-adjuvanted split H3N2 virus [194].  Even more 
encouraging is that the supplementation of current inactivated influenza vaccines with M2 VLPs 
completely prevented disease symptoms with no observed weight loss and this combination 
conferred cross-protection against lethal challenge with heterologous virus [143].  Thus, M2e 
vaccines still remain a viable option to confer greater cross-protection on the way to creating a 
‘universal’ vaccine.  
HA stalk 
Another potential target for broadly cross-protective universal influenza vaccines is the 
stalk region of the HA protein.  There are two phylogenetic groups of HA: group 1 and group 2 
with notable members of group 1 including H1, H5 and H9 while group 2 includes H3 and H7 
[106].  HA is a homotrimeric glycoprotein that consists of a disulfide-linked globular head of 
HA1, containing the receptor-binding pocket, and a stem composed of HA1 and HA2 which 
encapsidates the fusion peptide (Figure 1B) [195].  Protease-mediated cleavage of HA0 into HA1 
and HA2 is required for fusion and productive replication [38, 69, 70].  This cleavage forms an 
extended, highly exposed loop structure on the surface.  Current seasonal influenza vaccines 
induce neutralizing antibodies to the antigenically variable globular head of the HA protein and 
prevent viral attachment to the host cell [146].  However the HA protein does possess conserved 
structures and sequences in the HA2 segment that is anchored to the viral membrane called the 
stalk.   
HA2 represents the carboxy-terminus of HA and forms the stalk structure [196].  The 
fusion peptide is located at the amino terminus of the HA2 protein and is considered to be one of 
the most highly conserved regions of all influenza HA proteins [197, 198].  This region is 
invariant in influenza A viruses and only differs by one or two conservative amino acid 
replacements in influenza B [199]. Overall, the HA2 subunit has 85% sequence homology among 
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different subtypes and 95% homology within strains of the same subtype [200].  Antibodies 
targeting the stalk region are cross-reactive within a group but not across HA groups due to the 
high sequence conservation within each group.  The invariance of this domain is likely due to 
functional constraints as a series of conformational rearrangements of HA are required to mediate 
fusion [39].   At a neutral pH, the amino-terminus of the fusion peptide is inserted into the 
interspace of the HA trimer whereas at an acidic pH, this terminus is exposed and inserted into 
the endosome membrane to mediate fusion and allow for the RNP complex to be released into the 
cytoplasm [201-203].  The fusion peptide is accessible to antibody on the uncleaved HA 
precursor that is exposed on the plasma membrane of infected host cells as it is located in an 
exposed loop.  However, during natural infection or vaccination with seasonal influenza vaccines, 
the immune response against the fusion peptide or HA2 stalk are very weak, most likely due to 
the immunodominance and bulk of the globular HA1 head domain, making the stalk epitope less 
accessible to antibody binding [197, 204, 205].     
The ability to elicit broadly protective antibodies against HA2 began when the high 
sequence homology between HA2 as compared to HA1 subunits was noticed [204].  To 
determine if HA2 possessed antigenic properties, mature virus particles were treated with acid 
followed by dithiothreitol (DTT) or trypsin in order to alter the HA conformation and remove 
HA1, resulting in HA2 being displayed by both procedures.  These particles were injected into 
rabbits and three weeks post injection, antiserum was collected to evaluate the humoral response. 
Surprisingly, the rabbit antisera detected HA from both H1 and H3 subtypes, demonstrating 
cross-reactivity between groups [204].  It is unlikely, however, that antibodies of this nature 
would be induced by the immune response as the reduction in pH prior to cleavage stimulated a 
conformational change in HA2 that would not naturally occur and are not physiologically 
relevant.   
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However, more recent studies have investigated different methods to induce antibodies 
against HA2.  The first HA2 cross-reactive antibody, C179, was identified through the use of a 
hybridoma library made from mice immunized with an H2 strain and recognized group 1 
subtypes [206].  This single monoclonal antibody, upon further investigation, was broadly 
protective but did not prevent attachment of HA in an HI assay.  Only HA1 antibodies that 
prevent attachment are detected by HI assays and mapping of the binding region of C179 
revealed that this antibody bound to a conformational epitope on HA1 and HA2, with most 
contacts made in the stalk region [206, 207].  It was later discovered that C179 inhibited syncytia 
formation that is characteristic of normal HA fusion, suggesting that antibodies targeting this 
region are protective by preventing fusion of the virus to the endosomal membrane.   
Mechanistically, these antibodies could insert its heavy chain into the conserved pocket of the 
stem region or prevent HA conformational changes necessary to reveal the fusion peptide [105, 
106, 206].  Passive and active immunization of HA2 stalk antibodies led to neutralization of the 
virus, greatly decreasing morbidity and mortality [206].   
Several methods were undertaken to increase the frequency of inducing broadly 
protective HA antibodies.  The immunogenicity of HA2 was increased by removing the 
immunogenic globular head of HA1 [197].  These ‘headless’ HA trimers still form the conserved 
stalk domain so HA2 epitopes are more accessible to B cells than in native HA, leading to the 
discovery of more broadly cross-reactive antibodies [197, 205].  As C179 recognized an epitope 
that spanned HA1 and HA2, mice vaccinated with a peptide spanning the HA1-HA2 connecting 
region exhibited milder illness and fewer deaths upon a lethal viral challenge [208-210].  
Furthermore, immunization with chemically modified fusion peptides conjugated to KLH 
induced antibodies that reacted to different subtypes of HA by specifically recognizing the fusion 
peptide sequence [183].   
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The identification of further cross-reactive HA2-based monoclonal antibodies has been 
achieved through phage display and combinatorial libraries.  A highly cross-reactive antibody, 
CR6261, was isolated from a healthy, vaccinated individual through the use of phage display 
selection on recombinant H5 HA [106]. This IgG1 antibody neutralized multiple influenza 
subtypes from group 1 HA and prophylactically and therapeutically protected mice 5 days post 
infection with a lethal challenge of H1N1 and H5N1 viruses.  Crystal structure analysis of the 
CR6261 antibody in complex with HA’s from the 1918 H1N1 pandemic virus and an HPAI 
H5N1 virus revealed that it primarily bound to the HA2 central alpha helix (HA2 A; Figure 1B) 
with some contacts in the HA1 stem region [106].  Importantly, the HA2 A region is required for 
proper trimerization and pH induced unfolding [211].  The identification of this new conserved 
epitope helps to accelerate the design and implementation of improved therapies and/or vaccines 
based upon HA2-mediated immunity . 
A similar approach was used by Sui et al to identify F10, a monoclonal antibody that 
recognizes a conformational epitope comprised of HA1, HA2 A and HA2 [105].  Prophylactic 
and therapeutic administration of this antibody protected mice from lethal doses of H5N1 and 
H1N1 viruses and neutralized virus by inhibiting cell fusion.  Similar to CR6261, there was high 
sequence conservation within the binding region of F10 which enabled this antibody to neutralize 
across group 1 strains.  Crystal structure analysis demonstrated that F10 bound preferentially to 
two important tertiary structures that are conserved across all of these subtypes.  Multiple F10-
HA contacts were made in the HA2 A region that CR6261 also recognized, with the center of the 
binding epitope recognizing four hydrophobic amino acids that comprise a portion of the fusion 
peptide and is conserved across all IAV, including group 2 viruses [105].   However, the inability 
of F10 to recognize group 2 viruses is due to the glycosylation of residue 39 and 40 of HA2 in 
group 2 viruses, along with the orientation of tryptophan at position 21, which prevents epitope 
recognition and subsequent heterosubtypic protection [105, 212].  Importantly, nine out of ten 
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neutralizing antibodies discovered by this study employed the same heavy chain gene usage as 
CR6261, VH1-69 [105, 212], suggesting that this conserved gene usage can be induced in 
response to the correct conformational HA2 antigen.   
The first broadly reactive antibody against H3 viruses, 12D1, was isolated from mice that 
had been sequentially immunized with DNA coding for HA from three antigenically distinct H3 
viruses [213].  Of the group 2 viruses, H3 is currently the only human IAV thus, although 12D1 
was unable to neutralize other group 2 subtypes, it could still protect from seasonal group 2 
influenza strains.  Similar to CR6261 and F10, 12D1 prevented viral fusion however, unlike the 
group 1 broadly reactive antibodies that recognize a conformational epitope, 12D1 binds to a 
continuous region of HA2, the long alpha helix (LAH; Figure 1B).  This suggests that unlike the 
non-contiguous epitopes of the broadly reactive group 1 mAb, the LAH could serve as an 
effective immunogen.  A synthetic peptide containing the LAH of H3 was coupled to KLH and 
elicited protective antibodies against the stalk of the HA protein [213].  While the induced 
antibodies were most protective against H3 viruses, they demonstrated slight protection from 
H5N1 and H1N1 viruses, with less morbidity and a delay in time to death.  Importantly, multiple 
passages of H3 viruses in the presence of 12D1 did not select for escape mutants, most likely due 
to the secondary helix structure required for stabilization of the HA trimer and this suggests that a 
vaccine based upon immunity to LAH would not lead to significant antigenic drift [213].   
Monoclonal antibody, F16, that neutralizes both group 1 and group 2 viruses was 
discovered by Corti et al through a sensitive, high throughput screening method, utilizing IL-6 
supplemented PBMCs from human volunteers [214].  F16 bound to both recombinant and 
purified HA from all group 1 and group 2 viruses tested in vitro.  Furthermore, this monoclonal 
antibody prevented lethality and weight loss in mice challenged with H1, H3 and H5 viruses, 
highlighting its ability to overcome structural differences that have previously limited 
heterosubtypic antibodies from being cross-reactive to all IAV subtypes. Crystal structure 
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analysis of F16 in complex with HA demonstrated that unlike previously described group 1 
monoclonal antibodies that interact primarily through the heavy chain [105, 212], F16 uses both 
heavy and light chains to make contacts with HA1 and HA2, likely a result of multiple somatic 
mutations.  This allows for added flexibility due to different VH gene usage to overcome steric 
hindrance at Trp21 and glycosylation at residue 38 [214].     
While the isolation and identification of F16 from humans is encouraging for the future 
of universal vaccines, this antibody is extremely rare and was identified in only 4 out of 104,000 
plasma cells screened [214].  Even heterosubtypic antibodies like CR6261, F10 and 12D1 are 
uncommon, with F10 being identified out of a 27 billion human-antibody phage display library 
[105, 212, 213].  There are several potential reasons for the rarity of these broadly neutralizing 
HA antibodies.  The regions of HA2 that group 1 and group 2 heterosubtypic antibodies 
recognize are proximal to the viral membrane and are physically blocked by the globular head 
domain of HA1 [197].  Additionally, the globular head of HA1 is very immunodominant, with the 
majority of monoclonal antibodies identified targeting conformational epitopes that are likely 
presented often by MHC molecules.  Antibody production is dependent upon B-cell peptide 
recognition within the context of the MHC and if the conserved regions of the HA stalk are not 
presented, stalk antibodies would not be created [215].  Finally, the F16 antibody required 
multiple somatic mutations to increase the binding interface necessary to recognize structurally 
distinct group 1 and group 2 HA stalk regions [214].  The prevalence of mutations such as these 
are not known but are probably uncommon, based upon the rarity of the F16 antibody.  Thus the 
infrequency of these broadly protective antibodies cautions the use of HA2 as a vaccine antigen. 
The immunization of individuals with a conserved epitope recognized by broadly 
protective antibodies does not guarantee the natural induction of a heterosubtypic immune 
response.  Since several broadly neutralizing antibodies such as CR6261, 12D1 and F10 primarily 
make contacts with the HA2A, it was investigated whether the HA2A region itself was sufficient 
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to elicit broadly neutralizing antibodies.  HA2A was displayed on the capsid of Flock House 
Virus VLPs in a small helix-turn-helix scaffold to maintain secondary structure of the peptide 
[176].  While this VLP did display HA2A in the correct conformation, few mice produced 
antibodies against this region and they were not protective.  This suggests that the HA2A alone is 
not sufficient as an antigen to induce broadly neutralizing antibodies which is a common 
difficulty in vaccine development.  To overcome dependence on the immune system to develop a 
protective response against influenza, protective antibodies can be produced in vivo to bypass the 
uncertainty of immune induction by conventional antigens.  This system, termed vectored 
immunoprophylaxis (VIP) was developed in David Baltimore’s laboratory and used an adeno-
associated virus serotype 8 (AAV8) vector to express human IgG monoclonal antibodies CR6261 
and F10 that was encoded as a transgene [216, 217].  Upon a single intramuscular injection of the 
AAV8 vector, these monoclonal antibodies were expressed to high levels in vivo by one week 
post transduction and protected mice from challenge by group 1 influenza viruses.  While it has 
already been known that passive administration of antibodies is protective, this system allows for 
the expression of these antibodies in vivo rather than injection of in vitro cultured monoclonal 
antibodies.  Additionally, it was able to protect both young mice and immunocompromised 
elderly mice, two highly susceptible populations to influenza complications that either do not 
respond as well or are not suggested to receive current seasonal vaccines [217].  This 
demonstrates a prophylactic approach that could be utilized in combination with some of the well 
characterized broadly protective monoclonal antibodies for a universal vaccine approach. 
Cross-reactive cytotoxic T lymphocytes 
Seasonal influenza vaccines and most universal vaccine candidates rely upon the 
induction of protective antibodies however cell-mediated immunity does play a role in the control 
of influenza virus infections.  Cytotoxic T lymphocytes (CTL) can eliminate virus infected cells 
by recognition of viral antigens presented on MHC I to contribute to the clearance of virus from 
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infected tissue [218, 219].  Depletion of T cells in IAV infected mice have led to higher viral 
titers in the lung, increased mortality and more severe disease [219]. While CTL can be subtype 
specific, of importance to the development of a universal vaccine, they can also be broadly cross-
reactive, depending upon the antigen.   Early studies in influenza infected mice demonstrated that 
a majority of influenza-specific CTLs were cross-reactive across subtypes and this has also been 
described in naturally infected humans [115, 220].  This high crossreactivity can be explained by 
the antigenically conserved internal targets of CTL, mainly targeting NP, M1 and NS1 [114, 116, 
221, 222].   
While heterosubtypic immunity can be generated against conserved CTL epitopes, it is 
not a promising ‘universal’ influenza vaccine approach for multiple reasons.  First, there is 
immunodominance of CTL epitopes where only a small fraction of peptides created by 
proteasomes are presented by MHC I molecules and recognized by CTLs [215, 223].  This could 
be due to the HLA haplotype and its binding affinity to individual epitopes, repertoire of T-cell 
receptors, processing and presentation of viral peptides and interaction of CTL with APC [215, 
223], making it difficult to predict what conserved epitopes will be protective in a majority of the 
population.  Additionally, the efficiency of epitope processing is not the same for all epitopes and 
this has been shown to affect immunogenicity.  Most vaccines are first assessed for 
immunogenicity in a mouse model however, it is difficult to assess T cell-based vaccines as the 
most frequently used models are inbred mice: B57BL6 (H-2b) and BALB/c (H-2d) [224] with 
defined HLA genes.  While certain T cell epitopes may be immunodominant in these mice, not all 
epitopes are equally immunogenic thus it is hard to translate these epitopes into humans where 
the HLA genes are highly polymorphic.  While there are epitopes, such as M158-66, that are 
recognized by multiple HLA genes, only 80-90% of the population would be protected [225]. 
Ultimately, T cell responses are dependent upon an individual’s genetics, making mass 
vaccination of a CTL-based influenza vaccine unrealistic.  Furthermore, there is no known 
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correlate of T-cell mediated protection, making the assessment of vaccines even more difficult. 
Thus, the feasibility of designing an effective universal CTL epitope vaccine in humans is 
questionable without further knowledge and investigation into broadly protective epitopes across 


























Figure 1: Influenza A virus structure 
(A) Schematic diagram of a spherical influenza A virus particle [46].  The hemagglutinin (HA), 
neuraminidase (NA) and M2 protein are inserted into the lipid envelope derived from the host 






lipid envelope on the interior of the virus particle. The nuclear export protein (NEP)/NS2 protein 
is also incorporated into the virion.  The viral RNA exists as 8 segments coated with 
nucleoprotein (NP) and are bound to the polymerase [46].  (B) Ribbon diagram of HA trimer 
(left) and monomer (right).  HA2 alpha (HA2A) helix is labeled in blue (residues 38-58) and the 
long alpha helix (LAH) is labeled in red (residues 76-130). Produced using program PYMOL 
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The highly conserved influenza A virus M2 extracellular domain is not 













 The influenza A virus M2 protein has essential roles in both virus entry and assembly of 
infectious virus particles.  These functions have been mapped to the transmembrane and 
cytoplasmic domains, respectively.  However, there is currently no known function of the 
extracellular domain of the M2 protein (M2e).  The M2e is highly conserved suggesting that it is 
important for M2 function.  To investigate the role of the M2e, triple alanine substitution mutants 
spanning the entire 24 amino acid domain were made and expressed in MDCK stable cell lines.  
Mutant M2e function was assessed by transcomplementation assays of M2-null viruses. Neither 
directed alanine mutagenesis nor the deletion of the first nine amino acids of the M2e attenuated 
replication.  This suggests that the high conservation may be due to a functional role of the 













Influenza A virus (IAV) is a member of the Orthomyxoviridae family whose genome 
consists of 8 negative-sense RNA segments that code for 10 or 11 proteins [1]. Segment 7 
encodes the highly conserved 97 amino acid M2 protein as well as M1 by differential splicing [2]; 
therefore, M2 and M1 share the first 8 amino acids.  M2 is a disulfide-linked tetrameric type III 
integral membrane protein with an extracellular amino terminus and an intracellular carboxy 
terminus.  In the viral life cycle, M2 is required for virus entry, where it acts as a pH-gated, 
proton-selective ion channel and translocates ions into the virion interior [3].  This mediates the 
release of viral nucleoprotein complexes (vRNPs) from M1, allowing for vRNP transport to the 
nucleus for RNA transcription and replication [4-6].  The ion channel, in some influenza A 
species, also stabilizes the conformation of the HA protein in the trans-Golgi network [7].  
Sequences in the M2 cytoplasmic tail are essential for the formation of infectious virus particles 
at the plasma membrane by mediating incorporation of NP and vRNPs into budding particles [8-
11]. 
 The roles of the ion channel transmembrane domain and cytoplasmic domain of M2 in 
the viral life cycle have been well defined [3, 8-10, 12].  The 24 amino acid M2 extracellular 
(M2e) domain is highly conserved across all influenza A species which suggests that it is 
important for M2 function.  Despite this hypothesis, the role of this region in the viral life cycle is 
largely unknown.  One study suggests that the M2e is important for incorporation of M2 into 
virus particles [13] but there are no known interactions between M2e and the ectodomains of 
other viral glycoproteins.  
 To systematically investigate the role of the M2e domain in virus replication, triple 
alanine substitution mutations were made across the entire region and expressed in MDCK stable 
cell lines.  M2 function was assessed through transcomplementation assays with M2-null viruses.  
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All mutants replicated successfully as demonstrated by growth curves, suggesting that the M2e 
can tolerate numerous mutations without any apparent adverse affect on virus replication.  
Similarly, mutation or deletion of the first eight completely conserved amino acids led to no 
attenuation of the virus.  Therefore, despite the high conservation of the ectodomain, this region is 
not critical for the function of M2, as assessed by transcomplementation, in viral replication in 

















Materials and methods 
Plasmids and mutagenesis.   
The plasmid pCAGGS [14] encoding the cDNA for the full length M2 protein from 
A/WSN/33 (pC WSN M2), has been described previously [10].  M2 ectodomain mutations were 
introduced into pC WSN M2 by 4 primer overlap extension PCR [15, 16].  All inserts into 
plasmids were confirmed by sequencing. 
Cells  
Madin-Darby canine kidney (MDCK) cells and human embryonal kidney (293T) cells were 
cultured in Dulbecco’s modified eagle medium (DMEM; Sigma) containing 10% fetal bovine 
serum (FBS; Atlanta Biologicals), 100 U/mL penicillin (Invitrogen), 100 µg/mL streptomycin 
(Invitrogen), 1mM sodium pyruvate (Sigma) and 2mM Glutamax (Invitrogen) at 37°C and 5% 
CO2.  
All cell lines that stably express M2 WSN N31S [16] or M2 mutants were cultured in 
identical media as wild-type MDCK cells and were supplemented with puromycin (7.5 µg/mL; 
Sigma) and amantadine HCl (5 µM; Sigma).  The N31S mutation allowed for amantadine 
sensitivity to the M2 protein of A/WSN/33 virus and was added to culture medium to prevent 
toxicity from an active ion channel [3, 17]. Stable cell lines expressing mutant M2 ectodomain 
were generated by cotransfecting MDCK cells with plasmids expressing a puromycin resistance 
gene (pBABE) [18] and a pCAGGs M2 expression vector in six-well plates.  Two days post 
transfection, the cells were trypsinized, subjected to puromycin selection and cloned by limiting 
dilution in 96 well plates.  Cells were screened for M2 expression by indirect 
immunofluorescence of live cells for cell surface-expressed M2 and positive clones were detected 
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with a fluorescent plate reader.  Cell lines were screened by flow cytometry for homogenous M2 
expression by flow cytometry. 
Flow cytometry 
Cells were removed from the tissue culture plate by trypsinization.  The cells were stained for 
M2 surface expression using monoclonal antibodies 14C2 (1:500 dilution) [19] or TCN-032 (1:50 
dilution; Theraclone Sciences) [20] followed by Alexa Fluor 647-conjugated secondary 
antibodies goat anti-mouse immunoglobulin (IgG) or goat anti-human IgG (all at a 1:500 dilution; 
Invitrogen). C terminal flag-tagged M2 cell lines were fixed by 2% paraformaldehyde (Sigma) 
followed by permeabilization with 0.2% TritonX (Sigma).  Prior to analysis, all cells were fixed 
with 2% paraformaldehyde at room temperature (RT) for 15 min.  The cells were analyzed by 
flow cytometry (Becton Dickinson FACS Calibur) by using FlowJo software.  
Viruses 
Viruses used in this study were functionally M2-null viruses, rUdorn M2Stop and rWSN 
M2Stop [10], which are recombinant viruses of A/Udorn/72 [H3N2] and A/WSN/33 [H1N1] [3, 
21] that encode a truncated M2 protein as a result of codons 25 and 26 being altered to stop 
codons [9].  These viruses were propagated on MDCK cells stably expressing WSN M2 N31S in 
DMEM containing 4 µg/mL of N-acetyltrypsin (Sigma), 100 U/mL of penicillin, 100 µg/mL of 
streptomycin and 0.3% bovine serum albumin (BSA; Sigma).   
Virus infections  
Low-multiplicity growth curves were performed at a multiplicity of infection (MOI) of 0.001 
50% tissue culture infectious dose (TCID50) per cell.  For complementation assays, MDCK cells 
expressing mutant or WSN M2 N31S were infected with M2 stop viruses.  Confluent cells grown 
in 6-well plates were washed twice with phosphate-buffered saline with calcium and magnesium 
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(PBS+; Invitrogen) to remove FBS.  Cells were infected with indicated viruses in 500 µL 
infection medium (DMEM supplemented with 0.5% BSA, 100 U/mL penicillin, 100 µg/mL 
streptomycin, 1 mM sodium pyruvate, 2 mM Glutamax and 4 µg/mL N-acetyl trypsin [NAT; 
Sigma]) at RT with rocking for 1 hr.  Cells were then washed twice with PBS+ and incubated 
with 1 mL infection medium at 37°C.  At indicated time points, the media was removed, stored at 
-80°C and replaced with fresh infection medium.  The amount of infectious virus was determined 
by TCID50 assay on MDCK cells expressing M2 WSN N31S. 
TCID50 assay 
MDCK cells expressing WSN M2 N31S were plated in 96-well plates.  Upon confluency, 
cells were washed twice with PBS+, infected with 100 µl of ten-fold serially diluted virus in 
replicates of 4 and incubated for 4 days at 37°C. Cells were fixed by adding 50 µl of 4% 
formaldehyde (Fisher) in PBS, stained with Napthol Blue Black solution, and visually scored for 
cytopathic effect.  The TCID50 was calculated by the method of Reed and Muench [22]. 
Microscopy  
293T cells grown to 10-15% confluence on tissue culture-treated glass coverslips (Fisher 
Scientific) in 6 well plates were transfected using 1.5 µg of pCAGG M2 mutant plasmid DNA 
and 2.5 times LTI (Mirus Bio).  At 24 hours post transfection, cells were incubated on ice, 
washed twice with PBS and blocked for 30 min on ice with 3% normal donkey serum (Sigma) 
and 0.5% BSA in PBS. All further antibody dilutions were made in blocking media.  Lectin 
staining was performed for 1 hour on ice in blocking solution using wheat germ agglutinin 
Alexafluor 555 (WGA; 1:500 dilution; Invitrogen).  Cells were washed three times with PBS, 
fixed for 15 minutes with 2% paraformaldehyde at RT followed by permeabilization with 0.2% 
TritonX for 20 min at RT. Coverslips were removed from the 6 well plate and were washed 15 
times by immersion in 0.2% Tween in PBS and blocked for 45 minutes in a humidifying 
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chamber.  The cells were stained with anti-Flag antibody 14C2 (1:1000; Stratagene) for 1 hour.  
Coverslips were washed 15 times by immersion in 0.2% Tween in PBS and incubated in goat 
anti-mouse Alexafluor 488 (1:500; Invitrogen) secondary and 4’, 6-diamidino-2-phenylindole 
(DAPI; 1:1000; Roche Molecular Biochemical) for 1 hour.  Cells were washed fifteen times in 
0.2% Tween in PBS and five times with deioninzed water before being mounted with ProLong 
Gold antifade reagent (Invitrogen). 
Samples were imaged on a Nikon Eclipse 90i epifluorescence microscope.  Ten non-
overlapping pictures were taken of each sample using a 40x objective.  For each image, 
colocalization of anti-flag and WGA staining was examined to determine if M2 was present at the 
cell surface. 
Sequence alignments 
 All influenza A M2 protein sequences were obtained from the NCBI Influenza Virus 
Sequence Database [23].  Sequences, excluding 2009 pandemic H1N1, were aligned using 
ClustalW 2.0.10 [24]. The percent conservation of all influenza A virus M2 sequences encoding 
the human consensus M2e residue at each amino acid position was determined using WebLogo 3 
[25].  
Statistical analysis 
Growth curves were analyzed using mixed analyses of variance (ANOVAs) with time and 
virus as independent variables for transcomplementation assays.  All analyses were done using 






Expression of mutant M2 proteins in stable cell lines 
Influenza A viruses encode an M2 protein with a highly conserved ectodomain (Figure 1) 
however the function of this region is unknown.  To understand the biological function of this 
conserved region, triple alanine substitution mutations were made spanning the entire 24 amino 
acid ectodomain (Table 1).  Mutations were not made at the starting methionine or cysteine 
residues 17 and 19 that are involved in disulfide linkages in order to maintain oligomeric 
assembly and prevent destabilization of the M2 tetramer [26].  
MDCK cells were cotransfected with pBABE, to confer selective puromycin resistance, and a 
pCAGGs M2 expression vector using lipofectamine.  Two days post transfection, cells were 
subjected to puromycin selection and were diluted such that a single cell occupied one well of a 
96 well plate to obtain clonal, homogeneous colonies. Stably transfected MDCK cell lines were 
selected that constitutively expressed the wild type (WT) or M2e proteins. To determine if the 
mutant M2e proteins were expressed at the cell surface, two different monoclonal antibodies, 
14C2 and TCN-031, were used that recognize the extracellular domain (Figure 1).  Flow 
cytometry was performed on live cells and the total amount of surface mutant M2e expressed in 
the stable cell lines was comparable to a control cell line expressing WT M2 protein (WSN M2 
N31S) (Figure 2A and B).  This level of expression is above the level that is required to 
complement M2-null viruses [9].  Detection of the mutant M2e protein by flow cytometry 
suggests that the mutations did not affect the M2e native secondary structure since the epitope 
recognized by the TCN-032 antibody, used to recognize these constructs, is conformational [20] 
(Figure 2B).  
Although 14C2 and TCN-032 recognize distinct regions of M2e, 5-7 Ala, 8-10 Ala and 14-16 
Ala M2e constructs were not reliably detected (Figure 1).  Inconsistent results with attempting to 
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detect the 5-7 Ala construct were most likely a result of partial antibody binding due to the 
mutation at amino acid 6.  In order to detect M2 levels in 5-7 Ala, 8-10 Ala and 14-16 Ala M2e 
cell lines, these constructs were tagged with a flag epitope, DYKDDDDK, at the cytoplasmic tail 
(Table 1).  The addition of an antibody epitope tag to the M2 protein cytoplasmic tail does not 
affect its expression or ion channel activity [27] and previous data (unpublished) has 
demonstrated that a flag epitope tag does not affect the ability of M2 to complement an M2-null 
virus.  Because the epitope tag was added to the M2 cytoplasmic tail, it is impossible to determine 
the levels of cell surface expression however total expression could be detected. Flow cytometry 
was performed on fixed, permeabilized cells and the total amount of mutant M2e expressed in 
these stable cell lines was comparable to a control cell line expressing a flag-tagged WT M2 
(WSN M2 N31S Flag) (Figure 2C).   
M2e proteins complement M2-null viruses 
 To determine the effects of M2e mutations on M2 function, a complementation assay was 
utilized [9]. Stable cell lines expressing M2e mutations were infected with two strains of M2-null 
viruses, rWSN M2Stop, an H1N1 virus, (Figure 3A and C) and rUdorn M2Stop, an H3N2 virus 
(Figure 3B and D) in a modified TCID50 assay measuring endpoint titers.  Although all M2e 
mutations were made in the rWSN background, rUdorn M2Stop was used to determine if any of 
the mutated residues contributed to strain specific differences in virus complementation as 
assessed by virus replication.  Neither rWSN M2Stop or rUdorn M2Stop were able to produce a 
high endpoint titer on MDCK cells that did not express M2, compared to WT M2 N31S cells (Fig 
3).  All mutant M2e cell lines were capable of complementing both rWSN M2Stop and rUdorn 
M2Stop to equivalent titers as WT M2 N31S cells indicating that all mutated M2 proteins were 
capable of supporting several rounds of virus replication (Fig 3). 
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 In order to determine if M2e mutations had an effect on virus growth kinetics, these cells 
lines were infected at a low-MOI (MOI of 0.001) with rWSN M2Stop (Figure 4A, C, E and G) or 
rUdorn M2Stop (Fig 4B, D, F, and H) to allow for multiple rounds of virus replication.  MDCK 
cells not expressing M2 did not support replication of either M2-null viruses (Figure 4).  
Although there were minor differences in replication kinetics, all mutant M2-expressing cell lines 
were capable of supporting replication of rWSN M2Stop and rUdorn M2Stop and reached 
equivalent titers at 48hpi as compared to WT WSN M2 N31S (Figure 4).  The viral growth 
kinetics of viruses on mutant M2e expressing cells indicated that the conservation of these amino 
acids is not critical for M2 function as assessed by viral replication.  
Mutation of the conserved first nine amino acids of the M2e does not affect M2 function 
 The entire M2e is more than 50% conserved, however the first 9 amino acids are 100% 
conserved across all influenza A viruses (Figure 1) suggesting that it may play an important role 
in M2 function.  To determine if the entire region is essential for M2, two different constructs 
were created, one in which the 9 amino acids were mutated to alanines (2-9 Ala) and the other 
where these residues were deleted (2-9 Del) (Table 1).  Both constructs were flag-tagged at the 
M2 cytoplasmic tail for detection.   
 The M2 protein is a type III integral membrane protein [28] and it is possible that the 
mutation or deletion of 9 amino acids from the M2e might impact the ability of M2 to target to 
the plasma membrane.  This would inhibit the M2 protein from acting as an ion channel protein 
and complementation would not occur.  Prior to generating stable cell lines, confocal microscopy 
was used on 293T cells transfected with plasmids expressing 2-9 Ala Flag and 2-9 Del Flag.  
These cells were stained with WGA, as a marker for the plasma membrane, and anti-Flag.  
Significant co-localization was seen between the WGA and M2e flag-tagged mutants (Figure 
5A).  These mutants exhibited similar cellular staining as 293Ts transfected with WT M2 N31S 
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Flag, suggesting that 2-9 Ala Flag and 2-9 Del Flag M2 proteins were located at the plasma 
membrane.   
 Stable cell lines expressing 2-9 Ala Flag and 2-9 Del Flag were created.  Flow cytometry 
analysis showed M2 expression above the threshold needed to complement M2-null viruses [9] 
(Figure 5B).  These cell lines were capable of supporting high titer virus replication of both 
rWSN M2Stop and rUdorn M2Stop (Figure 6A and B) and there was no statistically significant 
difference in the replication of the M2-null viruses on 2-9 Ala Flag and 2-9 Del Flag cell lines as 
compared to the WT M2 N31S Flag cell line (Figure 6 C-F).  This suggests that the reason for the 
complete conservation of these amino acids is not due to a role that they play in M2 function in 














 The 24 amino acid sequence of the M2e is highly conserved but with no known function 
in the viral life cycle (Figure 1).  We created stable MDCK cell lines expressing triple alanine 
substitution mutants spanning the 24 amino acid region (Table 1, Figure 2). All of the M2e 
mutants were capable of complementing a homologous and heterologous strain of IAV that both 
lack functional M2 (Figure 3 and 4).  This suggests that the M2e is not critical for M2 function in 
the viral life cycle.  To further investigate the conservation of the first nine amino acids that are 
100% conserved, we made two flag-tagged stable cell lines where those residues were all mutated 
to alanines or were deleted.  Using immunofluorescence, both constructs exhibited staining 
patterns similar to WT M2 N31S in transfected 293T cells and appeared to colocalize with WGA 
suggesting that the mutation did not affect the ability of M2 to traffic to the plasma membrane 
(Figure 5A).  Stable cell lines expressing the 2-9 Ala Flag and 2-9 Del Flag M2e mutants (Figure 
5B) were capable of complementing both rWSN M2Stop and rUdorn M2Stop and reached similar 
peak titers as WT M2 N31S (Figure 6).  Even drastic mutations to a completely conserved region 
had no apparent affect on virus replication in vitro and further demonstrated that the first nine 
amino acids are not essential for M2 function in this assay.   
 The ability of M2 to tolerate mutations in a conserved region suggests that there is another 
explanation for the conservation of the M2e.  Differential splicing of the M segment results in M1 
and M2 sharing its first 8 amino acids [2, 29].  Thus any mutations to M2 in the virus would also 
affect M1 which could result in deleterious mutations. However, by complementing M2 null 
viruses in trans, we were able to circumvent mutating M1 and solely look at the function of these 
residues in M2.  Since there was no defect in growth kinetics when M2 was mutated, this region 
may be completely conserved because of a function in M1.  It would be interesting to take this 
same approach and determine if cell lines expressing M1 mutations in this region would be able 
to complement functionally null M1 viruses.  Another approach would be to make the mutations 
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of the first 8 amino acids in the virus itself.  This has not been done because it would not be 
possible to determine if a mutant phenotype was due to the mutation in M1 or in M2.  Since this 
study has demonstrated that mutating the first 8 amino acids in M2 has no effect on viral 
replication, any phenotype seen in the virus would be due to the mutations in M1. 
 It is also possible that the mutations made in the M2e could have an effect on viral replication 
and virulence in vivo.  Several mutations in the M2 protein have been described that exhibited 
little to no phenotype when investigated in vitro but demonstrated decreased virulence in vivo 
[16, 30, 31].  It would be interesting to make the M2e mutations in viable virus in order to assess 
the effect on replication in an animal model.   
 Due to its high conservation, the M2e is an attractive universal IAV vaccine target.  Although 
monoclonal antibodies raised against M2e are not neutralizing, they are capable of protecting 
animals from morbidity and mortality [19, 32].  However, natural infection of humans results in 
no significant M2 antibody responses [11, 22, 33].  It is possible that this region has maintained 
its conservation because of the lack of immune pressure that would result in escape mutants.  This 
brings up an interesting dilemma of whether a universal vaccine based on antibodies to the M2e 
would be effective or result in the selection of M2e escape mutants.  Virus grown in the presence 
of M2e monoclonal antibodies in a mouse model resulted in escape mutants in 65% of the 
animals [34].  However, the diversity of these escape mutants was extremely restricted and only 
resulted in two mutations: P10H and P10L.  There still remains the possibility that a polyclonal 
M2 antibody presence in the population would result in more diverse M2 escape mutant viruses. 
 Our results contrast with a study by Park et al., who demonstrated a role for the M2e in 
incorporation of M2 into virus particles [13].  In that study, chimeric mutants of M2 and Sendai 
virus F protein were made where the corresponding extracellular (499 amino acids), 
transmembrane (24 amino acids) and cytoplasmic (42 amino acids) domains were swapped.  
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Virions were then tested to see if any Sendai virus F protein in the chimeras was incorporated into 
influenza virions.  Of the chimeras, only three expressed at the cell surface and of these three, 
only one was incorporated into virus particles.  This incorporated mutant expressed the 
extracellular domain from M2 and the remainder from Sendai virus F protein.  The other two 
mutants that expressed at the cell surface contained the extracellular domain of the F protein and 
were not incorporated, suggesting a role for the ectodomain in M2 incorporation.  We took a 
more thorough approach to the role of the M2e and made stable cell lines expressing scanning 
alanine mutations of the M2e, all of which were capable of complementing M2 null viruses.  
Since low MOI growth curves were used to characterize these cell lines, this data not only 
suggests that the M2e does not affect M2 function but that it also does not affect M2 
incorporation since M2 is essential to virus replication. The discrepancy between these two 
studies may be due to the different scientific approaches taken and the relative size of the F 
protein domains trying to be incorporated.  Influenza M2 is comprised of a 24 amino acid 
extracellular, 19 amino acid transmembrane and 54 amino acid cytoplasmic domain.  Although 
the transmembrane and cytoplasmic domain between the M2 protein and Sendai virus F protein 
are similar in size, the extracellular domains are not.  It is possible that the virus was unable to 
incorporate a chimeric protein containing a 499 amino acid extracellular domain which is over 
20x the size of the M2e.  This would result in data suggesting that the M2e was important for 
incorporation of the M2 protein into virion particles.  However it is also possible that the triple 
alanine substitution mutations were not sufficient to cause disruption in M2 function.  Perhaps 
more drastic mutations are required for there to be an affect although the M2e was shown to be 
dispensable for ion channel activity [35]. 
 The M2Stop viruses create a functionally M2-null virus, however they express a truncated 
version of M2 that only consists of the ectodomain.  It is possible that this WT ectodomain is 
capable of complementing M2e mutants, masking any replication defect associated with the 
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mutations.  As WT MDCK cells do not stably express the M2 protein, M2-null viruses would not 
be expected to replicate.  Such complementation is most commonly associated with the lac 
operon where inactive N-terminal mutant β-galactosidase can return to its active state in the 
presence of a WT N-terminal fragment of the protein [36]. Analysis of MDCK cells infected with 
M2Stop viruses have not revealed any small protein fragments that react with 14C2. However if 
the 24 amino acid ectodomain was still being expressed by M2Stop viruses within cells, it would 
be hard to detect on a western blot due to its small size.  The ability of the WT M2e expressed 
from M2Stop viruses to complement mutant M2e remains a concern and this data can only be 
confirmed by mutation of the 24 amino acid ectodomain within the virus itself.   
 The transcomplementation assay utilized in this study does not demonstrate a requirement of 
the M2e for M2 function in the viral life cycle, as assessed by virus replication kinetics.  
Alternative explanations for the high conservation of this region exist but remain to be 
investigated.  HA and NA proteins mutate readily due to immune pressure and thus are poorly 
conserved.  Natural infection with IAV does not induce high titer antibodies to M2 and it is 
possible that its high conservation is due to the lack of immune pressure.  However, studies that 
have cultured IAV in the presence of M2e antibodies have shown a limited variety of escape 
mutants, suggesting a functional reasoning for the conserved sequence.  The NH2-terminal 
overlap of the M2e to the M1 proteins would suggest a reason for the first eight amino acids to be 
highly conserved, but the role of first eight amino acids of the M1 N terminus still remains to be 
determined. The overlap with M1 also does not explain the conservation of the rest of the 
extracellular domain, which this work showed could be mutated without compromising the core 








Table 1: Sequences of WSN M2 extracellular domain and alanine substitution 
mutants 
Sequence and antibody reactivity of wild-type M2e and mutants.  Flag tags are located at the M2 
C terminus (sequence not shown) and mutations are highlighted in yellow.  14C2 and TCN-031 













Figure 1: Conservation of the M2e amino acid sequence.  
Conservation of the M2e amino acid sequence, from residue 2 to 24, was compiled from all 
influenza A virus strains.  The percent M2e conservation was plotted against the consensus 
human M2e amino acid sequence on the x axis. Epitope regions were mapped for the M2 
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Figure 2: Analysis of clonal expression levels of the M2 protein in stable MDCK cell 
lines.  
The clonal expression levels and number of cells expressing M2 at the cell surface were analyzed 
using monoclonal M2 antibodies (A) 14C2, and (B) TCN-031.  (C) Expression levels of cell lines 
with an M2 C-terminal flag tag were permeabilized and detected using an anti-flag antibody.  
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Figure 3: Mutating the M2e does not affect the ability to complement a M2-null 
virus via a TCID50 assay.  
Titers of rWSN M2Stop (A and C) and rUdorn M2Stop (B and D) were determined for each 
indicated cell line by TCID50 assay.  The mean and standard error of the mean are graphed from 
three independent experiments. Total infectious virus production was analyzed by one-way 
ANOVA using Prism 4.0.  Statistical differences between M2 expressing cell lines and no M2 are 
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Figure 4: Mutation of the M2e does not affect complementation growth kinetics of 







MDCK cells expressing the indicated M2 protein were infected at a low MOI of 0.001 with either 
rWSN M2Stop (A, C, E and G) or rUdorn M2Stop (B, D, F and H) to determine the effect of the 
M2e mutations on growth kinetics of homologous (rWSN) and heterologous (rUdorn) viruses.  
The amount of infectious virus at each time point was determined by a TCID50 assay on WSN 
N31S M2 cells.  The mean and standard error of the mean of triplicate samples are graphed from 




























Figure 5: Expression and cell surface localization of 2-9 Ala and 2-9 Del Flag.  
(A) Transfection of 293T cells with pCAGG empty vector (left column), pCAGG WSN M2 
N31S (second column), pCAGG 2-9 Ala Flag (third column) and pCAGG 2-9 Del Flag (right 
column) plasmids.  Cells were stained with anti-flag (first row) to detect M2 tagged constructs, 










row) images.  Colocalization was determined from 10 non-overlapping images taken with an 
epifluorescence microscope.  One representative image is shown with colocalization indicated by 
white arrows.  (B) Clonal expression levels of M2 in stable MDCK cell lines expressing 2-9 Ala 
Flag and 2-9 Del Flag were determined by flow cytometry.  Cells were permeabilized and stained 






















Figure 6: Mutation of the highly conserved first nine amino acids of M2e does not 
affect complementation or growth kinetics of M2 stop viruses as compared to WSN 
M2 N31S.  
The TCID50 for rWSN M2Stop (A) and rUdorn M2Stop (B) were determined for 2-9 Ala Flag 
and 2-9 Del Flag. The mean and standard error of the mean are graphed from three independent 






4.0.  Statistical differences between M2 expressing cell lines and no M2 are indicated.  * p<0.05 
MDCK cells expressing the indicated M2 protein were infected at a low MOI of 0.001 with either 
rWSN M2Stop (C and E) or rUdorn M2Stop (D and F) to determine the effect of the M2e 
mutations on growth kinetics of homologous (rWSN) and heterologous (rUdorn) viruses.  The 
amount of infectious virus at each time point was determined by a TCID50 assay on WSN N31S 
M2 cells.  The mean and standard error of the mean of triplicate samples are graphed from a 
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Introduction 
Oral delivery of immunogens to the gut is regarded as the “Holy Grail” for vaccinologists 
[1]. The intestine is the largest lymphoid organ and gut-associated immune cells represent up to 
90% of immunocompetent cells [2]. Oral immunization offers immunological and logistical 
advantages including stimulation of mucosal immune responses preferentially at the site of entry 
for many infectious agents and ability to elicit strong systemic immunity.  This immunization 
route is cost effective and offers improved patient compliance due to the ease of vaccine 
administration, freedom from needles and from the requirement for trained medical personnel. All 
three oral vaccines licensed for use in the US [3] contain live virus.  Live-virus vaccines add to 
the inherent advantages of oral immunization the ability to immunize with small (and hence less 
expensive) doses, and induction of a breadth of immune responses similar to those induced by 
natural infection. These characteristics would facilitate routine immunization and response to 
epidemics or pandemics [4] and make live oral vaccine immunization attractive in resource-poor 
regions, where economy and logistical tractability are critically important. 
Licensed oral adenovirus (Ad) serotype 4 and 7 vaccines provide a model for use of live 
recombinant adenoviruses (rAds) for oral immunization.  Since the 1970’s, live oral Ad vaccines 
have been used by the United States military to prevent acute respiratory disease caused by Ad4 
and 7 [5].  These vaccines contain lyophilized live, wild type (WT) virus incorporated into enteric 
tablets that protect the virus against the low pH of the stomach.  After oral administration of the 
tablets, live virus is released into the intestine where asymptomatic replication occurs. In a single 
dose, the vaccines generate an immune response that was over 95% effective in preventing Ad4- 
and Ad7-induced respiratory illness in a clinical trial involving more than 40,000 soldiers [6-9].  
The historical success of Ad military vaccines suggests great potential for recombinant vaccines 
using the oral replicating Ad platform.  
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rAds have been used to deliver vaccine antigens in over 90 pre-clinical and clinical trials 
[10, 11].  The rationales for use of rAd vaccines include genome stability and ease of 
manipulation, natural tropism for mucosal inductive sites including the gut and upper respiratory 
tract and ability to elicit vigorous humoral and cellular immune responses.  rAds infect a broad 
spectrum of cells, including dendritic cells, allowing for efficient antigen presentation and can 
therefore also prime a robust cell-mediated response [12, 13].  Most rAd vaccine candidates are 
replication defective and not intended for oral administration.  Here, we review work on 
replicating rAd vaccines that may provide a route to effective oral immunization.  
Replicating rAd transgene vectors as vaccines   
Most current rAd vaccine candidates are transgene expression vectors, commonly 
engineered to express a foreign gene inserted into early region 1 (E1) or, occasionally, early 
region 4 (E4) of the genome [14]. E1 and E4 are essential for viral replication, and most such 
rAds are replication-defective. Extensive experience with defective recombinants in humans and 
animal models has shown promise in several cases [15].  
Replication-competent transgene vectors can be constructed by careful choice of the site 
of transgene insertion but relatively few have been extensively investigated.  Study of replicating 
rAd vaccines is complicated by the requirement for a host that supports viral replication if 
vaccines are to be evaluated under conditions that mimic its intended use in humans. Mice do not 
support human adenovirus replication.  However, golden hamsters, cotton rats, dogs, pigs, 
monkeys (see below), and chimpanzees all support replication of some human Ads, providing 
systems that might be exploited to test replicating vaccines [16-21].  Cotton rats and guinea pigs 
have found use in characterization of replicating oncolytic adenoviruses [16, 22], and dogs have 
been used in evaluation of live rAd vaccines [18].  In practice, however, well-developed 
immunological reagents, perceived similarity of primate and human immune responses, and 
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availability of suitable challenges to assess efficacy have restricted most studies of replication-
competent rAds in permissive hosts to primates (chimpanzees or monkeys), or to human 
volunteers. 
In early studies, replication-competent rAd7 and rAd4 expressing the hepatitis B virus 
surface antigen (HBsAg) were used to immunize (rAd7 HBsAg) and then boost (rAd4 HBsAg) 
two Ad4, Ad7-seronegative chimpanzees (rAd7/rAd4 HBsAg) by the oral route [20].  After 
primary vaccinations, both chimpanzees shed vaccine virus for 6-7 weeks and developed Ad7 
antibodies, suggesting successful Ad7 replication in the chimpanzee gut.  One developed transient 
seropositivity for HBsAg after the first inoculation; both developed modest titers after the second.  
A third chimpanzee immunized with WT Ad7 and then rAd4 HBsAg (WTAd7/rAd4 HBsAg) 
developed no HBsAg antibodies.  Both rAd7/rAd4 HBsAg chimpanzees were protected from 
acute clinical disease but were not protected from infection as evident by development of 
antibodies against the HBV core protein in response to HBV challenge.  The animal that did not 
seroconvert (WTAd7/rAd4 HBsAg), along with an unimmunized control, became clinically 
infected with HBV [20]. Three human volunteers in a small phase I vaccine trial immunized with 
the rAd7 HBsAg vaccine exhibited no adverse effects and shed virus between days 4 and 13 post 
vaccination with no evidence of person-to-person spread. Although all subjects had a significant 
increase in Ad7 antibodies, none made antibodies to HBsAg [23].  Protection from disease, if not 
infection, in chimpanzees, despite lack of seroconversion in humans, suggests potential value in 
using oral enteric vaccination with rAd to induce humoral immune responses to foreign 
pathogens. 
Most animal studies of replicating rAds have been conducted in macaques. WT Ad2 and 
Ad5 do not replicate in monkeys, and these experiments therefore require use of an Ad5 host 
range mutation (hr404), located in the 72k DNA binding protein, that permits replication in 
monkey cells and macaques [21, 24].  A transgene-type rAd5 hr404 (rAd5hr) virus expressing the 
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env and rev genes from SIV (Ad5hr-SIVenv/rev) was able to replicate in vivo in rhesus macaques 
[25]. Priming orally and intranasally, followed by intratracheal immunization 12 weeks later with 
Ad5hr-SIVenv/rev, generated proliferating T cells to env and strong serum neutralizing anti-env 
antibodies.  Mucosal secretions also contained env-specific IgG and IgA antibodies.  Although 
this vaccine did not induce sterilizing immunity, it conferred acute-phase protection following 
intravaginal challenge with SIV [25].  Partial protection of reboosted and rechallenged transiently 
viremic macaques was associated with both cellular and humoral immune responses [26].  To 
broaden rAd-induced immunity to SIV, additional rhesus macaques were immunized 
simultaneously with replicating constructs expressing SIV env, rev and gag through oral and 
intranasal administration [27].  Specific T-cell responses were generated against all SIV gene 
products and there was a persistent response to Gag evident for more than 10 weeks post-
immunization.  Interestingly, immunization primed CD8+ T cells for a persistent and potent 
response to both dominant and subdominant epitopes [27, 28].  Intrarectal challenge with SIV 
demonstrated that the vaccine did not induce sterile immunity but acute viral replication was 
suppressed.  Cellular immunity to SIV Gag and Env, along with nasal and vaginal env-specific 
IgG antibodies, correlated with a significant reduction of acute phase viremia [29].  Immunized 
groups exhibited significant protection, with 39% of macaques having either no viremia, cleared 
viremia or controlled viremia at the threshold of detection 40 weeks post-challenge.  
In these studies, only 35% of macaques exhibiting rAd shedding [27], suggesting that the 
protocol used, bicarbonate neutralization of the stomach prior to virus delivery, might not 
preserve rAd infectivity.  Use of enteric-coated capsules for virus administration resulted in 
shedding virus in stool samples of 100% of immunized macaques [30] emphasizing the 
importance of an optimal oral delivery method. 
Recently, phase I clinical trial data has been presented for a transgene-type replication-
competent rAd4 vaccine (rAd4-H5-Vtn) expressing influenza H5 hemagglutinin (HA) [31].  This 
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virus, which induced protective immune responses in a nonpermissive mouse model [32], 
contains an insertion of the H5 HA gene in place of part of E3. 166 healthy volunteers received 
vaccine dosages ranging from 107 to 1011 recombinant virus particles (VP) [31].  Each cohort 
received three rAd vaccinations orally and an intramuscular boost with inactivated H5N1 vaccine.  
Administration of the rAd was associated with significantly increased mild headache, abdominal 
pain, nasal congestion and diarrhea, and there was no confirmed transmission of the rAd4-H5-Vtn 
virus to household contacts. Pre-existing antibody to Ad4 was associated with a lower immune 
response to the vaccine, but this effect was overcome in the high-dose cohorts of 1010 and 1011 
VP. In mice, this recombinant elicits good humoral Ad4 and HA responses but a low cell-
mediated response [32].  In humans, the vaccine induced a significant level of Ad4 
seroconversion and HA-specific cellular immune responses in 70% of volunteers receiving 1011 
VP [31].  However, HA-specific antibody responses assessed by hemagglutination-inhibition 
(HAI) were minimal at all doses tested, with seroconversion in 4% to 19% of vaccinated 
volunteers.  Plasma IgA ELISA titers mirrored HAI, although IgG ELISA responses indicated 
50% seroconversion in the 1011 VP cohort. The H5 HA antigen is an intrinsically poor 
immunogen [33], however following boost of the inactivated H5N1 vaccine, 80% to 100% of 
volunteers seroconverted and 80% to 89% demonstrated antibody titers high enough to be 
considered protective in the 1010 and 1011 VP cohorts, respectively [31].  This indicates that 
although the Ad4-H5-Vtn vaccine can induce a cellular response, it is only capable of priming an 
HA-specific antibody response. The cellular immune response and replication of the vaccine as 
assessed by Ad4 seroconversion or PCR positive rectal swabs, primarily occurred after the first 
dose, suggesting that only one oral dose may be necessary to induce a cellular response and prime 
an antibody response. 
The doses required in this study to induce vector immune responses are 100-fold (or 
more) greater than that in the Ad4 vaccine (105 – 107 TCID50 [5]). rAd4-H5-Vtn lacks E3, which 
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functions in evading the host immune response [34] and may play an important role in the 
immunogenicity and safety of replicating rAd vaccines.  That possibility has not been 
experimentally addressed. 
Numerous clinical trials of replicating oncolytic rAds have been conducted.  In general, 
these studies do not include analyses of immune responses. Where Ad responses have been 
measured they are efficiently induced [35, 36], but there are no reports of responses to transgene 
products. 
Replicating capsid display rAds as vaccines 
Despite the efficacy of the oral Ad4 and Ad7 vaccines and efficient induction of 
antibodies against the vector, oral rAd vectors induce only modest antibody responses to 
transgene products in both replicating and non-replicating forms [20, 37] (Berg and Ketner, 
unpublished). However, a second rAd antigen expression method may offer a more potent 
approach to induction of humoral immunity.  In capsid-display recombinants, segments of foreign 
antigens are incorporated into one of the capsid proteins such that they are displayed on the 
surface of the virus particle. Capsid-incorporated antigens are available for binding by surface 
antibody on B cells and can be processed by the exogenous (MHC class II) pathway.  Thus, 
capsid display recombinants can be immunogenic without intracellular antigen expression, 
including in systems that do not support virus replication.  Replication in a permissive host would 
further allow persistent antigen presentation via both the exogenous and the endogenous (MHC 
class I) pathways, with the potential of inducing both humoral and cellular responses.  Capsid-
display vectors are extremely immunogenic in mice [38-40] and therefore may offer greater 
efficacy in inducing humoral responses in permissive systems than do transgene rAds.  
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Several capsid proteins can display foreign epitopes, including hexon, fiber, penton base 
and pIX (Table 1, Figure 1A, and below). Currently, immunogenicity data is available only in 
mice, and conclusions therefore have been drawn only in the absence of viral replication. 
Hexon (polypeptide II) The ~960 amino acid Ad hexon protein is the most abundant of the 
capsid proteins, present in 720 copies per particle [41]. Analysis of hexon amino acid sequences 
from different serotypes revealed 9 hypervariable regions (HVRs) that diverge in sequence and 
length among serotypes [42]. Crystal structures of Ad2 and Ad5 hexon show that HVRs reside in 
two loops that form the surface-exposed portion of hexon.  HVR 1-6 are located within the DEI 
loop and HVR 7-9 lie within the FGI loop (Figure 1 B and D) [42, 43]. These HVRs contain 
serotype-specific epitopes that are primary targets of neutralizing antibodies (nAb) [44].  
X-ray crystallography suggests that HVRs 2, 3, 5, 6 and 7 are unordered and protrude 
from the capsid surface. Ad5 virus containing insertions of His6 peptides with flanking spacers 
into those HVRs are viable, with normal virion thermostability and infectivity [45]. His6 in HVR2 
or 5 is capable of binding tightly to the His6 antibody, suggesting that the tag is exposed on the 
virion when incorporated into these regions [45]. Assessed with epitopes of increasing size, 
HVR5 was found to accommodate a maximum of 65 amino acids, while the maximum length 
accommodated in HVR2 was 33 amino acids [46]. While HVR1 of Ad5 has been shown to 
accommodate up to 24 amino acid insertions [47], the insertion of only 17 amino acids resulted in 
viable virus in Ad3 HVR1 [48]. Modifications in HVR1 or 5 reduced susceptibility to 
neutralization by preexisting immunity (PEI) to the Ad vector [38, 49].  Substituting all the HVR 
loops in Ad5 with those derived from Ad43, a serotype with a low seroprevalence in humans, 
produced a vector capable of escaping neutralization with anti-Ad5 sera from mouse, rabbit and 
humans [50] and which was still highly immunogenic in the presence of PEI to the WT virus.  
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  The first capsid display recombinants incorporated 8 amino acids of the poliovirus type 3 
VP1 capsid protein into regions now recognized as HVR1/2.  Antiserum raised against the rAd 
recognized the poliovirus epitope on the Ad virion and the poliovirus capsid itself [51]. Worgall 
et al. incorporated an immunodominant peptide from the outer membrane protein F (OprF) of 
Pseudomonas aeruginosa into HVR5 [40].  Immunization with this rAd induced IgG1 and IgG2a 
antibody subtypes, elicited epitope-specific CD4+ and CD8+ T cell responses, and was capable of 
protecting 60-80% of mice from a lethal pulmonary challenge with three different P. aeruginosa 
strains. Efficacy was increased with subsequent boosts [40, 52]. In contrast, a B-cell epitope from 
Bacillus anthracis protective antigen (PA), a subunit of the lethal toxin, incorporated into HVR5, 
induced non-neutralizing antibodies and failed to protect against a challenge with lethal toxin 
[53]. The discordant results from these studies may reflect differential antibody titers or differing 
properties of the selected epitopes.    
 Subsequently, Shiratsuchi et al., inserted a B cell epitope from the circumsporozoite 
protein (CSP) of the murine malaria parasite Plasmodium yoelii into hexon HVR1 or 5 in a 
recombinant that also expressed CSP as a transgene [38]. The HVR1 recombinant induced high 
titer antibodies even in mice pre-immunized with WT Ad, suggesting that alteration of HVR1 
allowed for evasion of neutralizing Ad antibodies. An rAd incorporating a B-cell epitope from P. 
falciparum CSP in HVR1 induced high-titer antibodies in mice that recognized parasites 
expressing the P. falciparum CSP and neutralized sporozoites bearing the P. falciparum CSP 
gene in vitro [47]. 
The location of epitopes inserted in hexon is an important determinant of immunological 
properties [46].  rAds that displayed an epitope from the VP1 capsid protein of Enterovirus 71, in 
HVRs 1, 2, or 7 were viable and protected neonatal mice from lethal challenge through passive 
immunization and maternally-acquired antibodies [54]. However, antibody isotype depended on 
the location of the epitope insertion: insertions into HVR1 induced mostly IgG2a antibodies 
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(Th1) while an HVR7 insertion predominantly produced IgG1 antibodies (Th2), demonstrating 
that insertion sites on hexon are not immunologically equivalent [54].  Similarly, of insertion of 
the conserved extracellular domain of matrix protein 2 (M2e) of influenza A virus into variable 
region 1 (VR1) or VR4 of hexon of the chimpanzee-origin adenovirus SAd-V25 (AdC68), only 
the VR1 recombinant provided partial protection from a lethal influenza challenge [55]. Capsid 
display recombinants induced more robust responses than a transgene type recombinant 
expressing an M2e fusion protein, supporting the hypothesis that antibody responses are best 
induced by antigen displayed in a repetitive and structured fashion to allow for cross-linkage of 
the B cell receptors [56].  
Recent studies of rAds with modifications in two hexon HVRs have demonstrated the 
potential for single recombinants to elicit simultaneous antibody responses against two distinct 
epitopes [57].   ‘Multivalent’ capsid display recombinants offer potential for broadening immune 
responses or inducing responses to genetically variable pathogens.  However, recombinants with 
different combinations of modified HVRs induced strikingly different responses, indicating that 
the design of effective multivalent hexon-modified rAds may not be straightforward [57]. While 
Gu et al [57] utilized multiple HVRs to insert epitopes, Zhong et al attempted to incorporate 
multiple epitopes into a single HVR [48] and found that antiserum was raised against a 
combination of the epitope and not against the individual epitopes themselves.  Thus, replacement 
of several HVRs is a more promising alternative to a polyvalent insertion to generate multivalent 
vaccine vectors. 
Penton base (polypeptide III) The penton base and fiber form the penton complex present at the 
12 vertices of the capsid (Figure 1A). Each penton base monomer (~570 residues) contains an 
Arg-Gly-Asp (RGD) integrin-binding motif located within a flexible loop at the capsid surface 
[58].  An influenza A virus HA epitope inserted into the RGD loop of penton base was accessible 
to anti-HA antibodies, confirming surface location [59].  However, anti-HA antibodies were not 
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detected in mice immunized with a penton base recombinant containing HA inserted into the 
RGD loop [59].  The insertion decreased infectivity for DC’s, potentially by interfering with 
integrin binding, which is involved in virion internalization.  
 Fiber (polypeptide IV) Fibers are homotrimers of the fiber protein (polypeptide IV) that 
protrude from the 12 vertices of the Ad virion and are responsible for attachment to the host cell 
(Figure 1A). The fiber protein has 3 domains: an N-terminal domain that attaches to the penton 
base, a central shaft with repeating motifs, and a C-terminal globular knob responsible for virus 
attachment to the host cell (Figure 1E). Ad5 fiber contains 582 amino acids and is 35-40 nM in 
length, but fiber length varies among serotypes due to differing numbers of repeats in the fiber 
shaft. 
 The crystal structure of the fiber knob reveals that the HI loop (Figure 1C and 1E) does 
not contribute to intramolecular interactions within the knob, consists mostly of hydrophilic 
amino acid residues, is exposed on the surface of the knob and is not involved in the formation of 
cell-binding sites [60]. A FLAG epitope inserted into the HI loop was also accessible to anti-
FLAG antibodies, confirming that the HI loop is exposed [61].  Therefore, the HI loop is seen as 
particularly suitable for manipulation and most modifications initially were made at this location 
[59, 62]. More recently, a series of rAds with insertions of the P. aeruginosa OprF Epi8 epitope 
in fiber loops CD, DE, FG, HI and at the C terminus [63] have been examined for effects of 
insertions on viral growth in vitro and for immunogenicity. Incorporation of Epi8 into the FG and 
HI loops had little effect on viral growth whereas insertion into the CD and DE loops or at the C 
terminus strongly reduced infectivity.  FG and HI loop insertions also elicited the strongest 
humoral and cell-mediated immune responses and were partially protective against challenge 
[63].  
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Fiber is a target for neutralizing antibodies and substitutions can contribute to evasion of 
PEI.  For example, modification of the HI loop circumvented nAb present in ascites fluid from 
ovarian cancer patients [64]. Consistent with this, FG and HI loop recombinants were more 
effective at inducing antibody and protection in the presence of PEI than was a transgene-type 
recombinant expressing all of OprF [63]. The ability to manipulate fiber at multiple sites to allow 
for the efficacy in the presence of PEI makes fiber insertions a promising modification for capsid-
display vaccines.   
Fiber modifications intended to redirect or ablate virus binding to specific cellular 
receptors have also been explored [40, 65-67]. However, immunogenicity generally is not 
addressed in those studies. 
pIX (polypeptide IX) pIX (approximately 140 amino acids) is present in about 240 copies per 
virion.  Trimers of pIX contribute to stability of the virus particle [68, 69]. The C-terminus of pIX 
is exposed on the surface of the virion and has been used as a substrate on which to attach large 
polypeptides including fluorescent proteins, fully functional enzymes and foreign antigens in 
viable rAds [70-74]. pIX fusions containing the envelope protein gp70 of the Friend murine 
leukemia virus (FV) [74] and the Yersinia pestis V and F1 capsular antigens [39] induced high-
titer antibodies.  The ability of pIX to accommodate very large proteins makes it an attractive site 
for display of conformational epitopes. 
Comparative immunogenicity. The immunogenicity of influenza A virus HA epitopes inserted 
into various Ad capsid proteins has been compared [59]. Insertion sites included hexon HVR5, 
the RGD loop of penton base, the HI loop of the fiber knob and the C terminus of pIX. All HA 
insertions were located on the virion surface, however, an anti-HA antibody demonstrated 
strongest binding to HA incorporated into hexon.  Infection of A549 cells and DCs showed that 
HA incorporation into hexon interferes minimally with virus entry in vitro, whereas incorporation 
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into fiber knob, pIX and penton base partially reduced the intracellular Ad genome copy numbers 
following infection. The humoral immune response was strongest against the hexon insertion 
when immunizing with the same number of particles but fiber was the most immunogenic when 
controlling for the number of HA copies per virion [59]. A comparison of an ovalbumin (OVA) 
epitope inserted into the fiber HI loop or hexon HVR5 indicated that fiber insertions were better 
detected in native virions and triggered a more dramatic increase in anti-OVA antibody responses 
upon re-administration [62]. 
Pre-existing Immunity and replicating rAds. Antibodies to many Ad serotypes are prevalent in 
the human population.  PEI to the vaccine serotype can interfere with a robust immune response 
against the foreign antigen even in non-replicating rAds [20, 75], although mucosally 
administered replication-defective rAd vaccines have elicited transgene-specific antibodies 
despite the presence of PEI, and homologous serotype boosts can be effective [29, 37, 76].  
Importantly, if capable of suppressing the growth of viable rAds, PEI might mitigate the inherent 
advantage of vaccine vector replication after administration of a low dose [77], and live rAds thus 
may be more sensitive to PEI than their defective counterparts. PEI can be addressed by use of 
uncommon human adenovirus serotypes or viruses from other species [37, 78, 79]  as vectors. 
Additionally, as noted above, modifications to both hexon and fiber have been shown to reduce 
susceptibility to PEI [38, 49, 50] and properly-designed capsid display rAds therefore may be 
inherently resistant to PEI.  Limited experience with replicating rAds has provided no data on the 
effects of PEI and this topic must be addressed. 
Safety of replicating rAds. Concerns have been expressed over the safety of replicating vaccines 
due to the possibility of inducing disease in the immunocompromised and to the possibility of 
unintentional spread to contacts.  Systemic adenovirus infections can be fatal in people who are 
profoundly immunocompromised, for example, in the course of bone marrow transplantation [80, 
81].  Further, Ad is commonly present in AIDS-related deaths, although it is not generally 
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believed that it was the cause [82, 83].  Clearly, live rAds cannot be administered to the severely 
immunodeficient.  However, unwitting administration of the military vaccine to a small number 
of recruits with early HIV infection produced no observed ill effects, nor did the concurrent HIV 
infection prolong shedding, suggesting a small margin of safety in that population [84].  
Transmission of the oral military Ad vaccine did occur, but required intimate contact, as it was 
not observed among recruits in the barracks [85, 86], and no confirmed transmission of the rAd4-
H5-Vtn virus to contacts in its recent clinical trial [31]. Thus, the hazard associated with live 
vaccines may not be insurmountable, although this aspect of use of live vaccines, rAd or others, 
must be carefully investigated. 
Conclusion 
 Replication-competent transgene or capsid display rAds delivered orally to the gut 
mucosa offer an unconventional immunization approach.  Transgene rAds have been shown to 
induce a robust cellular-mediated immune response, and capsid-display rAds promise to induce 
strong humoral responses.  Critically, transgene and capsid display designs possess 
complementary immunological characteristics and can be combined in single rAds [38], and such 
hybrid rAds offer a potential route to greater potency than either approach alone. Multiple-antigen 
hybrid rAds, in particular, may be capable of increasing the breadth of immune responses to 
pathogens with a high mutation rate, such as influenza A, or a complex biology, such as malaria.  
Continued innovation in vaccine research is critical in order to control diseases such as HIV, 
influenza and malaria that have proven resistant to conventional immunization strategies, and 
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a non-human adenovirus serotype with only 5 variable regions 
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Figure 1: Adenovirus capsid structure  
(A) Cartoon diagram of an adenovirus particle depicting capsid proteins and DNA. (B) Surface 
model of the trimeric Ad5 hexon protein showing the HVR regions.  The amino acid location of 







HVR3 (211-218), green: HVR4 (247-260), purple: HVR5 (267-282), brown HVR6 (304-315), 
orange: HVR7 (418-428), pink: HVR8 (435-436), cyan: HVR9 (440-451). Produced using 
program PYMOL and PDB 3IYN [95]. (C) Surface model of the trimeric Ad2 penton knob and 
shaft.  Red: FG loop (488-515), blue: HI loop (537-549), green: IJ loop (558-572). Produced 
using program PYMOL and PDB 1QIU [96]. (D) Map of the Ad5 hexon protein with labeled 
HVRs. (E) Map of the fiber protein with labeled ß-strands in black boxes and FG, HI and IJ loops 
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Construction and characterization of capsid-display recombinant 
adenoviruses expressing the highly conserved M2 extracellular domain 













Influenza vaccines are critical for reducing morbidity and mortality associated with 
annual influenza epidemics.  These vaccines protect primarily by inducing neutralizing antibodies 
targeting the hemagglutinin (HA) and neuraminidase (NA) proteins. Current influenza vaccines 
provide good protection from infection with antigenically matched virus strains but provide 
limited protection when circulating virus strains undergo either antigenic shift or drift [1]. The 
extracellular domain of the M2 protein has been proposed as a potential universal vaccine target 
due to its conserved nature and the ability of antibodies that recognize this domain to protect 
animals from influenza A virus (IAV) infection [2,3]. More recently, a highly conserved epitope 
of the HA protein located in the HA2 alpha helix (HA2A) has also been proposed as a universal 
target [4,5].  To further investigate M2 ectodomain (M2e) and HA2 based IAV vaccines, various 
M2e and two HA2A sequences were inserted into hypervariable regions (HVR) of the hexon 
capsid protein of recombinant adenovirus serotype 5 (rAd5) to display these epitopes on the 
surface of the virion.  While immunized mice had a robust immune response against the rAd 
vector, antibodies against M2e or HA2A were undetectable by western blot and flow cytometry.  
We hypothesize that the instability of the M2e insertion into hexon prevented effective 









Influenza A virus (IAV) infections remain a major threat to public health and are 
responsible for approximately 500,000 deaths worldwide per year [1].  Vaccination is the most 
effective means of controlling morbidity and mortality associated with annual influenza 
epidemics.  Current influenza vaccines provide protection primarily by inducing neutralizing 
antibodies to hemagglutinin (HA).  However, an important limitation of current vaccines is that 
the major vaccine target is an antigenic region of the head of the HA protein and this gene is 
susceptible to continuous mutation.  The high mutation rate allows for the selection of mutants in 
the human population and leads to antigenic drift [2].  Novel pandemic strains arise when a 
reassortment of genes occurs between animal and human influenza viruses leading to antigenic 
shift.  Current influenza vaccines provide good protection from infection with antigenically 
matched virus strains but are limited in protecting against antigenic drift or shift viruses [2].  The 
emergence of the 2009 pandemic H1N1 is a prime example of the generation of a new strain of 
virus that was capable of replicating in a largely naïve population since the seasonal vaccine 
provided little to no protection [3].  Due to the presence of antigenic shift and drift viruses, 
seasonal vaccine formulations need to be evaluated on a yearly basis to match the predicted 
circulating strain in the upcoming influenza season.  The development of a vaccine that can 
confer cross-protection against multiple influenza variants would eliminate a significant 
morbidity and mortality associated with seasonal influenza and provide more protection against 
pandemics. 
The influenza A M2 protein is a minor integral membrane protein with a highly 
conserved 24 amino acid extracellular domain (M2e).  It is translated from a spliced mRNA 
segment derived from RNA segment 7 [4].  Few M2 proteins are incorporated into virus particles 
but the protein is expressed at high levels on the infected cell surface and can serve as an 
antigenic target to the immune system [5].  Humoral immunity against M2 in a natural infection 
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is very weak compared to immunity against HA and NA but unlike HA and NA, there is no 
observed antigenic shift or drift to the M2 protein [6, 7].  Although antibodies to M2 are non-
neutralizing, they are capable of protecting animals from morbidity and mortality in vivo [8-11].   
Most HA antibodies are generated against the antigenically diverse head. However, 
several publications have identified HA epitopes that are conserved across multiple antigenic 
subtypes of HA [12-22].  Influenza A viruses can be grouped into two groups based upon their 
HA structure: group 1 contains H1 and H5, and group 2 contains H3 [23, 24]. The majority of 
IAV exhibit high degree of sequence conservation for the HA2A within a group however, there is 
significant sequence divergence between groups.  Antibodies that recognize these conserved 
epitopes were capable of protecting mice from IAV infection with multiple HA subtypes of one 
group but not across groups [13, 15]. The primary interaction of these antibodies were localized 
to the alpha helix region located on the HA2 subunit (HA2A) [13, 25] and were protective by 
preventing the low pH induced structural changes in HA that is associated with viral-cell 
membrane fusion [25].     
Historically, live adenovirus types 4 and 7 (Ad4 and Ad7) have been used for nearly three 
decades to safely protect US military personnel from serious respiratory disease.  These vaccines 
are orally administered enteric-coated tablets containing approximately 105 TCID50 of lyophilized 
virus which subsequently asymptomatically replicates in the gut [26].  This replication induces 
both humoral and cell-mediated immune responses which protect against greater than 90% of 
subsequent Ad4- and Ad7-mediated symptomatic infections [27-30]. The innate properties of Ad 
that makes it such an effective vaccine can be utilized in a vaccine vector.  The advantages of an 
Ad vector includes: natural induction of a robust cellular and humoral immune response, potent 
transient protein expression, efficient delivery of antigen to antigen presenting cells and easy 
scalable manufacturing in stable cell lines [31].  For these reasons, recombinant adenoviruses 
(rAd) have been used as vectors for gene therapy and for vaccination in studies using both 
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animals and humans [32].  Traditional rAd vectors express entire or large portions of a foreign 
epitope as a transgene, inserted into either early region 1 (E1), early region 3 (E3) or early region 
4 (E4) of the genome [33].  However, with the exception of E3-modified vectors, most transgene 
expression vectors are replication-incompetent and are only capable of inducing an immune 
response after infection of cells by virus particles in the inoculum to produce and present antigen 
intracellularly.  A second rAd antigen expression method exists in which shorter segments of 
foreign antigens are incorporated into one of the capsid proteins such that they are displayed on 
the surface of the virus particle.  These capsid-display vectors are replication-competent and 
potently immunogenic.  By displaying epitopes on the capsid surface, strong humoral and cell 
mediated responses similar to those against Ad capsid proteins can be elicited via the exogenous 
pathway.  It has been demonstrated that these vectors can be extremely immunogenic in mice and 
may offer greater efficacy in inducing humoral responses in permissive systems [34-37].   
Since antibodies against M2e and HA2 have been shown to protect against influenza, 
replication-competent rAds were constructed that display various M2e and both group 1 and 
group 2 HA2A sequences in either hypervariable region (HVR) 1 or 5 of hexon. Surprisingly, 
despite high Ad antibody titers, recombinants that display M2e or HA2A did not induce antibody 
against either influenza epitope in mice. Possible explanations include virion instability, or an 








Materials and methods 
M2e and HA2A sequences 
 All influenza A M2e and HA2A protein sequences were obtained from the NCBI 
Influenza Virus Sequence Database [38].  Sequences were aligned using ClustalW 2.0.10 [39].  
The percent conservation of all IAV M2 and HA2A sequences encoding the consensus M2e or 
HA2A residue at each amino acid position was determined using WebLogo [40].  M2e sequences 
were derived from the following strains: A/WSN/33 [H1N1], A/California/4/2009, 
A/Swine/Best/96 [H1N1], A/Vietnam/1196/04.  HA2A sequences were taken from these strains 
to represent group 1 and group 2 consensus sequences: A/WSN/33 and A/HK/1/68, respectively 
Construction of recombinants 
Insertions and substitutions in hypervariable region 1 (HVR1) and hypervariable region 5 
(HVR5) of hexon were made by overlap extension PCR using the mutagenesis primers listed in 
Table 2 and pJMG, a plasmid containing an intact wild-type (WT) adenovirus type 5 (Ad5) hexon 
gene [37], as a template.  The three-step reaction involved an initial amplification of two different 
products.  One was generated by using a universal left primer and a mutagenesis right primer 
containing M2e or HA2A sequences in the modified tail while the other product used a universal 
right primer and a mutagenesis left primer containing M2e or HA2A sequences in the tail.  These 
products were purified using 1% agarose (Becton-Dickenson) and the two products were 
combined to generate an overlap PCR product using the universal left and right primers. The final 
PCR products, about 1.6kb in length, were cloned into pJMG, using ApaI and SacI sites present in 
the viral portions of the overlap product. WSN M2e insertions contained a novel BamH1 
restriction site for screening of pJMG colonies. Other recombinants did not contain a novel 
restriction site and were screened for correct PCR product size using Ad5F and HVR1 R or 




Human embryonic kidney (293) cells were cultured in Essential Minimum Eagle Medium 
(EMEM; Lonza) containing 10% fetal bovine serum (FBS; Gibco), 100 U/mL penicillin, 100 
µg/mL streptomycin (Gibco) and 2mM L-Glutamine (Gibco) at 37°C and 5% CO2.  Madin-Darby 
canine kidney (MDCK) cells were cultured in Dulbecco’s modified Eagle medium (DMEM; 
Sigma) containing 10% FBS (Atlanta Biologicals), 100 U/mL penicillin (Invitrogen), 100 µg/mL 
streptomycin (Invitrogen), 1mM sodium pyruvate (Sigma) and 2mM Glutamax (Invitrogen) at 
37°C and 5% CO2. MDCK cells stably expressing WSN M2 were cultured in identical media as 
WT MDCK cells supplemented with puromycin (7.5 µg/mL; Sigma) and amantadine HCl (5 µM; 
Sigma). 
Calcium phosphate transfection and recombination 
Modified hexon fragments were incorporated into intact viral DNA by recombination in 
CaPO4-mediated transfected HEK 293 tissue culture cells [41].  pJMG plasmid DNA containing 
hexon modifications was digested with PmeI and BamHI and purified by ethanol precipitation.  
Parental viral DNA from NVDP404 (IIg) [37], an Ad5 virus containing a Plasmodium falciparum 
circumsporozoite (CSP) epitope insertion in HVR1, was digested with NdeI overnight.  An 
aliquot of cut and uncut viral DNA was further digested with EcoR5 to verify complete NdeI-
digestion. NVDP404 DNA digested with NdeI was precipitated with ethanol.  Digested plasmid 
(2-5µg) and viral DNA (2-5µg) was supplemented with salmon sperm DNA (10-16µg) for a total 
of 20µg of DNA and added to Hepes-buffered saline pH 7.5 (HBS) [42] for a final volume of 
950µL.  50µL of 2.5M CaCl2 was rapidly added to the DNA/HBS mixture and incubated for 20-
30 minutes before being added drop wise to two plates of HEK293 cells.  Media was replaced 
five hours later with fresh EMEM and cells were maintained in culture until approximately 50% 
of cells showed cytopathic effects (CPE).  Whole cell lysates were collected and analyzed by 
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western blot for recombination followed by three cycles of freeze/thaw to release cell-associated 
virus.  Viruses were declumped by the addition of NP40 or IPEGAL (Sigma) for a final 
concentration of 0.05% and 1/10 volume of 1,1,2-Tichlorotrifluoroethane (Sigma).  The organic 
mixture was mixed vigorously for 2 minutes and spun at 2500-5000 RPM for five minutes for 
phase separation.  Supernatant containing declumped viruses were used for plaque purification on 
HEK 293 cells.  Plaque-picked viruses were screened for purity and insertion of the antigen by 
western blot and sequencing.  Desired viruses were grown to high titer in 10-20 14cm tissue 
culture dishes of HEK 293 cells.  Upon showing CPE in 50% of the cells, whole cell lysates were 
collected and viruses were purified using CsCl. 
CsCl virus purification 
rAd infected cells were collected and centrifuged for 10 minutes at 6,000 rpm in a Sorvall 
GSA rotor.  Cell pellets were resuspended in 25 mL of supernatant per 200-400 mL of original 
culture.  HBS pH 7.4 (Gibco) was added to resuspended cells for a final concentration of 20mM.  
Concentrated cell suspensions were freeze-thawed three times or cell-associated virus was 
extracted using the declumping method described previously.  Freeze-thawing yielded in the 
highest plaque forming unit (pfu)/particle ratio while extraction using organic solvents resulted in 
the best particle yield.  The method for release of cell-associated virus depended on whether the 
virus was to be used for infections where a high pfu/particle ratio is desired or as an immunogen 
or for DNA extraction when yield is most important.  Large debris from the lysates were removed 
using a clinical centrifuge at 2,500 rpm for 5 minutes.  The supernatant was centrifuged again at 
15,000 rpm using a Sorvall SS34 or SA600 rotor for 10 minutes to remove more cell debris.  
Clarified lysate was layered over a discontinuous CsCl gradient containing 4 mL CsCl density 
1.25g/mL and 5mL CsCl density 1.70g/mL in a 35 mL centrifuge tube (Sorvall).  Gradients were 
centrifuged for 90 minutes at 17,000 rpm using the Sorvall SV288 vertical rotor.  The lowest and 
dominant band at the interface of the two CsCl solutions was collected drop-wise and centrifuged 
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in a continuous CsCl gradient of density 1.34g/mL for at least 16 hours at 35,000 rpm in a Sorvall 
TV865 rotor.  The dominant band was collected and recovered virus was dialyzed twice in 
500mL of storage solution containing 0.15M NaCl, 0.5mM Ca+2, 0.9mM Mg+2, 5% sucrose and 
20mM Hepes pH 7.4 at 4°C.  Particle number in gradient-purified virus preparations was 
determined from the A260 of SDS-disrupted particles using the formula A260 x dilution factor x 
1.1x1012 particles/mL [43].   
SDS-PAGE and western blots 
Infected cells were lysed in 1% SDS (Fisher Scientific) in PBS and lysates or purified 
virions were mixed 1:1 in 2x SDS-PAGE sample buffer [44].  Samples were resolved in a 10% 
poly acrylamide gel and either transferred to polyvinylidene difluoride membranes (PVDF-FL; 
Millipore) or used for Coomassie or silver stain (Bio-Rad) to view total protein.  For 
immunoblots, wash buffer contained PBS with 0.3% Tween 20 (Sigma) and the blocking buffer 
was wash buffer with 5% nonfat dry milk.  Membranes were blocked for 30 minutes at room 
temperature (RT), incubated for 2 hrs at RT with primary antibody, washed three times for 5 min 
each, incubated for 1 hr at RT with secondary antibody and washed four times 5 min each.  
Primary and secondary antibodies were diluted in blocking buffer.  Primary antibodies used were 
mouse anti-M2 14C2 monoclonal antibody (1:500 dilution), rabbit anti-late adenovirus late 
protein antisera (1:3000 dilution), mouse anti-CSP 2A10 antisera (1:3000) and V-314-511-157, a 
polyclonal goat anti-HA0 A/PR/8/34 antibody (1:500 dilution; National Institute of Allergy and 
Infectious Diseases). The Alexa Fluor 647-conjugated secondary antibodies used were a goat 
anti-mouse immunoglobulin (IgG) and a goat anti-rabbit IgG (all at a 1:500 dilution; Invitrogen).  
For visualization, membranes were scanned using an FLA-5000 phosphoimager (Fujifilm). 
Diagnostic PCR and sequencing of pure virus particles 
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All recombinant viruses to be used for PCR or for sequencing needed to undergo a 
proteinase K (Roche) treatment to disrupt the capsid in order to access the DNA [45].  Pure virus 
(~107 particles/mL) or plaque picks (50µL) were incubated with 5µg of proteinase K for 30 min 
at 37°C. Proteinase K was inactivated by a 20 min incubation at 95°C.  A portion of this treated 
sample was either sent away for sequencing or used for PCR. Recombinant viruses expressing 
HA2A were screened by diagnostic PCR using Ad5 F and either WSN HA2A R or HK68 HA2A 
R (Table 2) depending on the sample.  Products were run on an agarose gel and visualized with 
ethidium bromide staining.   
Plaque purification/assay 
Plaque assays were carried out by infecting confluent 60mm tissue culture petri dishes 
(Nunc) of 293 cells with the indicated declumped viruses serially diluted in medium.  Cells were 
infected with 1mL of diluted virus and incubated for 2 hrs at 37°C, occasionally rocking the 
dishes to distribute the inoculum evenly.  Inocula were aspirated and cells were overlaid with 
5mL of 0.9% Bacto-agar (Difco) and 2% FBS in MEM (Gibco) without phenol red, 100 U/mL 
penicillin and 100 µg/mL streptomycin (Gibco). After overlays had solidified, cells were 
incubated at 37°C and were fed with an additional 2.5mL of fresh agar medium every three days.  
On the sixth day, 2.5mL agar medium was added containing neutral red (Sigma) at a 1:40 dilution 
for visualization of plaques.  For plaque purification of viruses, individual plaques were picked 
using a glass Pasteur pipette and frozen in 0.5mL EMEM media to be analyzed at a later time.  
For plaque assay, plaques were counted until no new plaques arose.   
Mouse immunization and serum sample collection 
Inbred 4- to 8- week old female BALB/c mice (NCI) in groups of five or 10 were 
immunized subcutaneously three times at three week intervals with a fourth immunization 12 
weeks later in one experiment.  Mice were immunized with 1010 particles of human papilloma 
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virus (HPV) L2 recombinants (Q or 2.6.1), WSN M2e or WSN HA2A (Table 3).  For 
immunizations supplemented with adjuvant, 50 µg/mouse Alum (AlOH3) and 5 µg/mouse MPL 
were used.  Viruses were mixed with adjuvant overnight to ensure that adjuvants did not fall out 
of solution and mice were immunized as above.  Blood was collected in serum separator tubes 
(Microtainer) from each mouse by tail bleeds three weeks after each immunization and prior to 
the subsequent immunization.  Tubes were spun in a microcentrifuge (Denville Scientific) at 5000 
rpm for 10 min to separate the sera from cells and clotting factors.  Sera were collected and stored 
at -80°C in microcentrifuge tubes. 
Ad5 and L2 ELISA     
ELISA plates for Ad5 (Immulon 2HB; Thermo Scientific) and L2 (MaxiSorp; Thermo 
Scientific) were coated with either 1µg of Ad5 or 100ng of L2 protein per well in 100µL and 
incubated at 4°C overnight.  Ad5 plates were washed three times with PBS containing 0.1% 
Tween 20 (PBS-T) followed by three washes with PBS.  Both Ad5 and L2 plates were blocked 
with 1% BSA in PBS (PBS-BSA) for 1 hr at RT followed by dilutions of sera in PBS-BSA 
starting at 1:500 (five-fold serial dilutions) for Ad5 or at 1:50 (two-fold serial dilutions) for L2 for 
1 hr at RT.  Plates were washed as described previously and incubated with secondary 
horseradish peroxidase-conjugated anti-mouse IgG (1:5,000 dilution; GE Healthcare) or anti-
monkey Ig (1:1000 dilution, Nordic) at RT. Plates were washed a final time and developed for 15 
min with ABTS Peroxidase Substrate System (KPL).  The developing reaction was stopped with 
1% SDS and optical density at 405nm was measured using a Molecular Devices Emax microplate 
reader.  Experiments were performed in triplicate and the endpoint ELISA titer was determined as 
the highest dilution at which the optical density was two times greater than background (wells 
containing sera but no antigen).  Positive controls was human sera for Ad5 and RG-1, a 




Influenza virus infection  
Confluent MDCK cells grown in 6-well plates were washed twice with PBS with calcium 
and magnesium (PBS+; Invitrogen) to remove FBS.  MDCK cells were infected with rWSN, a 
recombinant virus of A/WSN/33 [47], at a multiplicity of infection (MOI) of 5 50% tissue culture 
infectious dose (TCID50) per cell in 250µL infection media (DMEM supplemented with 0.5% 
BSA, 100 U/mL penicillin, 100 µg/mL streptomycin, 1 mM sodium pyruvate, 2 mM Glutamax 
and 4 µg/mL N-acetyl trypsin (NAT; Sigma)) at RT with rocking for 1 hr.  Cells were then 
washed twice with PBS+ and incubated with 1 mL infection media at 37°C for 9 hrs.  Media was 
aspirated off, wells were washed two times with PBS and incubated at 37°C in 0.5 mL of 2x 
trypsin to remove cells.  Cells were then processed for use in western blotting or flow cytometry.     
Flow cytometry 
Cells were removed from the tissue culture plate by trypsinization and fixed by 2% 
paraformaldehyde (Sigma) in PBS for 15 min at RT.  Cells were spun down at 1200 rpm for 3 
min and washed 2x with PBS.  Samples were stored at 4°C in 1mL PBS overnight.  Cells were 
resuspended in blocking buffer containing 0.5% bovine serum albumin (BSA; Sigma) and 3% 
normal goat serum (NGS) in PBS for 45 min on ice, incubated for 1hr in primary antibody or 
mouse sera on ice, washed three times with PBS, incubated for 1 hr on ice in secondary antibody, 
washed three times with PBS and fixed with 2% paraformaldehyde for 15 min at RT.  Cells were 
washed twice with PBS and transferred to Falcon 5mL polystyrene round-bottom tubes (Becton-
Dickenson) for analysis.  All mouse sera, primary and secondary antibodies were diluted in 
blocking buffer.  Monoclonal primary antibody 14C2 and goat anti-mouse Alexa Fluor A647-
conjugated secondary were used at 1:500.  The cells were analyzed by flow cytometry (Becton 
Dickinson FACS Calibur) by using FlowJo software.   
Influenza challenge of Balb/c mice 
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 Ten 9 month old female Balb/c mice previously immunized 3x with either rAd WSN 
HA2A or 2.6.1 supplemented with Alum and MPL adjuvants were challenged.  Mice were 
anesthetized with 100 µL of a ketamine (100mg/kg of body weight) – xylazine (20mg/kg) 
cocktail administered via intraperitoneal injection.  Mice received a 20 µL intranasal inoculation 
of 10 LD50 of rWSN virus diluted in DMEM with penicillin-streptomycin and 2 µg/mL N-acetyl 
trypsin (Sigma).  1LD50 of rWSN was previously determined to be 5.8x103 PFU/mL [48].  
Animals were monitored for 16 days postinfection for morbidity and mortality. Mice were 
















Construction of rAd expressing conserved influenza A epitopes 
Current seasonal influenza vaccines and natural infection with influenza A viruses 
primarily induce antibodies to the immunodominant HA head and NA proteins.  However, due 
the selective pressure imposed by the immune system, these epitopes evolve rapidly, resulting in 
antigenic drift and the ability of different viral strains to evade the immune response.   Although 
these epitopes have high variability, there are other epitopes within HA and other IAV proteins 
that are much more conserved.  However antibodies are not raised readily raised against these 
epitopes by seasonal vaccines or natural infection.  These include the HA2A located in the stem 
of the HA molecule and the M2e which is expressed at high levels on the surface of infected cells 
(Figure 1).  Antibodies specific for either the M2e or HA2A epitopes have been shown to be 
protective in vivo albeit by different mechanisms.  HA2A antibodies are capable of neutralizing 
infection by preventing the low pH structural changes in HA necessary for viral fusion with the 
endosomal membrane [25]. Antibodies targeting the M2e, while not neutralizing, are capable of 
protecting mice from a lethal challenge in vivo, potentially by antibody-dependent cell 
cytotoxicity (ADCC) [8, 49].   
 While each of these epitopes are more conserved than the diverse antigenic HA head and 
NA proteins, there is still some variation between viral strains.  M2e is highly conserved within 
viruses from a particular animal species making this an attractive vaccine target for a ‘universal’ 
influenza vaccine (Figure 1A ).  However, it has been shown that monoclonal antibodies raised 
against human IAV M2e do not recognize the M2e of swine, avian and the 2009 H1N1 influenza 
viruses due to amino acid changes in the epitope region, which spans amino acid 6-15 (Figure 1A 
and 1B).  Monoclonal antibodies have been raised against the more highly conserved N-terminal 
region of the M2 protein [9], amino acids 1-8, and these were capable of recognizing M2e from 
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multiple animal species including an H5N1 and the 2009 pandemic H1N1 (pH1N1) (Figure 1A 
and 1B).  To create an M2e-based ‘universal’ vaccine that would protect from seasonal and 
pandemic influenza A viruses, it would be necessary to vaccinate with each M2e sequence 
specific for human, swine, avian and the 2009 pH1N1.   
 Due to the many different strains of IAV, HA molecules can be grouped in either group 1 
or group 2 depending on their structure [23, 24].  The majority of IAV exhibit high degree of 
sequence conservation for the HA2A helix within a group however, there is significant sequence 
divergence between groups (Figure 1C-E).  Antibodies targeting this region exhibit little to no 
cross-reactivity to HA molecules within a different group [13, 15].  Thus to protect against all 
IAV, both group 1 and group 2 HA2A sequences would need to be utilized in a vaccine.   
 To make a prototype ‘universal’ vaccine, the influenza M2e and HA2A sequences were 
inserted into either HVR1 or HVR5 of rAd of serotype 5 (Ad5) by four-primer PCR (Table 1 and 
Table 2).  Two independent PCR reactions took place, one with a universal left primer (Ad5F) 
and a mutagenesis right primer containing either M2e or HA2A sequences.  The other reaction 
contained a universal right primer (Ad5R) and a mutagenesis left primer containing either M2e or 
HA2A sequences (Table 2).  The mutagenesis primers overlapped by approximately 20 base pairs 
in order to facilitate the fusion of the two mutagenesis products.   These products were purified 
and used in the subsequent reaction as the template with the Ad5F and Ad5R universal primers to 
create an overlap PCR product of approximately 1.6 kb in length.  The final product was verified 
by screening for a novel restriction enzyme site, in the case of rAd expressing WSN M2e (rAd 
WSN M2e), or diagnostic PCR primers in the case of the HA2A constructs and sequencing.   
 The modified hexon fragments containing the IAV epitopes were incorporated into intact 
Ad5 viral DNA by recombination in 293 cells through calcium-phosphate mediated transfection 
[41].  Briefly, the pJMG plasmid containing the modified hexon fragments and the parental viral 
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DNA from NVDP404, an Ad5 virus containing a Plasmodium falciparum CSP epitope insertion 
in HVR1 [37], were restriction digested overnight and ethanol precipitated.  Digested plasmid 
DNA and parental viral DNA were transfected into 293 cells.  Recombinants from the 
transfection reconstitutes an intact viral genome incorporating the IAV epitope and whole cell 
lysates were collected when approximately 50% of the cells showed signs of CPE.   
 Viruses from the whole cell lysates were plaque-purified to isolate a single virus clone.    
These plaque picks were screened for the presence of recombinant viral DNA containing M2e or 
HA2A sequences by western blot and diagnostic PCR (Figure 2).  To confirm the presence of Ad 
structural proteins in the plaque pick, blots were probed with a polyclonal anti-late antibody that 
detects hexon, penton, protein IIIa, V and VI.  WT Ad5 was used as a control for the size and 
correct banding pattern of each of the structural proteins.  Plaques from the rAd WSN M2e, rAd 
WSN HA2A and rAd HK68 HA2A recombination showed the correct banding pattern and 
approximate size for the Ad structural proteins, indicating that Ad was present in the samples 
(Figure 2A and D).   
The parental viral DNA in the recombination events expressed a P. falciparum CSP 
epitope [37] and a successful recombination event would result in viruses lacking this epitope.  
To determine the presence of the CSP epitope, blots were probed with 2A10, a monoclonal 
antibody recognizing the repeat region of CSP.  While the parental NVDP404 virus and P. 
berghei sporozoites expressing the P. falciparum CSP 2A10 epitope showed the presence of the 
CSP epitope, the rAd expressing WSN M2e, WSN HA2A or HK68 HA2A were negative, 
demonstrating that the plaque picks were devoid of parental virus and solely contained virus 
lacking the CSP epitope (Figure 2B and E).   
In order to demonstrate that the plaque picks contained recombinant virus expressing the 
M2e epitope, blots were probed with 14C2, a monoclonal M2e antibody.  Only the rAd WSN 
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M2e virus plaque pick reacted with the 14C2 antibody, indicating that this virus contained the 
M2e epitope.  Antibodies recognizing the HA2A sequence do not currently exist, so to determine 
if plaque picks contained the HA2A epitope, diagnostic PCR primers were used, with the 
sequenced plasmid containing WSN or HK68 HA2A as a positive control. Both WT Ad5 and 
NVDP404 were negative for HA2A while the pJMG HA2A plasmids, rAd WSN HA2A and 
HK68 HA2A plaque picks contained the HA2A sequence (Figure 2F). The plaque picks 
containing the correct epitope or sequence for rAds WSN M2e, WSN HA2A and HK68 HA2A 
were confirmed by sequencing.   
Analysis of purified rAd particles expressing M2e or HA2A 
 Multiple plaque picks from rAd WSN M2e were associated with products of multiple 
sizes that contained the M2e epitope, as demonstrated by its recognition by 14C2 (Figure 2C).  
We hypothesize that these represent cleavage products of hexon where the M2e epitope was 
inserted.  Several sizes of these M2e cleavage products correlated with anti-late reactive bands 
that were only present in the rAd WSN M2e plaque picks and were not of the correct size of any 
known Ad structural protein (Figure 2A).  To determine if such products were being produced in 
the rAd HA2A viruses and if any of the rAds were incorporating such products into the virion we 
examined purified virus particles.  Plaque picks from rAd WSN M2e, WSN HA2A and HK68 
HA2A were used to infect 293 cells and virus was purified by CsCl gradients.  Purified virus was 
loaded onto an SDS-PAGE gel and analyzed either by silver stain (Figure 3A) or Coomassie stain 
(Figure 3B) in order to view the total protein incorporated into the virus particles.  The banding 
pattern for WT Ad5, rAd WSN HA2A and rAd HK68 HA2A were similar and the rAd HA2A 
viruses did not appear to contain unexpected proteins in its virions in substantial amounts (Figure 
3A and B).  In contrast, rAd WSN M2e virions contained multiple unknown proteins that were of 
fairly dark intensity, indicating a high concentration of those proteins within the virion.  
Interestingly, two of the proteins, one slightly smaller than hexon and another slightly smaller 
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than penton but larger than IIIa, correlated to the sizes of cleavage products seen in the plaque 
picks that were reactive with 14C2 (Figure 2C) suggesting that some of the unknown proteins 
incorporated into the rAd WSN M2e virions are hexon-M2e cleavage products. 
 To assess the overall impact that the HVR insertion had on viral growth characteristics, 
WT Ad5, rAd WSN M2e and WSN HA2A were plaqued to determine the average particle to 
PFU ratio.  This ratio is indicative of how infectious these viruses are and whether the purified 
virus contains a large proportion of non-infectious particles.  WT Ad5 had an average 
particle:PFU ratio of 70 which was similar to rAd WSN HA2A, with a particle:PFU ratio of 64.7.  
In contrast, rAd WSN M2e had a particle:PFU ratio of 188, more than 2x that of WT Ad5, 
indicating a larger amount of non-infectious particles.  While the insertion of the WSN HA2A 
sequence into HVR5 did not appear to have any significant adverse affects on virus, the insertion 
of the WSN M2e sequence into HVR1 impacted the infectiousness of the virus, most likely due to 
the incorporated cleavage products.   
Protein production and growth kinetics of rAd WSN M2e 
 The high particle:PFU ratio and presence of potential cleavage products into the virion 
suggests that the rAd WSN M2e virus is not stable.  It also grew to lower titer and during CsCl 
purification, a substantial fraction of virus was lost during the equilibrium centrifugation, leading 
us to further suspect instability of the virion.  To investigate this observation further, 293 cells 
were infected with WT Ad5 or rAd WSN M2e at an MOI of 5 PFU.  Cell lysates were collected 
at various time points and were analyzed by western blot for the production of Ad structural 
proteins (Figure 4A) and hexon-M2e cleavage products (Figure 4B).  Hexon was detected as 
early as 16 hours post infection (hpi) in both viruses and the production of Ad capsid proteins was 
similar until 32hpi when it was apparent that cells infected with WT Ad5 had more capsid 
proteins than those infected by rAd WSN M2e (Figure 4A).  At this same time point, cleavage 
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products of hexon-M2e were apparent in the rAd WSN M2e virus (Figure 4B).  The presence of 
hexon-M2e cleavage products steadily increased alongside the increase in capsid proteins, 
indicating that as more hexon proteins were produced, more cleavage products were produced as 
well and accumulated within the cell, suggesting instability of the hexon protein. 
 Lysates from this growth curve were also plaqued to determine the amount of infectious 
virus in each sample.  By 16hpi, there was a high titer of infectious WT Ad5 virus that continued 
to increase until 48hpi.  The rAd WSN M2e displayed similar growth kinetics however, it was 
always at least 1 log lower in infectious virus formation, demonstrating a delay in infectious virus 
production.   
 The insertion of the WSN M2e sequence into HVR1 of rAd5 did have an impact on the 
overall viral fitness, with the production of an unstable hexon and delay in infectious virus 
production.  However, virus was still able to productively infect cells, albeit at a lower rate than 
WT Ad5.  Although the rAd WSN M2e virus was more unstable than WT Ad5, it was still 
possible that the virus could act as an efficient immunogen for a vaccine.   
Immunogenicity of rAd WSN M2e 
 The immunogenicity of the rAd WSN M2e virus was investigated in female Balb/c mice.  
Ten 4-8 week old mice received three subcutaneous (subQ) injections at 3 week intervals of 
1x1010 particles of recombinant virus (Figure 5A).  A group of 5 control mice were injected 
similarly with an rAd expressing the human papilloma virus serotype 16 (HPV16) L2 [46] 
epitope in HVR1 (Q virus; Table 3).  Individual sera was collected every three weeks, prior to 
viral boost, and was analyzed by ELISA for Ad5 antibodies.  All rAd WSN M2e mice developed 
a robust immune response to Ad5 and reached similar peak titers after the 3rd imunization (Figure 
5B).  Although Q mice were immunized similarly, their Ad5 antibody titers were much lower.  
Pooled sera from the 3rd bleed was used to probe Western blots of MDCK cells stably expressing 
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M2 to detect M2 antibodies.  M2 was visible around 14kD when probed with 14C2, however 
pooled sera from rAd WSN M2e immunized mice was unable to detect the protein indicating the 
absence of an antibody response against a linear M2e epitope (Figure 5C).  Although there is a 
crystal structure for the M2 transmembrane and C terminal domains [50-52], the structure of the 
M2e is unknown.  To determine if M2e antibodies were induced against a conformational 
epitope, immunostaining for M2 with 14C2 or pooled sera from rAd WSN M2e or Q virus was 
performed by flow cytometry of M2 expressing and non-expressing MDCK cells.  While 14C2 
was able to recognize M2 on the surface of MDCK cells, pooled sera from rAd WSN M2e and Q 
mice was unable to detect any M2.  These results indicate that although the vaccinations were 
successful, with the mice developing an immune response against the rAd capsid, M2e-specific 
antibodies, recognizing either a linear or conformational epitope, were not detectable. 
Immunogenicity of rAd WSN HA2A 
 To determine the immunogenicity of the rAd WSN HA2A virus, in collaboration with 
Dr. Richard Roden and Tanwee Alkutkar, 5 Balb/c female mice were injected subQ with 1x1010 
particles of either rAd WSN HA2A or 2.6.1, an rAd expressing HPV16 L2 antigen in HVR5 
(Table 3) [46].  Mice were vaccinated every 3 weeks and antibody titers against Ad5 were 
monitored by ELISA (Figure 6A).  Both rAd WSN HA2A and 2.6.1 mice developed equivalent 
peak antibody titers after the 2nd immunization (Figure 6B).  To demonstrate that an immune 
response could be induced against a foreign antigen inserted into the HVR5 region, L2 antibodies 
were measured by ELISA.  Although the response was variable, all mice did develop a detectable 
immune response against the L2 antigen (Figure 6B).  Since the immune response to the L2 
antigen was low, mice received a 4th immunization 20 weeks after priming.  Pooled sera was 
used to probe western blots of infected cell lysates for the presence of HA2A antibodies.  While 
the pooled rAd WSN HA2A sera does react with several bands at the size of HA0, these bands 
are also present in uninfected cell lysates and also reacts with the 2.6.1 pooled sera, indicating 
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that these bands are due to nonspecific antibody binding.  More convincingly, rAd WSN HA2A 
sera was unable to react with HA2, which contains the HA2A epitope and is recognized by the 
anti-HA0 PR8 sera, indicating that there are no detectable antibodies against the HA2A region 
(Figure 6C).  To determine if conformation specific antibodies against HA2A were induced, 
immunostaining by flow cytometry of rWSN infected cells HA2A with pooled sera from rAd 
WSN HA2A was conducted. However, conformational antibodies against HA2A were not 
detected by flow cytometry of infected cell lysates (Figure 6D).  M2 was readily detected by 
14C2 confirming that cells were infected with rWSN. 
 L2 is known to be an immunogenic epitope [53, 54] however the immune response 
against it was variable and low in comparison to the antibody response against Ad5.  Little is 
known about the immunogenicity of the HA2A region.  In order to increase the immune response 
against L2 and potentially be able to detect antibodies against HA2A, vaccinations were 
supplemented with monophosphoryl lipid A (MPL) and aluminum salts (alum) adjuvants.  Both 
of these adjuvants induce an immune response by different mechanisms.  Alum has a depot effect 
to ensure a long lasting immune response that is induced by activation of the NLRP3 
inflammasome and release of DNA from dying cells which mediates a strong TH2 adjuvant effect 
while MPL activates antigen presenting cells by interaction with TLR2 and TLR4 leading to a 
Th1 immune response [55, 56]. It has been shown that the combination of these adjuvants can 
successfully prime long-lived memory CD8+ T cells and protect mice from a lethal influenza A 
challenge [57]. 
 10 Balb/c female mice were immunized similarly with 1x1010 particles of rAd WSN 
HA2A or 2.6.1 every 3 weeks but immunizations were supplemented with MPL and alum 
adjuvants (Figure 7A).  The Ad5 antibody titers increased in all the mice, along with the L2 
antibody titers for the 2.6.1 mice (Figure 7B).  Despite the drastic increase in the anti-L2 immune 
response and the increase in the anti-Ad5 immune response, there was still no detectable 
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antibodies to HA2A by western (Figure 7C) or flow cytometry (Fig 7D) of infected cells.  Since 
an antibody response was generated against an immunogenic epitope, L2, inserted into the same 
location of the hexon protein as HA2A, the lack of an immune response against HA2A suggests 
that its insertion in this region is not sufficient to induce a detectable humoral immune response.  
 While mouse sera did not test positive for the presence of anti-HA2A antibodies, it is 
possible that antibodies to this region were induced but not detectable or that immunization 
stimulated a T cell response.  To test if mice immunized with rAd WSN HA2A exhibited any 
protection from homologous influenza challenge, both adjuvant-supplemented rAd WSN HA2A 
and 2.6.1 immunized mice were challenged with 10 LD50 of rWSN.  All mice initially exhibited 
weight loss however, there was no statistical difference between rAd WSN HA2A and 2.6.1 
vaccinated mice, suggesting that rAd WSN HA2A did not induce a humoral or cellular immune 
response that was protective (Figure 8).  While this challenge used 10 LD50, both groups 
recovered from the challenge.  This indicates that while mice did become productively infected, 
as depicted by the initial morbidity, it was not a lethal challenge.  Diluted virus stock used to 
infect the mice was backtitered and it was determined that the mice received the correct dose.  
Thus, it is likely that the age of the mice was a significant factor in the challenge as the number of 
PFU of rWSN that constituted 1 LD50 was based on experiments with 8-12 week old female mice 









With the emergence of the 2009 H1N1 and outbreaks of avian H5N1 in countries around 
the world, there has been resurgence in the development of a ‘universal’ vaccine to protect 
against seasonal and pandemic IAV.  With current vaccination strategies, most antibodies are 
induced against the immunodominant head of the HA protein.  However, due to the variable 
nature of this region, there is a lack of cross-protection between viruses that do not closely 
correspond to the vaccine strain.  Current efforts towards a universal vaccine have mainly focused 
on the development of antibodies against conserved regions of the virus.  The 24 amino acid 
sequence of the M2e is highly conserved and antibodies against this region are protective in vivo 
but are not induced in natural infection.  Studies with a ‘headless HA’ construct in which the 
immunodominant globular domain was removed from the full-length HA has demonstrated the 
ability to induce more broadly protective antibodies towards the more highly conserved stem 
region of HA [19, 58].   
 Our strategy for creation of a ‘universal’ influenza A vaccine was based upon the 
exemplary safety and success of the oral US military vaccine against respiratory disease caused 
by Ad4 and Ad7 [26], along with the knowledge that an immune response can be elicited against 
foreign epitopes inserted into capsid proteins of Ad.  We inserted the influenza A M2e epitope 
and HA2A region into either HVR1 or HVR5 of the hexon protein (Table 1), creating a total of 6 
different rAd.  The hypothesis was that while the M2e by itself is poorly immunogenic and the 
immunogenicity of HA2A was unknown, the insertion of these epitopes into rAd would enhance 
immunogenicity by acting as a natural adjuvant and an immune response, similar to that against 
Ad capsid proteins, would be developed against the foreign epitopes.   Two rAds, rAd WSN M2e 
and rAd WSN HA2A, were successfully constructed and characterized in vitro. 
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 The human WSN M2e was inserted into HVR1 of hexon and was readily recognized by a 
monoclonal antibody, 14C2, to the M2e (Figure 2).  However, the 14C2 antibody also recognized 
smaller products that reacted with a polyclonal antibody to the Ad capsid proteins.  This suggests 
that the insertion of the M2e sequence into HVR1 resulted in virion instability specifically within 
and around the insertion, leading to cleavage products that contained hexon and M2e sequences.  
These products were incorporated into the virus particle and appeared to accumulate over time in 
the viral life cycle with their presence being evident immediately upon hexon translation (Figure 
4A).  Although the M2e-containing virions appeared to be unstable and the virions were 
extremely difficult to purify by conventional cesium chloride methods, the insertion only had a 
small affect on viral replication as the rAd WSN M2e virus was still capable of multiple rounds 
of replication (Figure 4B).  Given that the virus was stable enough to replicate in vitro, it was 
tested in vivo as a vaccine.  Protective M2e antibodies have been induced in a variety of ways 
including injection of the full length protein with adjuvant [59], DNA administration [60], fusion 
to carrier proteins such as hepatitis B core protein [61, 62], keyhole limpit hemocyanin [63, 64], 
flagellin [65], incorporation into liposomes [66] and various viral vectors [67-71].  Thus it was 
hypothesized that a robust humoral immune response would be induced against M2e inserted into 
HVR1.   While the vaccine did stimulate antibodies against the vector, there were no detectable 
M2e antibodies present.   
Subsequently, Zhou et al published a study where the M2e was inserted into hexon 
variable region 1 (VR1) and VR4 of chimpanzee-derived replication-defective Ad vector, AdC68 
[71].  This vector also expressed a transgene of three copies of the M2e sequence fused to the 
IAV nucleoprotein (NP) gene.  Insertion of the epitope into VR1 or VR4 did not alter vector 
fitness as these hexon-modified vectors rescued easily and had similar growth characteristics to 
WT AdC68.  In mice, the construct inserted into VR1 induced a robust antibody response to M2e 
and T cell response against NP.  Moreover, it protected 80% of inbred and 100% of outbred mice 
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from a lethal challenge of influenza [71].  The results of this study contrast with the inability of 
our rAd WSN M2e to induce an immune response.  This is most likely due to the instability of the 
rAd WSN M2e construct.  It is unclear why our vector was unstable.  While it could be due to 
insertion of a foreign epitope into HVR1, we have successfully inserted epitopes into this region 
previously [37].  Additionally, all tested rescued clones of rAd WSN M2e demonstrated the same 
issue suggesting that this was not due to an artifact of a particular clone and we were unable to 
plaque-purify rAd containing avian, swine or pH1N1 M2e sequences inserted into HVR1 or 
HVR5, most likely due to similar instability.  It is also possible that there is some innate property 
of the M2e sequence that induces cleavage or degradation however, the same sequence was 
successfully inserted into AdC68, suggesting that the instability may be a combination of the M2e 
insertion into Ad5.  Inserting the M2e into HVRs of a different Ad serotypes could prevent 
breakdown and allow for an immune response to be induced in vivo.  However, it would be 
interesting to insert M2e into other rAd capsid proteins such as pIX and fiber to test if the 
construct is more stable and increase its immunogenicity.   
 Several publications have described the isolation and characterization of broadly 
protective HA antibodies that recognize epitopes conserved across multiple antigenic subtypes 
[13, 15].  These antibodies recognized a conformational epitope, binding to residues on HA1 and 
HA2.  Most of the interacting surface between the antibody and its epitope was localized to the 
HA2A helix, suggesting that the HA2A helix alone could serve as a rationally designed antigen.  
The HA2A helix is conserved within the phylogenetic group 1 HA but not subtypes of group 2 as 
there is significant sequence divergence across groups and antibodies recognizing this region are 
only cross-protective within subtypes of the same group. A ‘universal’ vaccine based upon HA2A 
would have to consist of both WSN (group 1) and HK68 (group 2) HA2A sequences.  Both the 
WSN and HK68 HA2A sequences were inserted into HVR5 and successfully rescued (Figure 2).  
Neither of these viruses exhibited any of the similar instability issues associated with the rAd 
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WSN M2e construct as they grew to high titer and did not incorporate any detectable cleavage 
products (Figure 3) however, in vivo experiments were conducted with only the rAd WSN HA2A.    
Our hypothesis was that the rAd WSN HA2A virus would induce antibodies in mice against the 
HA2A region that would be protective against a lethal rWSN but not an HK68 challenge due to 
amino acid differences in the sequences.   As a positive control for the ability to induce an 
immune response against an inserted epitope into HVR5, we collaborated with Dr. Richard 
Roden and immunized additional mice with 2.6.1, an rAd expressing the HPV16 L2 epitope in 
HVR5 (Table 3).  Despite the ability to induce antibodies against L2 and rAd, there were no 
detectable antibodies by western blot or flow cytometry against HA2A (Figure 6).  The addition 
of MPL and alum adjuvants to the vaccination regimen increased the humoral response against 
L2 and Ad5 but was not able to induce antibodies to HA2A (Figure 7) and mice were not 
significantly protected from challenge with rWSN as compared to the 2.6.1 immunized controls.  
This data suggests that, while antibodies can be naturally induced against the HA2 stem region, 
making primary contacts with HA2A, this region alone is not immunogenic and fails to induce a 
detectable immune response even in the presence of adjuvants.   
 Our results describing the inability to induce a humoral response against HA2A is in 
agreement with Schneemann et al where they inserted the HA2A helix from the human 1918 
H1N1 pandemic virus into loops of the Flock House Virus (FHV) capsid [72].  It is important to 
note that the 1918 H1N1 HA2A sequence that was inserted into FHV is identical to the WSN 
HA2A sequence used in our study.  To preserve the helical conformation of HA2A, the helix was 
inserted into a B2 scaffold, a small helix-turn-helix nonstructural protein encoded by FHV, with 
respect to the B2 helix turns in order to maximize solvent exposure of residues that make contacts 
with previously characterized HA2 antibodies, such as CR6261 [15].  While antibodies were 
induced against FHV and the B2 scaffold, a very weak humoral immune response was induced in 
only two out of four mice and with only one B2/HA2A construct.  Antibodies to HA2A that were 
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induced did react with multiple HA subtypes of the same group however these were insufficient 
to protect mice from a lethal PR8 challenge which belongs to group 1 HA in addition to the 1918 
H1N1.  One amino acid difference exists in the HA2A sequence between 1918 H1N1 sequence 
and the challenge PR8 virus thus a new B2/HA2A construct was made that displayed the HA2A 
sequence of PR8.  Despite the addition of adjuvant to the vaccination regimen, only 25-37.5% of 
mice created antibodies to HA2A and sera from these mice were unable to neutralize PR8 in vitro 
[72].  While it is possible that in vitro and in vivo neutralization did not occur because of 
insufficient antibody titers, low avidity or affinity antibodies, or potential steric restrictions 
preventing neutralization, given our data, it is likely that HA2A alone is not sufficient as an 
antigen to induce broadly neutralizing antibodies.   
 We have demonstrated that, even though capsid display rAd approaches have worked in 
the past, it did not induce an immune response against two highly conserved epitopes of 
influenza.  However, these studies were conducted in a mouse model where Ad does not 
replicate.  It is possible that in a productive host such as monkeys or humans, the replication of 
the rAd IAV constructs would facilitate antibody production and induce a T cell response against 
the IAV epitopes.  These epitopes could also be presented in the context of other Ad capsid 
proteins.  Insertions could be made into the amino terminus of fiber or into the carboxy terminus 
of pIX.  Several studies have suggested that insertions into the HI loop of the fiber knob are better 
detected in native virions and are more immunogenic [73, 74].  Alternatively, other conserved 
IAV epitopes could be utilized to develop a ‘universal vaccine’, such as the HA2 long alpha-helix 
[22], the HA fusion peptide [75] or uncleaved HA0 [76, 77].  These epitopes and rAd capsid 
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Figure 1: Conservation of the M2 ectodomain (M2e) and HA2 alpha (HA2A) helix 
amino acid sequence.   
A)  Sequence alignment of the M2e, amino acids 2 to 24, for WSN H1N1 (human), 2009 pH1N1 
and a representative swine H1N1 and avian H5N1. Amino acid differences between species are 
highlighted in yellow.  B) Conservation of the M2e amino acid sequence, from residue 2 to 24, 
was compiled from all IAV strains.  The percent M2e conservation was plotted against the 
consensus human M2e amino acid sequence on the x axis.  C) Sequence alignment of the HA2A 
helix, amino acids 38 to 58 of HA2, for WSN H1N1 and X31 H3N2, representing the two HA 
clades.  Amino acid differences between species are highlighted in yellow.  Conservation of the 
H1 (D) and H3 (E) HA2A helix amino acid sequences, from residue 38 to 58, were compiled 
from all H1 or H3 virus strains.  The percent HA2A conservation was plotted against the WSN 













Figure 2: Creation and confirmation of rAd constructs expressing M2e or HA2A.  
 Infected cell lysates from plaque-purified recombinant viruses WSN M2e, WSN HA2A and 
HK68 HA2A, were analyzed for expression of the major capsid proteins with Ad5 anti-late serum 
(A and D), absence of the malaria CSP epitope with the 2A10 antiserum (B and E) and expression 
of the influenza conserved epitope M2e, using monoclonal 14C2 antibody (C) or by diagnostic 
PCR for HA2A (F).  The positions of the major Ad capsid proteins are marked on the right of A 
and D.  Three red stars in A and C indicate extra bands underneath hexon and penton that were 
detected by anti-late and 14C2 in the WSN M2e infected lysates.  WSN HA2A and HK68 HA2A 
diagnostic PCRs (F) were performed with Ad5F and either WSN HA2A R or HK68 HA2A R 
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were performed at different times. The positive control was the corresponding pJMG HA2A 



















Virus Particles/mL Avg PFU/mL Particle:PFU 
WT Ad 5 1x1012 1.42x1010 70 
WSN M2e 2.6x1011 1.38x109 188 
WSN HA2A 1.57x1011 2.41x109 64.7 
Figure 3: Analysis of purified Ad particles expressing M2e or HA2A.  
A) Silver stain of 5.2 x 109 particles of WT Ad5, WSN M2e and WSN HA2A.  B) Coomassie gel 
of 1x1010 particles of WT Ad5 and HK68 HA2A.  The positions of the major Ad capsid proteins 
are indicated on the right.  C) Table of the number of particles per mL, average plaque forming 
units (PFU) per mL and the particle to PFU ratio of WT Ad5, WSN M2e and WSN HA2A after 
cesium chloride virus purification.  Virus purifications occurred on different days and are based 
on a different number of infected cells which would affect comparison of viruses based on the 
particles per mL and average PFU per mL.  The particle to PFU can be used for comparison of 















































Virus Particles/mL Avg PFU/mL Particle:PFU
WT Ad5 1x 012 1.42x 010 70
WSN M2e 2.6x1011 1.38x109 188







Figure 4: Protein production and growth kinetics of rAd WSN M2e.   
WSN M2e was further characterized by analyzing the protein production and growth kinetics 
through western blot (A and B) and titer by plaque assay (C) compared to WT Ad5.  HEK 293 
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infection (MOI) of 5 and cell lysates were collected at the indicated time points.  Samples were 
run on an SDS-polyacrylamide gel and proteins were probed with the Ad anti-late serum (A) to 
view the production of capsid proteins over time or 14C2 (B) to see the creation of 14C2-reactive 
hexon cleavage products over time.  C) Samples were taken at 24, 36, 48 and 72 hours post 
infection (hpi) to determine the amount of infectious virus, presented as log pfu/mL, at each time 

















Figure 5: rAd WSN M2e induces Ad5 antibodies but not M2e-specific antibodies.   
A) 15 female Balb/c mice were immunized by subcutaneous injection with 1x1010 particles of 
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Mice were vaccinated and boosted twice at 3 week intervals and were bled prior to each boost or 
3 weeks post boost.   Ad particles indicate immunization with rAd and the red triangle denotes 
mouse tail bleeds.  B) Mouse sera was analyzed for Ad5 antibodies by ELISA for both Q (mouse 
1-5) and WSN M2e (mouse 6-15) for all bleeds.  Sera was diluted in five-fold steps starting at 
1:1000.  Values were normalized against wells containing antigen but no sera.  Sera was analyzed 
for reactivity against M2 by western blot (C) or flow cytometry (D) of M2 expressing cells or no 
M2.  C) MDCK cells (-) and MDCK cells expressing M2 (+) were probed with the monoclonal 
M2 antibody 14C2 (left panel) or pooled sera from the third bleed of mice immunized with WSN 
M2e (middle panel) or Q (right panel) at 1:500.  D) Representative flow diagram of M2 
expression on M2 expressing versus non-expressing MDCK cells using 14C2 (1:500), and Q or 
WSN M2e immunized mouse sera from the third bleed (1:100). The plots come from the same 
experiment and each plot represents two cell types probed with the same antibody or sera.  Each 












Figure 6: rAd WSN HA2A induces Ad5 antibodies but not HA2-specific antibodies.  
 A) 20 female Balb/c mice were immunized by subcutaneous injection with 1x1010 particles of 
either recombinant virus WSN HA2A or 2.6.1, a virus expressing HPV16 L2 antigen in HVR5.  
Mice were vaccinated and boosted twice at 3 week intervals with a third boost eleven weeks later.  
The first 5 mice of each group were bled prior to each boost or 3 weeks post boost. Ad particles 











































was analyzed for Ad5 (right) and L2 (left) antibodies by ELISA for both WSN HA2A (mouse 11-
15) and 2.6.1 (mouse 21-25).  Sera was diluted in five-fold steps starting at 1:1000 for Ad5 and in 
two fold dilutions starting at 1:50 for L2.  Values were normalized against wells containing 
antigen but no sera.  Bleed #4 was not assayed for L2 antibodies.  Sera was analyzed for 
reactivity against HA2 by western blot (C) or flow cytometry (D) of uninfected or WSN infected 
cells.  C) Uninfected (-) and WSN-infected (+) MDCK cells were probed with the polyclonal 
anti-HA0 PR8 antibody (left panel) or pooled sera from the third bleed of mice immunized with 
WSN HA2A (middle panel) or 2.6.1 (right panel) at 1:500.  The positions of HA0, HA1 and HA2 
are indicated on the right.  D) Representative flow diagram of M2 or HA2 expression in 
uninfected versus WSN-infected MDCK cells using 14C2 (1:500) to confirm infection and 2.6.1 
or WSN HA2A immunized mouse sera from the fourth bleed (1:100).  The plots come from the 
same experiment and each plot represents two cell types probed with the same antibody or sera.  












Figure 7: MPL and alum adjuvants do not induce HA2-specific antibodies.  
A) 10 female Balb/c mice were immunized by subcutaneous injection with 1x1010 particles of 
either recombinant virus WSN HA2A or 2.6.1, supplemented with 50ug alum and 5ug MPL.  
Mice were vaccinated and boosted 2x at 3 week intervals and bled prior to each boost or 3 weeks 











































bleeds and the skull and crossbones represents influenza challenge at week 29.  B) Mouse sera 
was analyzed for Ad5 (right) and L2 (left) antibodies by ELISA for both WSN HA2A (mouse 11-
15) and 2.6.1 (mouse 6-10).  Sera was diluted in five-fold steps starting at 1:1000 for Ad5 and in 
two fold dilutions starting at 1:50 for L2.  Values were normalized against wells containing 
antigen but no sera.  Sera was analyzed for reactivity against HA2 by western blot (C) or flow 
cytometry (D) of uninfected or WSN infected MDCK cells.  C) Uninfected (-) and WSN-infected 
(+) MDCK cells were probed with the polyclonal anti-HA0 PR8 antibody (left panel) or pooled 
sera from the third bleed of mice immunized with WSN HA2A (middle panel) or 2.6.1 (right 
panel) at 1:500.  The positions of HA0, HA1 and HA2 are indicated on the right.  D) 
Representative flow diagram of M2 or HA2 expression in uninfected versus WSN-infected 
MDCK cells using 14C2 (1:500) to confirm infection and 2.6.1 or WSN HA2A immunized 
mouse sera from the third bleed (1:100).  The plots come from the same experiment and each plot 
represents two cell types probed with the same antibody or sera.  Each serum comes from one 














Figure 8: Adjuvant-supplemented vaccination with rAd WSN HA2A does not protect mice 
from a sub-lethal homologous influenza A challenge.  
10 female Balb/c mice immunized 3x with 1x1010 particles of either recombinant virus WSN 
HA2A or 2.6.1, supplemented with 50ug alum and 5ug MPL were challenged with 10 LD50 of 
rWSN.  Mice were weighed daily to monitor morbidity.  The percent weight loss was plotted 
against the days post challenge for each individual mouse.  Note: 2 rAd WSN HA2A and 1 2.6.1 









Epitope Hypervariable Region Insertion 
WSN M2e HVR1 
Swine M2e HVR5 
Avian M2e HVR1 
2009 pH1N1 M2e HVR5 
WSN H1N1 HA2A HVR5 
X31 H3N2 HA2A HVR5 
 
Table 1: Recombinant capsid-display vaccines expressing M2e or HA2A sequences 
in either the hypervariable region (HVR) 1 or HVR5 of hexon. 








Table 2: Primers used for sequencing and insertion of M2e and HA2A epitopes 
List of name, function and sequences of primers used for either insertion of influenza epitopes 
into HVR1 or HVR5 of Ad5 hexon or for sequencing and diagnostic PCR.  All sequences present 






WSN HVR1 F WSN M2e insertion into HVR1
gcctatcagaaacgaatgggggtgcagatgcaacgattcaagtgatcCTGC
TACTGCTCTTGAAATAAACC
WSN HVR1R WSN M2e insertion into HVR1
gcacccccattcgtt ctgataggcgt tt cgacctcggtcagaaggctAGCTT
CATCCCATTCGCAAGG
Avian HVR1 F Avian M2e insertion into HVR1
ctaccagaaacgaatgggagtgcagatgcagcgattcaagtgatcCTGCTA
CTGCTCTTGAAATAAACC
Avian HVR1 R Avian M2e insertion into HVR1
gcactcccattcgtt ctggtaggcgt tt cgacctcgt t agaagactAGCTT
CATCCCATTCGCAAGG
Swine HVR5 F Swine M2e insertion into HVR5
ctaccagaaacggatgggagtgcagatacagcgattcaaatgatcctGCGA
CCGCAGGCAATGGTG
Swine HVR5 R Swine M2e insertion into HVR5
gcactcccatccgtttctggtaggcgtt cgacctcggt agaagactCTCAG
TAGTTGAGAAAAATTGCATTTCCAC
2009H1N1HVR5 F 2009H1N1M2e insertion in HVR5
ctaccagaagcgaatgggagtgcagatgcagcgattcaagtgatcctGCGA
CCGCAGGCAATGGTG
2009H1N1HVR5 R 2009H1N1M2e insertion in HVR5
gcactcccattcgct ctggtaggcgt tt cgacctcgt t agaagactCTCAG
TAGTTGAGAAAAATTGCATTTCCAC
WSN HA2A HVR5 F WSN HA2A insertion in HVR5
gccatcgaccaaatcaatgggaaattgaacagggtaatcgagaagGCGAC
CGCAGGCAATGGTG
WSN HA2A HVR5R WSN HA2A insertion in HVR5
cttgtt gtaatcccgt t aatggcat t ctgtgtgct tttt gCTCAGTAGTTG
AGAAAAATTGCATTTCCAC
HK68HA2A HVR5 F HK68HA2A insertion in HVR5
cgaccaaatcaatgggaaattgaacagggtaatcgagaagGCGACCGCA
GGCAATGGTG
HK68HA2A HVR5R HK68HA2A insertion in HVR5
ccctgttcaatt cccat tgat tt ggtcgatggctgctt gagtct ttt aagCTC
AGTAGTTGAGAAAAATTGCATTTCCAC
Name Function Sequence
JMG1 (Ad5F) Universal hexon forward binding at beginning of hexon CGGCGTGCTGGACAGGGGCCC
JMG4 (Ad5R) Universal hexon reverse binding at end of hexon GCTGGCTCCGTCAACCC
HVR1R Universal hexon reverse binding in HVR1 CGTCTTCGTTGTCATCG
HVR4F Universal hexon forward binding in HVR4 GGAGGGCAAGGCATTC
HVR5R Universal hexon forward binding in HVR5 GTTATCACCATTGCCTGC
HVR6R Universal hexon reverse binding in HVR6 GTTGGCCCATTAGTTCTCG
WSN HA2A R WSN HA2A primer for diagnostic PCR ctcgataacagagttcacc
HK68HA2A R HK68HA2A primer for diagnostic PCR cttctcgat accctgt t c
Influenza Epitope Inserti on Primers






Virus Epitope Hypervariable Region Insertion 
WSN M2e WSN M2e HVR1 
WSN HA2A WSN HA2A HVR5 
Q HPV16 L2 HVR1 
2.6.1 HPV16 L2 HVR5 
 
 
Table 3: rAds used for mouse immunizations. 
List of rAds, the epitope expressed and insertion location with hexon that were used for mouse 
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Despite decades of research, malaria continues to be a highly significant global health 
problem and the most important tropical parasitic disease, accounting for the deaths of more 
children under five than any other disease [1].  Among infectious diseases, malaria ranks fourth 
as a cause of death and in Africa in 2010, the WHO estimates that there were nearly 3 million 
clinical cases and roughly 700,000 deaths [2].  However, recent analysis suggest that this figure 
greatly underestimates the true burden of disease, with the global death toll actually exceeding 1.2 
million [3].  Malaria is a disease of the impoverished, having the greatest impact on the world’s 
poorest countries.  More than 80% of malaria cases and 90% of malaria-related deaths occur in 
sub-Saharan Africa [2].  The malaria burden is further increased by enhanced susceptibility to 
other infections and life-long health effects due to prenatal malaria exposure [4].  It has been 
reported that malaria incidence has been reduced by approximately 17% since 2000, with 
mortality rates by 26%, through efforts of malaria control involving insecticides to control the 
mosquito vector, indoor residual spraying programs, antimalarial drugs and treated bednets to 
reduce exposure to infected mosquitoes [2].  However, these efforts will be difficult to sustain in 
the face of growing drug resistance among parasites, insecticide resistance in the vector 
population and economic difficulties due to reduced malaria control funding [2].  Currently, a 
licensed vaccine against malaria does not exist and many promising experimental malaria 
vaccines have failed to protect or only partially protect residents of malaria-endemic areas.  
Research shows this may be in part due to B and T cell exhaustion resulting from chronic 
exposure to malaria [5].  The most advanced candidate, RTS,S, which aims to prevent infection, 
confers only partial protection.  Eradication will not be feasible with our current existing tools 
and knowledge.  In order to maintain sustainable reductions in malaria morbidity and mortality 




There are many lines of evidence that indicate that a vaccine could be made to protect 
against malaria.  Individuals born in endemic areas who survive the first year of exposure 
continue to develop parasitemia but are resistant to the severe, life-threatening malaria that plague 
children and eventually, become resistant to clinical disease [6].  However, to maintain this level 
of protection, frequent re-exposure is required and sterile immunity rarely if ever develops 
naturally.  Clinical protection from malaria is possible as gamma-globulin from semi-immune 
individuals can mitigate malaria disease in naïve humans [7].  Researchers have even achieved 
sterile immunity by inoculating humans with irradiated sporozoites by mosquito bite [8, 9].  This 
has been shown to reproducibly prevent the emergence of blood-stage parasites that are 
associated with clinical disease.  However, this approach presents many practical challenges, 
requiring research into different vaccination methods.   
The development of an effective vaccine has been hindered by many challenges, 
primarily through the complexity of the immuno-evasive parasite and its multi-stage life cycle.  
Malaria is a protozoan parasite of the genus Plasmodium of which four different species can 
cause malaria in humans: P. falciparum, P. vivax, P. malariae and P. ovale [2].  Recently a fifth 
species, P. knowlesi, a parasite infecting wild macaques, has been detected in humans [10].  
While disease caused by infection with P. malariae and P. ovale is less severe and rarely fatal, 
infection with P. falciparum and P. vivax can lead to serious disease outcomes such as anemia, 
encephalopathy, coma, respiratory distress and organ failure, usually resulting in death.  Of these 
parasites though, P. falciparum is responsible for greater than 90% of disease [2].   
Infection by all malaria species starts with the bite of an infectious female Anopheles 
mosquito, that upon blood feeding, injects sporozoites, the motile stage of the parasite, into the 
host (Figure 1).  A relatively small number of sporozoites are injected into the skin, 
approximately 10 to 200, and they rapidly enter the bloodstream in order to migrate to the liver, a 
process which can take minutes to hours.  Within the liver, sporozoites invade hepatocytes where 
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they develop into their exoerythrocytic form over one to two weeks; this stage marks the pre-
erythrocytic stage and ends when hepatocytes rupture, releasing thousands of merozoites into the 
blood stream.  Merozoites mark the erythrocytic stage of the parasite life cycle and upon invasion 
of red blood cells (RBCs), they undergo asexual development from rings to trophozoites, then 
dividing to form schizonts.  These schizonts rupture RBCs, releasing merozoites which then 
infect new RBCs.  The repeated cycling and infection of RBCs is responsible for the cyclical 
fever associated with malaria infection and leads to the majority of pathology.  Less than 5% of 
parasites in the blood undergo sexual differentiation to form gametocytes [11].  These are 
ingested by a mosquito during a blood meal where they undergo sexual reproduction forming 
zygotes which develop into oocysts.  Oocysts develop in the hemocoel of basal lamina of the 
mosquito midgut and upon rupturing, release sporozoites into the hemocoel.  This allows the 
sporozoites to traffic to the salivary glands of mosquitoes, thus rendering the mosquito infectious 
and completing the parasite life cycle.    
Targets of current malaria vaccines 
Current malaria vaccines are directed against the 3 different stages of the Plasmodium 
life cycle: the pre-erythrocytic stage of sporozoites and liver invasion, the erythrocytic phase 
involving the invasion and asexual reproduction within RBCs and finally, the transmission stage 
involving the uptake of gametocytes and further development of the parasite within the mosquito 
(Figure 1) [2].  In general, pre-erythrocytic vaccines are designed to induce an immune response 
against sporozoites and/or the liver stage through the induction of antibodies that will inhibit 
sporozoite motility and prevent invasion of hepatocytes and/or the induction of CD8+ T cells that 
will recognize and kill infected hepatocytes.  Effective vaccines targeting this stage would 
completely prevent the asexual and sexual blood stages from developing thus preventing the 
manifestation of disease and transmission of the parasite.  The predominant targets of these 
vaccines that are under current development include the circumsporozoite protein (CSP) that is 
180 
 
the major surface antigen of sporozoites, thrombospondin-related adhesion protein (TRAP) 
involved in motility and sporozoite invasion [12, 13], and liver-stage antigen (LSA) involved in 
liver stage differentiation [14-16].  Importantly, this stage represents a bottleneck in the malaria 
life cycle, where only a small number of sporozoites are injected upon mosquito bite leading to 
few infected hepatocytes, making this type of vaccine extremely advantageous as only a limited 
number of parasites need to be controlled in order to be successful.  However, every single 
parasite needs to be neutralized in order to achieve sterile immunity. 
Unlike pre-erythrocytic vaccines, blood stage (erythrocytic) vaccines do not prevent 
infection but reduce severity of the disease by decreasing the number of parasites in the blood.  
Studies have suggested that individuals who survive regular exposure to malaria develop this 
immunity over time although this immunity is not sterile [17, 18].  These vaccines aim to 
accelerate the development of this immunity by inducing antibodies that prevent merozoite 
invasion of RBCs or target antigens expressed on the surface of RBCs.  While there are hundreds 
of potential targets expressed by the blood-stage parasites, several targets have been utilized in 
the development of erythrocytic vaccines including merozoite surface protein (MSP-1), MSP-2, 
MSP-3, apical membrane antigen 1 (AMA-1), serine repeat antigen 5 (SERA5), and P. 
falciparum erythrocyte membrane protein 1 (PfEMP1) [19].  However, while several of these 
antigens appear to be protective in a non-human primate (NHP) model [20-23], none have 
achieved protective efficacy against clinical malaria as there is significant diversity of these 
targets among P. falciparum isolates which limits their utility in the field.   
Lastly, transmission blocking vaccines target the sexual gametocytes within the human 
host and antigens expressed during the developmental stages within the mosquito vector.  These 
vaccines would not confer protection directly to the vaccinee but prevent infection of the 
mosquito host in order to lower the parasites transmission efficiency, thus eliciting herd immunity 
within the general population.  Antibodies induced against antigens such as the Plasmodium 
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ookinete surface protein Pfs25 [24-26] would be ingested by a feeding mosquito and would 
prevent the parasite from developing into infectious sporozoites within the mosquito.  While 
attempts at developing transmission blocking vaccines have demonstrated protection in an animal 
model, they have demonstrated poor immunogenicity in humans thus far [27]. 
Rationale for pre-erythrocytic vaccines 
Pre-erythrocytic vaccines have the potential to prevent clinical disease and transmission, 
thus making it one of the most advantageous vaccine targets for malaria control.  Protective 
immunity against sporozoites has been induced by inoculation with radiation-attenuated 
sporozoites in both animal models and human volunteers [9, 28-30].  While irradiated sporozoites 
are the most effective and only approach to induce sterile immunity to date, there are significant 
logistical limitations that have prevented licensure of this vaccine.  Sterile protection in humans 
by irradiated sporozoites can either be induced by the bite of more than 1000 irradiated infected 
mosquitoes [9] or through five intravenous (i.v.) injections of irradiated sporozoites [29].  Both of 
these methods are tedious and labor intensive, requiring sterility and cold-chain storage to ensure 
sporozoite viability; i.v. injections also require administration by highly-trained personnel.  The 
clinical feasibility of meeting all of these requirements in areas where malaria is a significant 
public health problem such as Africa or India, is very slim.   
While logistical problems are associated with irradiated sporozoite vaccines, the 
knowledge that they are capable of providing sterile immunity has helped advance the field of 
malaria pre-erythrocytic vaccines.  By focusing on the immune response that is elicited by 
irradiated sporozoites, it has been possible to better understand the protective aspects of this 
immune response.  Research has demonstrated that the predominant immune response in 
sporozoite vaccinated volunteers was antibody directed against CSP [31].  CSP is a protein that 
covers the surface of sporozoites and is involved in many important functions during the 
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sporozoite stage of the Plasmodium life cycle.  In the mosquito vector, it aids in sporozoite 
formation and egress from oocysts along with sporozoite invasion of the salivary glands [32, 33] 
while in the human host, CSP helps with hepatocyte invasion and parasite development [34].   It 
was actually the first Plasmodium gene to be cloned and provided evidence for antibody-based 
protection in mice [35].  Further studies demonstrated that the majority of anti-CSP antibodies 
recognized a common epitope (NANP)3 [35-38].  This central NANP repeat B cell epitope is 
species-specific but is highly conserved across P. falciparum isolates from different geographical 
regions, although these isolates can differ in CSP size due to the variable number of repeats [37].  
Antibodies raised against synthetic NANP peptides have been shown to prevent sporozoites from 
invading hepatocytes in vitro [38] and passive transfer of monoclonal antibodies against this 
epitope can completely protect from disease in both a mouse and NHP model [39].  Thus, this 
immunodominant B-cell epitope is commonly used in current malaria vaccines and the ability to 
elicit the formation of antibodies that recognize these repeats has been shown to be a crucial 
component of effective pre-erythrocytic vaccines [40, 41].  However because of the short period 
of time that sporozoites are exposed to antibodies in the skin and blood stream before invading 
hepatocytes, a high sustained level of CSP-specific antibodies are required for a solely humoral-
based protective immune response.   
CSP not only contains a central B-cell epitope but also contains both conserved and 
variable T cell epitopes [42].  These regions serve to induce CD8+ T cells that are capable of 
killing sporozoite-infected hepatocytes.  While a majority of research has focused on the 
importance of antibodies in protection from malaria, it is thought that a cell-mediated immune 
response is also important as CD8+ T cell-ablated mice did not respond as readily to 
immunization with sporozoites [43, 44].  T cell responses are HLA-type dependent but 
examination of irradiated sporozoite vaccinated volunteers uncovered a universal T-cell epitope, 
known as T*, that is independent of the HLA class II composition of the host [45].  This T-cell 
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epitope has been shown to induce a protective immune response in animals and immunized 
volunteers [46, 47], becoming another major component of many sporozoite-based vaccines.  
Current pre-erythrocytic vaccine candidates in clinical trials 
While many attempts have been made to induce an immune response against the pre-
erythrocytic phase for a malaria vaccine, only one has reached a phase III clinical trial.  This 
vaccine, RTS,S, began as a collaborative effort between GlaxoSmithKline (GSK) and the Walter 
Reed Army Institute of Research (WRAIR) in the 1980’s.  They initially attempted to increase the 
immunogenicity of CSP as a T cell epitope by fusing the C terminus containing 19 CSP NANP 
repeats and a T cell epitope to the hepatitis B surface protein (HBs) and formulated it with excess 
HBs, forming virus-like particles (VLP) [48].  The reasoning was the belief that particulate 
antigens were processed and presented in a more immunogenic manner than soluble proteins.  
This vaccine was not effective until an oil-in-water adjuvant, ASO1, was added, which was later 
optimized to the liposomal MPL and QS21-bearing adjuvant ASO2 [49, 50]. RTS,S was shown to 
be ~50% efficacious against a homologous challenge in malaria-naïve individuals [51] and 
further extensive field trials confirmed that it prevented 26% of clinical malaria and 58% of 
severe malaria immediately after vaccination in children 5-17 months of age [46, 52, 53].  
Subsequent data demonstrated that while RTS,S was also effective in preventing clinical malaria 
in adults, the vaccine only provides protection after multiple doses and for a limited period of 
time, with protection waning after several months, dropping to ~16% efficacy within 4 years [46, 
52-56]. Protective efficacy of the vaccine is highly region specific and protection may actually be 
only 30% within 6-12 week old babies [57]. The disappointing protective efficacy may rise from 
its relatively poor induction of a cell mediated response and waning antibody titers.  However, 
despite these results in the Phase III trial, RTS,S may still be recommended for licensure and 
implementation because of its anticipated ability to reduce severe malaria in children [58].  
Surprisingly, although this vaccine only targets the pre-erythrocytic stages of the parasite life 
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cycle, there was a reduction in the incidence of uncomplicated and severe malaria amongst 
vaccinated children [59].  It is possible that the vaccine is significantly reducing the number of 
liver-stage shizonts reaching maturity, thereby allowing the host immune system more time to 
mount an effective immune response to limit blood-stage parasite replication.  From a public 
health standpoint, even a small amount of protection for a short period of time could be useful.        
While RTS,S induced anti-CSP IgG titers and a modest CD4+ T cell response, the 
induction of a CD8+ T cell response was low or completely absent [60].  This is in contrast with 
what is observed with viral vectored vaccines, specifically adenovirus (Ad) vectors.  A key 
attraction of using this vector for vaccination against malaria is the potential to prime all aspects 
of the immune response to induce a far greater cell-mediated response without the use of 
adjuvants.  Thus, many Ad-vectored malaria vaccines have entered clinical trials [61].  Initially, 
most research was conducted using the Ad serotype 5 (Ad5) vector that is the best characterized 
and lends itself well for use in preliminary studies.  However, there are many disadvantages to 
this serotype as it is the most common human serotype with greater than 50% of the population in 
Africa having neutralizing antibodies to Ad5 [62, 63].  The potential interference of pre-existing 
immunity on the efficacy of an Ad5-vectored malaria vaccine is unknown however it is thought 
to be disadvantageous as the antibodies would prevent initial cell infection by the virus and would 
reduce the CD8+ T cell response, thus reducing the vaccine efficacy [64-67].  Concerns about 
using this serotype were exacerbated by the HIV STEP trial where a recombinant Ad5-vectored 
HIV vaccine demonstrated a high rate of HIV infection in the vaccinated group with an increased 
risk of HIV infection post-vaccination in uncircumcised males or those with high pre-existing 
neutralizing Ad5 antibodies [68, 69].  Although subsequent investigation has failed to establish a 
causal link between pre-existing Ad5 immunity and HIV infection [70], the HIV-STEP trial still 
represents a roadblock in using Ad5 for prophylactic vaccines. Fortunately, other Ad serotypes 
exist that have a lower seroprevalence in the population such as Ad35 [71] and AdCh63, a 
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chimpanzee serotype.  A non-replicating Ad35-vectored CS vaccine induced strong IFN-γ and 
CD8+ T cells responses in mice [72, 73].  This has been moved into Phase 1a and 1b clinical 
trials to be used in combination with RTS,S as a prime-boost approach with the hopes of 
improving RTS,S efficacy through the induction of CD8+ T cells [74]. 
Some vaccines use multiple pre-erythrocytic epitopes (ME) to broaden the immune 
response and prevent development of blood-stage infection.  One example is the AdCh63/MVA 
ME-TRAP vaccine that has thus far been highly immunogenic.  This vaccine is comprised of a 
pre-erythrocytic fusion antigen of 17 B cell, CD4+ and CD8+ epitopes from six different P. 
falciparum antigens, including CSP, fused to thrombospondin-related adhesion protein (TRAP), a 
protein that is expressed on sporozoites and in infected hepatocytes [75].  The rational for this 
vaccine was the concept of IFNγ-mediated killing of infected hepatocytes.  During pre-clinical 
development, the AdCh63 ME-TRAP prime followed by the MVA (modified vaccinia virus 
Ankara) ME-TRAP boost elicited strong, long-lasting, polyfunctinal CD8+ T cells [75, 76].  In 
this situation, a heterologous boost, being MVA, was utilized to prevent acquired immunity from 
the AdCh63 prime to interfere with the boost.  Heterologous prime-boost approaches have been 
utilized frequently and with great success.  They are particularly promising when a desired 
outcome is the induction of a strong CD8+ T cell response.  Currently, a phase I adult Kenyan 
and phase Ib field trial in Gambia have occurred and the vaccine was found to induce high levels 
of T cells, with a median of greater than 1300 spot forming units (SFU) per million peripheral 
blood mononuclear cells (PBMC) as assessed by IFNγ ELISPOT [77].  This vaccine has now 
moved onto a phase I study in the UK and a phase 2 sporozoite challenge study [74].      
Another ME approach has recently entered clinical trials that contains antigens from four 
pre-erythrocytic proteins: CSP, TRAP, LSA-1 and exported protein-1 (EXP-1).  This is a DNA 
vaccine administered through electroporation and is currently being assessed in Phase Ia clinical 
trials in naïve US volunteers [74].  Although this trial started in 2010, little information or details 
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have become available.  While electroporation has augmented immune responses in animal 
models [78] and in an HIV trial [79], typically the immunogenicity of DNA vaccines in animals 
has not been reproduced in humans.   
Most of the pre-erythrocytic vaccines currently in clinical trials attempt to provide 
protection by inducing an immune response against at least CSP and/or TRAP.  However, another 
antigen has emerged as a potential target for vaccines, the cell-traversal protein for ookinetes and 
sporozoites (CelTOS) [80, 81].  This protein plays an important functional role in the cell 
traversal in both the mosquito vector and human host.  It is very highly conserved among 
Plasmodium species thus it represents an important target for the immune response to interfere 
with the malaria life cycle.  Currently, there is one phase Ia clinical trial using recombinant 
CelTOS expressed from Escherichia coli [74].  Preclinical characterization studies in mice 
demonstrated that vaccination with PfCelTOS resulted in potent humoral and cellular immune 
responses and, importantly, induced sterile protection in mice from a heterologous challenge with 
a P. berghei strain [82].  Induced antibodies targeting this protein likely function by inhibiting 
motility of sporozoites and preventing hepatocyte invasion.  This is the first pre-erythryocytic 
candidate malaria vaccine that is cross-protective between malarial species and represents a very 
important step forward in the quest for an effective malaria vaccine.  
There have been many successes on the road to developing a malaria vaccine with RTS,S 
being the first one to ever reach Phase III clinical trials.  The Malaria Vaccine Technology 
Roadmap set goals in 2006 for the development of malaria vaccines with the eventual goal of 
eradication.  First, to have a licensed vaccine with greater than 50% efficacy lasting for a year 
against severe disease and mortality by 2015 and second, to develop a vaccine by 2025 that 
induces protective efficacy against clinical disease of more than 80% lasting for over four years 
[83].  While a licensed RTS,S vaccine may meet the first goal, it fails to meet the requirements of 
the second goal, necessitating continued research on malaria vaccines.  Conventional vaccination 
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approaches, to date, have not worked to make an 80% effective malaria vaccine.  However, 
current knowledge about protection from malaria may still inform efforts to create a completely 
different approach: induction or “unnatural” immunity.  Instead of relying on the immune system 
to develop a protective response against malaria, a protective component of the immune system, 
such as antibodies, can be given directly as purified monoclonal antibody (mAb) or via a viral 
vector, thereby harnessing engineered immunity and thus bypassing the uncertain pathway of 
immune induction by conventional antigens.  
Adeno-associated virus 
The potential application of recombinant adeno-associated virus (rAAV) as gene transfer 
vectors was realized over three decades ago.  Today, numerous preclinical studies have 
demonstrated the efficacy of utilizing rAAV vectors for gene therapy and vaccine purposes.  
AAV was first discovered as a contaminant of Ad stocks in the 1960’s [84] and knowledge of 
basic AAV biology and its diverse tissue tropism helped to drive the development of rAAV 
vectors, with these vectors being used most frequently in gene therapy.   The development of 
rAAV in gene therapy is in large part due to the lack of pathogenicity of the wild-type (WT) 
virus, ability to establish long-term transgene expression, ability to transduce both dividing and 
nondividing diverse cell types and low immunogenicity. Within the first 10 years of AAV use in 
humans, rAAV1 and -2 vectors were in clinical trials to treat cystic fibrosis, hemophilia B, 
Canavan’s disease and α-antitrypsin (AAT) deficiency [85].  The first breakthrough in clinical 
efficacy in humans was made when data demonstrated that patients treated with rAAV2-RPE65 
to combat Leber’s congenital amaurosis, an autosomal recessive disease resulting in functional 
blindness due to inability to recycle retinoids in the visual cycle, resulted in long-term 
improvements in sensitivity to light and improvements in vision [86-89].  Hemophilia B trials 
continued to progress with the use of an rAAV-factor IX vector that was delivered systemically 
for liver transduction [90].  Patients demonstrated a significant reduction in need for recombinant 
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protein replacement.   Children with Parkinson’s disease and congenital aromatic amino acid 
decarboxylace (AADC) deficiency showed improvement in gross motor development, including 
the ability to walk by 16 months in a single patient, upon treatment with an rAAV2-AADC vector 
[91, 92].   
It was quickly realized that AAV serotypes had varying transduction efficiencies for 
certain tissues.  AAV1 capsids were more effective at transducing skeletal muscle than AAV2 
[93] whereas AAV5 and -6 were more efficient at transducing murine airway epithelia [94].  This 
knowledge and the ability to pseudotype vector genomes with AAV2-ITRs into capsids of other 
serotypes led to the engineering of more effective vectors [95], leading to the development of 
rAAV1-lipoprotein lipase (LPL) that was used to treat lipoprotein lipase deficiency.  
Intramuscular injection of this vector resulted in lowering of serum cholesterol levels and 
pancreatitis in LPL patients [96].  rAAV1-LPL was licensed in Europe in November 2012 [97, 
98], becoming the first licensed AAV-vectored gene therapy and thus demonstrating the power 
and potential of this virus for gene therapy, vaccines and other therapeutic applications. 
AAV structure and replication    
AAV is a helper-dependent DNA virus of the Dependovirus genus of the parvovirus 
family that depends upon helper functions supplied by coinfecting helper viruses such as Ad or 
herpes simplex virus (HSV) for productive infection.  Like all members of the parvovirus family, 
AAV is a small (~25nm) nonenveloped icosahedral capsid comprised of three capsid proteins: 
VP1, VP2 and VP3.  These proteins share a C-terminal region that forms the T=1, icosahedrally 
symmetric portion of the capsid.  Each VP subunit consists of a conserved core of an eight 
stranded, β-barrel motif and an α-helix [99].  The outer surface of the capsid is formed by large 
loops that connect the β-barrel strands.  These loops are comprised of nine conformationally 
variable regions, designated VRI-VRIX [100].  The variable interstrand loops of this motif 
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determine receptor usage, transduction efficiency and serology. VPI also contains an N-terminal 
conserved phospholipase A2 sequence that is crucial for infectivity as it is implicated in viral 
escape from endosomes [101].   
Within the nonenveloped capsid, the AAV genome is single-stranded DNA of 
approximately 4.7kb, flanked by inverted terminal repeats (ITRs) that form T-shaped, base-paired 
hairpin structures with cis-elements required for replication and packaging.  The genome contains 
three viral promoters (p5, p19 and p40) and codes for two genes, rep and cap, which encode four 
nonstructural Rep proteins (Rep78, -68, -52, and -40) required for replication and the three 
structural capsid proteins. The basis for the production of rAAV vectors is the fact that rep and 
cap genes can be deleted from the viral genome and provided in trans, making room to insert a 
transgene with transcriptional control elements, flanked by the viral ITRs [102].  There are 
inherent limitations of packaging genes into AAV due to its small size.  However, extensive AAV 
research has determined ways to bypass this limitation by using a dual vector system that can 
expand the rAAV packaging capacity [103].  Vectors have also been created that offer a rapid 
onset of transduction for more efficient gene expression by circumventing the rate-limiting 
requirement for double-stranded DNA conversion but this does limit the transgene capacity [104].   
Much of the knowledge surrounding the AAV life cycle has been discovered in vitro.  It 
is thus possible that some of these processes do not occur in natural isolates.  Ambiguity also 
arises due to the extraordinary promiscuity of the virus and its’ ability to infect a wide range of 
cell types.  Most of what is known is based on AAV2, the best-studied serotype, and may not be 
relevant to other serotypes.  Only in-depth characterization of each serotype will result in a full 
understanding of relevant host factors and pathways involved in AAV infection.   
AAV attaches to its target cell through a variety of receptors.  Glycan recognition for cell 
entry has been studied for several AAV serotypes and can be separated into three major groups: 
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those that bind sialic acid (AAV1, -4, -5 and -6), those that bind heparin sulfate (AAV2, -3 and -
6) and those that bind galactose (AAV9) [105].  For AAV2, heparin sulfate was first identified as 
the receptor in vitro although viral isolates from human tonsils do not bind as they lack two 
essential amino acids from the binding site [106, 107].  It has also been demonstrated that AAV2 
can bind to fibroblast growth factor receptor 1 (FGFR1) [108].  While glycan receptors have not 
been identified for AAV 7 and -8, the 37/67-kD laminin receptor (LamR) has been identified as 
playing a role in cellular recognition for AAV8, a serotype isolated from rhesus macaques [109]. 
This receptor also plays a role in transduction with AAV2, -3, and -9.  While several receptors 
have been identified, little is known about the particular signaling pathways and trafficking that 
occur after receptor binding.    
It is thought that AAV2 enters the cell via clathrin-coated vesicles [110] and researchers 
currently hypothesize that it is trafficked to the nucleus via endosomes [111].  AAV replication 
initiates in the nucleus although how and where the DNA is released from the virion is unknown 
[112].  Inside the nucleus, helper virus functions are essential for a productive infection.  If these 
factors are absent, limited expression of Rep68 and -78 occur leading to repressed AAV gene 
expression, inhibition of DNA replication and integration of AAV DNA into the host genome 
[113].  Helper virus co-infection can rescue the AAV genome in a latently infected cell.   
Productive replication of AAV can be divided into three major steps: the single-stranded 
DNA genome must be turned into a double-stranded template for transcription, unidirectional 
strand-displacement replication occurs, and it is completed with terminal resolution of the self-
annealed ITR.  Rep genes are the first to be transcribed as Rep is involved in both negative (in the 
absence of helper proteins) and positive regulation of transcription [113].  Co-infection with Ad 
or HSV activates p5 and p9 promoters in order to transcribe Rep68 and -78 along with Rep 52 
and -40 [114-117].  Following transcription of rep genes, extensive DNA replication occurs of 
which Rep is essential [118].   
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The general model for AAV DNA replication consists of unidirectional strand-
displacement replication where the ITRs serve as the viral origin of replication, containing the 
Rep binding site (RBS) and terminal resolution site (TRS) [119, 120].  DNA replication starts 
with the ITR’s self-annealing and providing a base-paired 3’ hydroxyl group for unidirectional 
DNA synthesis.  This is believed to be mediated by host replication machinery including 
polymerase δ [121], although some components of the replication machinery may be provided by 
the helper virus.  Once the AAV template has been copied, terminal resolution, via Rep, occurs in 
order to replicate the self-annealed ITR.  The 3’ hydroxyl end is regenerated by a strand-specific 
nick at the TRS which then provides the necessary hydroxyl group for replication through the 
viral ITR [122].  This replication cycle results in two possible products: double-stranded full 
length AAV and single-stranded full-length AAV displacement product.  Currently, it is unknown 
whether either of these products can serve as templates for downstream events.   
Viral helper and cellular proteins necessary for AAV replication 
Productive AAV infection requires helper functions that can be supplied by co-infection 
with helper viruses such as Ad and HSV.  From Ad, helper functions are provided by E1a, 
E1b55K, E2a and E4orf6 along with viral associated RNA (VAI RNA).  E1a activates other Ad 
promoters and relieves repression for the AAV p5 promoter [123].  The product of the E2a gene, 
a single-strand DNA binding protein (DBP) stimulates processivity of AAV replication in vitro 
[124] while E1b55K and E4orf6 cooperate to promote AAV replication and second-strand 
synthesis [125, 126].  These proteins also function as a ubiquitin ligase and degrade targets such 
as DNA repair proteins that limit AAV transduction [127].  VAI RNA stimulates expression of 
AAV proteins, most likely by preventing phosophorylation of EIF2alpha translation factor [128].  
All of these Ad helper proteins work to alter the cellular environment to promote and enhance 
AAV replication.  
192 
 
The helper proteins that can be provided by HSV-1 are defined as HSV-1 replication 
proteins: the helicase/primase complex (UL5, UL8, and UL52) and the DBP ICP8 that is encoded 
by UL29 [129].  These are only the minimal proteins needed to replicate AAV but other HSV-1 
proteins are capable of enhancing AAV replication.  This includes the ICPO transactivator that 
activates rep gene expression [130] and the DNA polymerase complex (polymerase UL30 and its 
cofactor UL42) can contribute to efficient replication [131]. 
It has been demonstrated that AAV can replicate in vitro if purified Rep proteins are 
reconstituted with the following cellular enzymes: DNA polymerase δ, proliferating cell nuclear 
antigen (PCNA), replication factor C (RFC) and the minichromosome maintenance complex 
(MCM) [121].  This replication is enhanced by the addition of DBPs from the cell such as RPA 
[124].  Cellular proteins that have been shown to bind to Rep or ITR are either required for 
replication or regulate aspects of the viral life cycle.  Biochemical methods, genetic screens and 
cell-based assays have identified that importin alpha receptor which mediates nuclear import 
[132], Sp1 that mediates transcriptional activation [133] and the high mobility group protein 1 
(HMG1) all interact and affect Rep functions [134].  Cellular factors that have been shown to 
bind to AAV ITR to regulate transcription include the chaperone-associated protein FKBP52 
[135], cellular-zinc finger protein ZF5 [136] and human APOBEC3A [137].  These cellular 
proteins can function as negative regulators as ZF5 and FKBP52 block second-strand synthesis.  
Both cellular and viral factors help to regulate the temporal and spatial requirements of AAV 
DNA replication, capsid assembly and genome packaging with AAV replication taking place in 
the nucleus, viral DNA co-localizing at viral replication centers [138, 139] and cap proteins 
passing through the nucleoli to accumulate with Rep in the cytoplasm.   
Gene expression and Rep proteins 
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There are four Rep proteins: Rep78, -68, -52 and -40.   In general, Rep52 and -40 are 
required for the accumulation and packaging of single-stranded genomes [140, 141] while Rep78 
and -68, are involved in almost every step in the viral life cycle including: DNA replication [118, 
142], site-specific integration [143-145], rescue of integrated genomes [146] and regulation of 
viral and cellular promoters [113, 114, 117, 142, 147-149] .  Consistent with their multifunctional 
role in the life cycle, the Rep proteins possess a variety of biochemical functions with three of the 
major functional domains being present on Rep78, the largest Rep protein.  The amino terminus 
is able to specifically bind DNA and has endonuclease activity while the central domain contains 
a nuclear localization sequence and motifs necessary for ATPase and helicase activity [150, 151]. 
Rep 78 carboxy-terminal domain contains a Zn-finger that has been shown to interact with many 
different cellular factors.  The remaining Rep isoforms, Rep68, -52 and -40 have a combination of 
these functional domains which arises from alternative splicing and differential promoter usage 
within the rep open reading frame.  All four isoforms possess helicase activity and this domain is 
highly conserved among parvoviral nonstructural proteins [150].  Despite the number of 
biochemical studies and characterization that has occurred, the molecular mechanisms underlying 
the biological functions carried out by Rep proteins are still not fully understood. 
Genome integration and safety 
rAAV vectors are promising vectors for gene therapy and vaccines since they are capable 
of mediating long-term gene expression in vivo.  However, serious safety concerns have arisen 
due to the ability of WT AAV to integrate into the transduced cell genome which could lead to 
the upregulation of genes and promote tumor formation.  A significant amount of research has 




The molecular mechanism of AAV integration was initially characterized in vitro using 
WT AAV2.  It was found that viral-cellular junctions consistently mapped to one region in the 
human genome, chromosome 19q13.42, now referred to as AAVS1 [152, 153].  Further research 
demonstrated that recombinant viruses lacking the rep genes randomly integrated, suggesting that 
Rep is responsible for site-specific integration [154].  By supplying the large Rep proteins in 
trans, the site-specific integration into AAVS1 was restored and further evidence was provided 
when functional RBS and TRS motifs located within AAVS1 were found to be necessary and 
sufficient for site-specific integration [144, 145, 155].  However, the presence of alternative 
integration sites has been postulated and using a linker-selection mediated (LSM) PCR to enrich 
for AAV-chromosome fusion sequences, AAV integration sites were found throughout the entire 
genome, with only 10% of total events occurring in AAVS1.  This suggested that targeted AAV 
integration is not as specific for AAVS1 as previously hypothesized [156].  Other hotspots for 
integration were found near consensus RBS sequences and included chromosome 5p13.3 denoted 
AAVS2 and on chromosome 3p24.3 denoted AAVS3.  It was then proposed that when helper 
proteins are not present, Rep targets the AAV genome for integration near consensus RBS sites 
by initiating replication at this location [143, 156].  Once the DNA replication is initiated, strand-
switching between the chromosome and viral DNA template allows for the incorporation of 
multiple copies of AAV genome into the locus.  However, this mechanism remains hypothetical. 
A mouse ortholog to AAVS1 was discovered and allowed for in vivo functional studies to 
be carried out [157].  Utilizing this system, it was shown that targeted integration of a marker 
gene resulted in strong transgene expression that persisted through differentiation of cells into 
multiple lineages [158].  When this occurred in blastocytes, site-specifically integrated cells were 
found throughout all tissues in the absence of a discernible phenotype in the animals, suggesting 
that AAVS1-targeted gene integration could result in the safe genetic modification of target cells 
[158].  Further studies using human embryonic stem cells identified that the initial Rep-mediated 
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integration involved a partial duplication of the target sequence, suggesting an AAV evolved 
mechanism for targeted gene addition.  To date, it is still unknown whether integration is a 
significant component of the viral life cycle in vivo since most studies have been conducted in 
vitro.   
While it is known that the preferred integration site for WT AAV2 in vitro is near RBS 
hotspots, the location and frequency of integration has not been demonstrated in vivo.  Schnepp et 
al tested 175 tissue samples for the presence of AAV DNA.  Only 9 samples were positive for the 
presence of AAV and using linear amplification-mediated-PCR (LAM-PCR), it was determined 
that the majority of AAV genomes were primarily arranged in a head-to-tail array with extensive 
deletions and rearrangements in the ITRs [159].  Only one AAV-cellular junction was identified 
and it was mapped to a highly repetitive satellite DNA element on chromosome 1.  Due to the 
low frequency of AAV integration that was found, it was hypothesized that a majority of AAV 
genomes exist extrachromosomally.  Using a linear rolling-circle amplification assay, it was 
demonstrated that most of WT AAV DNA exists as circular double-stranded episomes in human 
tissue [159].  
rAAV vectors for therapeutics lack the rep gene which codes for the proteins responsible 
for integration thus theoretically, rAAV vectors should rarely integrate.  However, it is still 
presumed that such vectors integrate to some degree.  To determine the integration rate of an 
rAAV therapeutic vector, muscle and liver samples were taken from mice and patients that 
received an intramuscular injection of the licensed AAV1-LPLS447X vector [160].  It was found 
that the majority of AAV existed as concatameric rearrangements with deleted ITRS.  In contrast 
to the in vitro data, no preferential vector integration within genes, CpG islands, palindromic 
sequences or ribosomal DNA loci were found.  Instead, AAV was found integrated into random 
nuclear and mitochondrial hotspots.  While integration was found in patients in vivo presenting a 
potential safety issue, the integration frequency of AAV is still well below that of integration-
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competent retroviral vectors, suggesting that the use of AAV for therapeutics is safe [160].    
Research has demonstrated that the integration frequency of AAV, in general, is higher in liver 
transductions compared to muscle [161-163].  A study investigating the genetic fate of rAAV 
genomes in mouse muscle demonstrating that >99.5% of vector DNA did not integrate and 
instead, existed as transcriptionally active monomeric and concatameric episomes [164].  This 
was confirmed in primates where rAAV integrated inefficiently but predominantly resided 
extrachromasomally, with gene expression persisting for years due to its bona fide chromatin 
structure [165]. 
However, even a low frequency of integration can still lead to potential genotoxicity 
[166].  Mice transduced with a high-dose, liver-directed, AAV-mediated gene transfer did not 
show a significantly higher rate of hepatocellular carcinomas 18 months post-transduction when 
compared to the control mice [167].  While integration was detected in active genes, CpG islands 
and G/C rich regions, gene expression data demonstrated that genes located near the integration 
sites did not show significant changes in gene expression pattern when compared to genes that 
were more distal to integration sites.  This suggested that AAV integration into active genes did 
not upregulate gene expression and that there was no significant association between increased 
oncogene expression and AAV transduction [167].  While this study did support the safety of 
rAAV vectors, this will continue to be an active area of study, especially as the increase in AAV 
technology continues.   
Epidemiology and consequences of pre-existing immunity to AAV serotypes 
For the universal application of AAV-mediated therapeutics, the presence of neutralizing 
anti-AAV antibodies is extremely problematic.  Both pre-existing and acquired antibodies 
generated as a result of therapeutic use of rAAVs can inhibit the efficacy of this technology, 
especially if it requires repeated vector administration.  Approximately 80% of the population is 
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seropositive for anti-AAV antibodies against serotypes 1, 2, 3 and 5 [168].  AAV2 is the most 
common human serotype and in several epidemiological studies, it was shown that 67% of the 
studied population had preexisting IgG antibodies [168, 169].  In all geographic regions studied, 
neutralizing antibodies (nAb) to AAV2 are the most prevalent, followed by antibodies to AAV1.  
Even binding antibodies that are incapable of neutralizing virus can trigger vector clearance by 
the immune system [170].  It has been demonstrated that in NHP with pre-existing immunity 
against AAV8, vector particles fail to reach the liver and instead accumulate in the spleen [171].  
Unfortunately, individuals become seropositive for AAV quite quickly. It is most desirable to 
administer gene therapy shortly after birth or in early childhood however, anti-AAV antibodies 
can be detected at birth, suggesting vertical transmission of maternal antibodies and after birth, 
antibody levels, specifically IgG, increase after the first year of life [172].  While a majority of 
these studies detected antibodies by ELISA, which does not distinguish between neutralizing and 
non-neutralizing antibodies, high levels of IgG1, IgG2 and IgM correlate with nAb titers thus a 
certain estimation of neutralizing activity can be extrapolated [168, 173].   
The high frequency of seropositivity within the human population has necessitated the 
use of alternative serotypes.  While AAV1 and -2 are the most common human serotypes, there 
are AAV serotypes that are not as prevalent, such as AAV5, -6, -8 and -9.  Of these, neutralizing 
factors to AAV8 and -9, are much lower compared to other vector types, with AAV8 being 
initially isolated from rhesus monkeys [168, 169, 174].  While the prevalence of nAb to AAV8 is 
lower compared to other serotypes, 19% of a sample population had low titers of nAb with an 
additional 38% positive for total IgG by ELISA [168].  Data indicates that even low levels of nAb 
can completely prevent transduction [171].  In addition, there is high sequence and structural 
homology among AAVs, differing by less than 15%, with some serotypes differing by only one 
amino acid [174].  The presence of AAV-reactive antibodies in a large proportion of the 
population can make it difficult to circumvent the detrimental effects of preexisting immunity 
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with the use of any AAV vector.  For all serotype combinations, crossreactivity exceeds 50% 
[168].   Successful serotype switching not only relies on the lack of cross-reactivity between 
AAV variants but also depends upon the alternate AAV serotype having a similar tissue tropism.  
Due to the use of different receptors, AAV serotypes have different affinities for certain types of 
tissues.  Thus while alternative serotypes may be utilized, there are still other challenges to 
overcome.   
To bypass potential cross-neutralization activity between AAV serotypes, there has been 
a renewed effort in developing new AAV variants that show increased resistance to nAbs.  
Neutralizing epitopes have been identified for AAV2 [175] and AAV8 [99] and some approaches 
to design new serotypes alter the known antigenic regions of a particular serotype.  For situations 
where multiple injections of the AAV vector would be required, to prevent the acquisition of 
immunity to the vector, it has been demonstrated that deleting CpG motifs which are recognized 
by TLR9, permits vectors to evade the adaptive immune response and establish prolonged 
transgene expression [176].  Several other approaches utilize an approach coined directed 
evolution where error-prone PCR, DNA shuffling of capsid sequences or staggered extension 
PCR  [177] create new variants resistant to neutralization by preexisting antibodies [170, 178].  
While these attempts at capsid engineering have been successful in isolating new AAV variants, 
none of these variants are completely resistant to nAbs and their infectivity and tissue tropism can 
be affected with the accumulation of various mutations [178].   
Other strategies to minimize the effect of nAbs on transduction with rAAV have utilized 
plasmapheresis to decrease the total number of nAbs present in the blood [179, 180], 
immunosuppression [181, 182] or direct injection of the vector into the target tissue [183].  
Unfortunately, while plasmapheresis and immunosuppression may be useful for gene therapy, it 
is not feasible for use in global vaccination as it can only be used on an individual basis.  
However, direct injection of the vector to the target tissue could reduce the effects of preexisting 
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immunity in AAV-mediated vaccines as it limits contact of the vector with the circulatory system 
and thus, with nAb.  It has become routine for many vaccines to be administered intramuscularly 
and, to avoid nAb, this is a very promising option. 
Unfortunately, the presence of nAb is not the only preexisting immunity in a given 
individual, there is also an adaptive cell-mediated immune response.  While the presence of nAb 
to AAV serotypes is more problematic than cell-mediated immunity as AAV vectors do not give 
rise to a strong cellular immune response against the vector [184], a weak immune response that 
is generated against AAV capsids can still be detrimental to transduction efficiency [185-187].  
However, the presence of an AAV-specific T cell response does not always result in the ablation 
of transduced cells.  All patients that received an rAAV.hAAT vector designed to treat α1-
antitrypsin deficiency developed a detectable nAb and a cellular immune response as detected by 
interferon-γ enzyme-linked immunospot responses to the capsid [188].  While there was even 
evidence of inflammatory cells in muscle biopsies close to the injection site, hAAT levels were 
elevated and sustained out to at least 90 days post-injection suggesting that the cellular immune 
response against the AAV capsid does not necessarily suppress transgene expression in every 
situation.  Thus, the role that the cellular immune response will play on AAV-mediated transgene 
expression cannot easily be predicted.  However it has been shown that a serotype’s ability to 
bind heparin through the RXXR motif directly activates capsid-specific T cells [186].  Site-
directed mutants of this motif and naturally lacking serotypes failed to activate a T cell response 
leading to prolonged transduction of cells.  Thus, through the careful choice of AAV serotype, a 
capsid-specific T cell response leading to the loss of transgene expression through cell-mediated 
killing of transduced can be avoided.  
rAAV vectors for vaccines and immunotherapy  
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While the majority of rAAV vectors have been created to be used in gene therapy, the 
utility of this virus for vaccines was quickly realized, as it exhibits long-term transgene 
expression. For example, rAAV was used to express Nipah virus G protein and protect mice from 
challenge [189].  AAV vectors were also used for immunotherapy where a full-length monoclonal 
antibody was expressed in vivo instead of an antigen. An antibody heavy chain and light chain are 
linked by a self-processing peptide and furin cleavage site so as to self-assemble upon translation.  
Engineered immunity delivered this way has been accomplished and protective against HIV [190, 
191], anthrax [192], respiratory syncytial virus (RSV) [193], simian immunodeficiency virus 
(SIV) [194], influenza [195] and cancer [196].  Vectors not only have been engineered to 
continually stably express monoclonal antibodies but also express antibodies only in the presence 
of a given inducer via a regulated promoter, allowing for regulated delivery of therapeutic 
monoclonal antibodies in the clinic [197].   
The potential uses for AAV technology in the biomedical field is just being realized.  
With the first AAV gene therapy vector being licensed recently in Europe, the path has been 
paved for more AAV-mediated therapies to follow, especially as research continues to reinforce 
the safety of this vector.  Importantly, AAV is now being utilized in the fairly new field of 
engineered immunity in order to deliver protective monoclonal antibodies in vivo.  In particular, 
an AAV-vectored HIV monoclonal antibody, b12, is set to begin clinical trials shortly.  
Continued investigation and monitoring of AAV vector safety needs to occur in addition to 









Figure 1: Life cycle of the malaria parasite.  
Pre-erythrocytic vaccines targeting antigens expressed on sporozoites or infected hepatocytes can 
prevent both disease and transmission.  Blood-stage vaccines targeting antigens expressed on 
merozoites and infected red blood cells work to reduce disease severity and transmission blocking 
vaccines targeting either gametocytes or developmental stages within the mosquito prevent 
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Plasmodium sporozoites can be neutralized in vitro by monoclonal antibodies (mAb) against the 
circumsporozoite protein (CSP).  Passively transferred mAb against P. falciparum CSP can block liver 
invasion by sporozoites of a transgenic rodent parasite that expresses P. falciparum CSP (Pb-Pf), 
preventing infection in mice.  A single un-neutralized sporozoite can initiate infection, necessitating 
sustained high-titer neutralizing antibodies for lasting protection.  Despite this, attempts at targeting CSP 
for a vaccine have fallen short of expectations, in part due to inability to induce durable high-titer 
antibodies.   
Recently, David Baltimore’s laboratory developed an adeno-associated virus type 8 (AAV8) 
platform that efficiently delivers pre-formed mAb genes in vivo and directs sustained, high-level mAb 
production.  In collaboration with the Baltimore laboratory, we have adopted that technology to express 
humanized mAbs against the central repeat region of the CSP protein of P. falciparum in mice.  Mice 
developed high titer human IgG antibodies as early as 1 week post transduction and levels have remained 
constant for more than 28 weeks at 200 to 1000 µg of IgG/ml.  Mice transduced with humanized CSP 
mAb 2A10 (2A10-AAV) and challenged intravenously with 104 Pb-Pf sporozoites, exhibited a 
statistically significant decrease in parasite liver burden.  Furthermore, 2A10- and 2C11-AAV mice 
challenged by infected mosquito bite displayed a statistically significant delay in time to patency, with 
70% and 30%, respectively, being sterilely protected.  Examination of antibody levels in individual 2A10-
AAV mice revealed that all mice with human IgG concentrations above 1mg/mL were completely 
protected. This suggests that exceeding this antibody threshold results in consistent sterile protection and 






Despite tremendous efforts at control and prevention, malaria continues to represent a major 
public health burden and results in approximately 219 million cases, with 660,000 deaths in children 
under 5 each year [1].  Among infectious diseases, malaria ranks fourth in causes of death.  With 
emerging drug resistance among parasites, insecticide resistance among mosquito vectors and the political 
and economic difficulties associated with sustained traditional malaria control, efforts on the development 
of new approaches to malaria prevention are a high priority [2].  Although multiple approaches to 
inducing effective immunity by vaccines have been employed, only one has proven sufficient to elicit 
durable protection but is not clinically feasible for deployment in developing countries.  The development 
of a vaccine against malaria is complicated by the complexity of the Plasmodium falciparum parasite life 
cycle and its unique potential target antigens for each of the developmental stages in the human host [3].  
These stages include the sporozoites that are injected upon mosquito bite, infected hepatocytes, the 
merozoites that infect and rupture red blood cells, leading to the clinical disease, and the gametocytes 
which are infectious for Anopheles mosquitoes.  This wealth of potential immune targets has led to a 
diversity of approaches to induce anti-malarial immunity, with research underway that focuses on each 
stage of the life cycle, employing diverse antigens and a wide variety of systems for antigen expression 
[3]. 
Among these potential strategies, a vaccine against sporozoites, the pre-erythrocytic stage, would 
be the most advantageous because of its potential to prevent infection completely, eliminating both 
pathology and transmission.  This stage also represents a bottle-neck in the Plasmodium life cycle, with a 
few dozen to a few hundred sporozoites deposited in the skin upon mosquito bite [4, 5].  Protective 
immunity against sporozoites in humans has been achieved by the use of irradiated sporozoites however, 
this vaccine is not practical for global use, as protection requires individuals to be bitten by roughly 1000 
irradiated infectious mosquitoes or receive 5 intravenous injections of irradiated sporozoites [6-9].  The 
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predominant immune response in immunization with radiation-attenuated sporozoites is elicited against 
the circumsporozoite protein (CSP) which coats the surface of sporozoites [10].  Importantly, it has been 
demonstrated that antibody targeting the central tetrapeptide (NANP) repeat region of CSP can 
completely protect from sporozoite infection in mice and monkeys by preventing sporozoite motility [11-
13].  This immunodominant epitope is found in 30 or more consecutive copies and is stringently 
conserved in P. falciparum isolates throughout diverse geographical areas [14, 15].   The induction of 
CSP antibodies is a central goal of many pre-erythrocytic immunization efforts, including the most 
advanced malaria vaccine candidate RTS,S/AS01, a hepatitis B virus-like particle (VLP) vaccine that 
induces both antibody and cell-mediated responses to CSP in humans [16, 17].  While preliminary data 
from a phase 3 clinical trial indicated that this vaccine was 50% effective in preventing clinical and severe 
malaria over the course of a year post immunization in children 5 to 17 months of age, there was no 
detectable reduction in malaria deaths [17].  Results from this trial also suggested that vaccine-mediated 
protection wanes fairly rapidly, within 6 months post vaccination, and therefore, this vaccine is not 
suitable for deployment [18, 19].  The difficulty in developing a vaccine to induce protective immunity 
against CSP lies in the brief period of time that sporozoites are exposed to antibody before invasion of 
liver cells and that a single un-neutralized sporozoite is capable of initiating a full-blown infection [5, 20].  
Thus, permanent, unnaturally high levels of CSP antibodies would be required for effective anti-malarial 
humoral immunity. 
Adeno-associated virus (AAV) is a helper dependent virus of the parvoviridae family with an 
~5kb single-stranded DNA genome flanked by inverted terminal repeats (ITRs).  Productive AAV 
infection requires helper functions that can be supplied by either adenovirus or herpes simplex virus.  
AAV is ubiquitously prevalent in the population, with 60% of the human population having neutralizing 
antibodies to human serotypes by age 10 [21]. However this virus causes no known disease.  Due to its 
ability to effectively transduce cells and exist primarily as an episome in the nucleus, recombinant AAV 
(rAAV) has been utilized as gene therapy vectors in 47 clinical trials with an exemplary safety record 
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[22].  The first AAV vectored gene therapy was approved in Europe in 2012 to treat lipoprotein lipase 
deficiency (LPLD) [23].  Due to preexisting immunity to common serotypes such as AAV2 [24, 25], 
recent research has looked at alternative serotypes with low prevalence such as rhesus monkey derived 
AAV8 [26].  This particular serotype also lacks heparin binding activity that has been shown to be 
associated with an increased T cell response against the vector, making this vector long-lived in vivo [27].  
Antibody gene transfer involves the delivery of genes via an AAV8 vector that encodes 
previously isolated and characterized broadly neutralizing monoclonal human IgG antibodies in vivo 
resulting in durable, high level expression upon a single intramuscular injection, capable of protecting 
mice from HIV and influenza [28, 29]. This malleable system allows for the expression of new human 
IgG monoclonal antibodies by inserting the sequences of the monoclonal variable regions into this 
transgene (Figure 1). Termed vectored immunoprophylaxis (VIP), this approach utilizes a vector that was 
systematically optimized to improve transgene expression of a human IgG1 mAb in vitro and in vivo. The 
VIP expression vector consists of AAV2 ITRs necessary for genome packaging and transcription of the 
transgene, a novel promoter that combines a cytomegalovirus (CMV) enhancer, β-actin promoter, and 
ubiquitin (UBC) enhancer region flanked by a splice donor and splice acceptor (Figure 1A), along with a 
human cDNA IgG1 transgene, a woodchuck hepatitis posttranscriptional regulatory element (WPRE) for 
improved expression and an SV40 late-polyadenylation signal (Figure 1B).  Antibody expression was 
improved by optimizing the IgG1 transgene.  Human growth hormone (HGH) derived signal peptides 
were fused to the antibody variable regions. The heavy and light chain genes were separated by an F2a 
self-processing peptide, mutated to better reflect mammalian codon usage with an incorporated furin 
cleavage site at the N-terminus for optimal processing; this allows for secretion of independent light and 
heavy chains.  Predicted splice donor and acceptor sites were mutated in the constant regions to prevent 
potential inappropriate splicing of the transcript (Figure 1C).  Importantly, this system allowed for 
swappable light and heavy chain variable regions by restriction enzyme digest of the modular VIP vector 
plasmid [28]. Thus, only the mAb sequence of the variable regions is needed to create a vector that 
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expresses humanized IgG1 mAb in vivo upon a single intramuscular injection.  This system has conferred 
highly effective protection against HIV in humanized mice and from influenza in both healthy and 
immunocompromised animals [28, 29], making it a powerful system for infectious diseases in which 
antibody alone is protective. 
Here we describe a novel means of generating high protective levels of antibodies against the 
CSP of P. falciparum using the VIP system.  We demonstrate that by expressing high levels of 
neutralizing CSP mAb, we are able to protect mice from stringent P. falciparum sporozoite challenges. 
Our results suggest that with successful translation to humans, this prophylactic approach could be 













Materials and Methods 
AAV virus production and functional validation 
To express b12, 2A10 and 2C11 antibodies in mice, the variable regions of these antibodies were 
synthesized from published sequences [30] and cloned into the VIP expression vector as previously 
described (Figure 1) [28, 29].  Purified AAV was quantified using qPCR as previously described [28, 31].  
To validate the functional activity of each lot of virus, each stock was used to infect 293T cells and the 
concentration of antibody in the cell supernatant was measured.  In a 12-well plate containing 500,000 
cells per well, 1011 genome copies (GC) of each virus were added per well.  6-days post infection, 
supernatants were removed and quantified for total human IgG production by ELISA [28].  This work 
was done in Dr. David Baltimore’s laboratory at California Institute of Technology by Dr. Alex Balazs.   
 AAV intramuscular injection and serum collection 
Aliquots of previously titered viruses were thawed on ice and diluted in TFB2 (100mM sodium 
citrate, 10mM Tris, pH 8) to achieve the predetermined dose of 1x1011 genome copies in a 50 µL volume.  
Inbred 5-to 8-week old C57BL/6 (NCI) female mice, in groups of five or ten, were given a single 50 µL 
intramuscular (i.m.) injection into the cranial thigh muscle with a 29G needle.  At various times after 
vector administration, blood was collected from the cheek vein into serum separator tubes (BD).  Tubes 
were spun for 10 minutes at 5,000 RPM in order to separate sera from red blood cells.  Sera was collected 
and stored at -80°C. 
For radiation-attenuated sporozoite immunization, five inbred 5-to-8 week old C57BL/6 female 
mice were vaccinated intravenously with 1x105 to 1.5x105 Pb-Pf sporozoites (see below) exposed to 
20,000R in a γ irradiator. Mice received a total of three doses of irradiated sporozoites spaced apart by at 




Quantification of antibody production by ELISA 
For detection of total human IgG, ELISA plates were coated with 0.1µg per well of goat anti-
human IgG-Fc antibody (Bethyl) overnight [28].  Plates were washed three times with PBS containing 
0.1% Tween20 (PBS-T) and three times with PBS followed by blocking with 1% BSA (Sigma) in PBS 
(PBS-1% BSA) for 1 hr.  Samples were serially diluted three-fold in PBS-1% BSA starting at 1:1500 and 
incubated for 1 hr at room temperature (RT).  Plates were washed as above and incubated with HRP-
conjugated goat anti-human kappa light chain antibody (1:10,000; Bethyl) for 1 hr.  Plates were washed a 
final time and samples were detected using ABTS Peroxidase Substrate System (KPL).  A standard curve 
was generated using Human Reference Serum (Bethyl) and mouse prebleed sera was used to establish 
background.  Plates were read using a Molecular Devices Emax microplate reader. 
For detection of CSP antibodies, plates were coated with 0.05µg per well of recombinant P. 
falciparum CSP purified from MR-272 plasmid (Malaria Reference and Research Resource MR-272) 
overnight [32].  All subsequent steps are described above except a standard curve was not utilized.  
Purified 2A10 was used as a positive control and the endpoint ELISA titer was determined as the highest 
dilution at which the optical density was two times greater than the background.  For detection of CSP 
antibodies in irradiated sporozoite-immunized mice, an HRP-conjugated anti-mouse IgG (1:5000 dilution; 
GE Healthcare) was used as a secondary. 
To detect anti-human Fc antibodies, plates were coated with 1µg per well human IgG from the 
Human Reference Serum (Bethyl) overnight.  All subsequent steps are described above except sample 
dilutions started at 1:100, plates were incubated with an HRP-conjugated anti-mouse IgG and a standard 
curve was not utilized.  Anti-human kappa light chain antibody was used as a positive control.  The 
endpoint ELISA titer was determined as the highest dilution at which the optical density was two times 




Transgenic murine P.berghei sporozoites expressing the human P. falciparum CSP repeat region (Pb-Pf) 
were used in all experiments.  It has previously been demonstrated that antibodies specific to the repeat 
region of P. falciparum CSP are capable of recognizing and neutralizing Pb-Pf sporozoites [33].   
Immunofluorescent assay (IFA) 
To determine whether serum bound to sporozoites, slides (Tekdon Inc; Poly-L-Lysine coated) 
were coated with 10µL of Pb-Pf  [32] at a concentration of 4-6x105 sporozoites per mL and air-dried.  
Slides were blocked for 1 hr with 10 µL of PBS-1% BSA.  Serum samples from each mouse per group 
were pooled and 500ng of human IgG, determined from human IgG ELISA titers, were diluted in PBS-
1% BSA and incubated on slides for 1 hr at RT.  Slides were washed in PBS-1% BSA and 10 µL of 
FITC-labeled goat anti-monkey IgG (H+L) (KPL) was added for 1 hr at RT.  Prior to visualizing, slides 
were washed with PBS-1% BSA and coverslips were mounted with Prolong Gold antifade reagent with 
DAPI (Molecular Probes).  Fluorescent sporozoites were visualized using an upright fluorescence 
microscope (Nikon Eclipse 90i). 
Sporozoite challenge. 
C57BL/6 mice were used since they have been shown to be highly susceptible to sporozoite 
challenge [34].  Infected Anopheles stephensi mosquitoes were dissected in IMDM media for isolation of 
salivary glands which were spun down at 7000 rpm for 1 minute at 4°C.  Most of the supernatant was 
aspirated off the resulting pellet and this pellet was ground in ~100 µL of media to break open the 
salivary glands.  This suspension was spun at 1000rpm for 1 minute at 4°C to collect sporozoites present 
in the supernatant which were counted using a hemocytometer.   Mice were challenged intravenously with 
1.0 x104 to 2.0 x104 transgenic Pb-Pf parasites [33].  Approximately 40 hours later, mice were euthanized 
to assess parasite burden in livers.  Whole livers were homogenized in denaturing solution and RNA was 
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extracted as previously described [35, 36].  After cDNA synthesis, parasite loads were determined by 
quantitative PCR for P. berghei 18S rRNA [37] and mouse GAPDH was used as an internal control.   
For the assessment of sterile protection, Anopheles stephensi mosquitoes infected with Pb-Pf 
parasites were starved overnight.  Mice were anesthetized with 300 to 350 µL of 2% Avertin and were 
subjected to feeding from 10 or 15 mosquitoes for 5 minutes.  The number of mosquitoes that fed on each 
mouse, as indicated by the presence of blood in the midgut, was recorded.  Starting on day 4, blood 
smears were made daily until day 14 and observed under a microscope for blood stage parasites.  Smears 
were fixed with methanol for 30 seconds before staining with a 10% Giemsa stain solution (Sigma) for 15 
minutes.  The day post infection that blood stage parasitemia was evident was recorded as day of patency.  
After confirmation of parasitemia, mice were euthanized.  Mice were considered to be sterilely protected 
if there was no evidence of parasitemia by day 14. 
Statistical analysis 
The majority of data and statistical analysis were performed using Prism software (GraphPad) 
using a Kruskal-Wallis test.  Differences were found to be significant when p was less than 0.05 (*) or 










Characterization of VIP vectors expressing mAb against P. falciparum CSP in vitro and in vivo 
Current vaccination strategies have not resulted in an effective malaria vaccine despite decades of 
effort.  It is known that CSP antibodies alone can neutralize and prevent infection by sporozoites, but this 
requires very high sustained levels [12, 13].  Recently, it has been demonstrated that genes encoding HIV-
neutralizing antibodies delivered to mice by a newly-designed AAV8 vector can direct long-lived high-
level mAb production (Figure 1) [28].  These mAbs protected humanized mice from high doses of HIV.  
This approach, termed vectored immunoprophylaxis (VIP), bypasses the uncertain pathway of immune 
induction by antigen and is potentially applicable to any disease against which an antibody response alone 
is protective [28, 29].  Due to the existence of protective CSP antibodies and given the long-lived nature 
of VIP-directed mAb expression, it seemed plausible that the VIP approach could be used against malaria. 
In collaboration with Dr. David Baltimore, AAV vectors with the capsid from serotype 8 were 
made that expressed the sporozoite humanized IgG1 mAbs 2A10 or 2C11, both directed against the repeat 
region of CSP.  2A10 and 2C11 arose independently from mice immunized with P. falciparum 
sporozoites and completely block sporozoites attachment and invasion of hepatic cells in vitro.  The AAV 
vectors expressing CSP mAb were characterized in vitro for human IgG antibody expression in the 
supernatant of infected 293T cells (Figure 2).  Antibody was expressed to high titer six days after 
infection and notably, 2A10- and 2C11-AAV vectors produced similar levels of human IgG antibody as 
b12-AAV, a previously characterized antibody expression VIP vector control [28]. 
To determine expression by these VIP vectors in vivo, C57BL/6 mice were injected i.m. with 
1x1011 GC of 2A10-AAV, 2C11-AAV, b12-AAV or media alone.  Within one week post transduction, all 
AAV-transduced mice expressed between 50-1000 µg/mL of human IgG antibodies.  Expression 
continued to increase to 4 weeks post administration and was sustained out to 8 weeks (Figure 3A).  To 
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ensure that the initial manipulation of the CSP-specific mAb did not affect their ability to bind to CSP, 
sera from transduced mice were used to probe recombinant CSP by ELISA (Figure 3B) and whole 
P.berghei sporozoites expressing the P. falciparum repeat region (Pb-Pf, Figure 3C) by 
immunofluorescence.  2A10- and 2C11-transduced mice expressed antibodies that bound to recombinant 
CSP with similar kinetics as human IgG antibody expression (Figure 3B).  Transduced mouse sera also 
were able to recognize whole sporozoites by immunofluorescence (Figure 3C).  Sera from b12-AAV mice 
did not recognize recombinant CSP or Pb-Pf sporozoites, demonstrating the specificity of the 2A10 and 
2C11 antibodies.     
Intravenous challenge of AAV-transduced mice with Pb-Pf sporozoites 
To test the ability of VIP to protect mice from a rigorous sporozoite challenge in vivo, 1.0x104-
2.0x104 Pb-Pf sporozoites isolated from infected Anopheles stephensi mosquitoes were injected 
intravenously (i.v.) into mice eight weeks post transduction with 2A10-, 2C11- or b12-AAV vectors.  
Antibodies to CSP block invasion of liver cells therefore, mice were sacrificed 40-42 hours post infection, 
a time when viable sporozoites will have successfully invaded and replicated in liver cells.  RNA was 
extracted from liver homogenates to quantitate, via qPCR, the P. berghei 18S rRNA copies in the liver to 
reflect the parasite burden [37].  In two independent experiments, 2A10-AAV mice had a statistically 
significant reduction in parasite burden as compared to b12-AAV mice (Figure 4A).  Notably, 7 2A10-
AAV mice had 18S rRNA levels that were indistinguishable from levels in uninfected mice.  A 
statistically significant reduction in parasite burden was achieved with the 2C11-AAV mice in one 
challenge (data not shown).   
It is reasonable to hypothesize that the varying parasite burden within the 2A10-AAV mice is due 
to variable human IgG antibody concentrations.  To determine if there is a correlation between antibody 
concentration and liver parasite burden, the human IgG antibody concentration immediately prior to 
challenge was graphed against the Pb-Pf 18S rRNA copies in the liver for each 2A10-AAV transduced 
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mouse (Figure 4B).  While there was no statistically significant correlation (p=0.9640, r=0.03030; Figure 
4B), there was a trend where mice with higher human IgG antibody titers exhibited lower parasite burden.   
Challenge of VIP-transduced mice with Pb-Pf sporozoites by infected mosquito bite 
While an i.v. sporozoite challenge is advantageous to control for the number of sporozoites each 
mouse receives, it is an unnatural route of infection and sporozoite viability is variable.  A mosquito bite 
challenge utilizes the natural route of infection and allows for determination of sterile protection.  
However, the number of sporozoites per mouse is variable.  To assess the protective capacity of VIP via a 
more natural route of infection, in two separate experiments, mice were exposed to the bites of 10 Pb-Pf 
infected A. stephensi mosquitoes for 5 minutes 11 weeks after transduction.  Mice that received three 
doses of 1x105 to 1.5x105 irradiated Pb-Pf sporozoites were included as a positive protection control, as 
irradiated sporozoites are the gold standard for malaria vaccines.  Since there is a potential correlation 
between human IgG antibody concentration and protection, mice were bled prior to challenge to 
quantitate their individual antibody levels.  
In a mosquito bite challenge, mice can be partially protected, as indicated by a statistically 
significant delay in time to patency where a single day delay in patency represents 90% of the sporozoites 
being neutralized [38], or mice can be sterilely protected through neutralization of all infectious 
sporozoites. Therefore, starting at 4 days post infection, mice were bled daily and blood smears were 
visually assessed for blood-stage parasitemia.  The presence of parasitemia indicates that sporozoites 
escaped anti-CSP mAb and successfully invaded the liver where they replicated and differentiated into 
merozoites in order to invade red blood cells.  Immunization with 2A10- and 2C11-AAV vectors 
produced a statistically significant delay in time to parasitemia (Figure 5C).  In addition, 60% of 2A10- 
and 30% of 2C11-AAV transduced mice were sterilely protected.  B12-AAV mice and mice that only 
received media all exhibited blood stage parasitemia by day 6 while irradiated sporozoite vaccinated mice 
were completely protected from challenge (Figure 5C).   
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While there was a trend associated with reduced liver burden and mouse antibody concentration 
in the i.v. challenge, another layer of complexity was added to the mosquito bite challenge with each 
mouse receiving a variable number of sporozoites.  To investigate potential correlations of protection with 
antibody concentration or number of blood-fed mosquitoes, the human IgG antibody concentration was 
measured immediately prior to challenge.  Both the number of blood-fed mosquitoes and human IgG 
concentration were graphed against the day to patency to detect any protective correlations. All AAV 
transduced mice exhibited 100-1000 µg/mL of human IgG (Figure 5A), with 2A10- and 2C11-AAV 
having high titers of anti-CSP antibodies (Figure 5B).  Mice that received irradiated sporozoites did not 
have any human IgG but did have CSP-specific antibodies that were a log lower in titer compared to 
2A10- and 2C11-AAV.  However, irradiated sporozoite vaccinated mice, unlike AAV-transduced mice, 
do not solely have a humoral response against CSP but also have a T cell response to offer protection 
against sporozoite challenge. A statistically significant correlation was seen between antibody 
concentration and protection for 2A10-AAV mice (p=0.0105, r=0.7814; Figure 6A).  However, this was 
not the case in 2C11-AAV mice (p=0.2058, r=0.4377; Figure 6B).  Although the number of mosquito 
bites per mouse varied, thus resulting in mice inoculated with different numbers of parasites, this did not 
correlate with day to patency in either 2A10- (p=0.5042, r=0.3022; Figure 6C) or 2C11-AAV mice 
(p=0.9460, r=0.01573; Figure 6D).   
Dose-response of AAV vector in mice 
To determine the effect of vector dose on antibody concentration and protection from sporozoite 
challenge, mice were transduced with decreasing doses of the 2A10-AAV vector.  Antibody expression 
measured over time revealed a clear dose-dependent expression at all time points analyzed (Figure 7A).   
All mice were challenged, via infected mosquito bite, at eleven weeks post transduction and were 
monitored for infection by blood smear.  While all b12-AAV mice reached patency by day 6, 2A10-AAV 
mice exhibited a dose-dependent protection response with the lowest AAV dose, 3x109 GC, reaching 
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patency by day 7.  Sterile protection was achieved in 10 percent of the 1x109 GC mice, 40 percent of the 
3x109 GC mice and 70 percent of the highest AAV dose, 1x1011 GC (Figure 7B). The correlation between 
2A10 antibody concentration and day to patency was statistically significant (p=0.0013, r=0.4424; Figure 
7C), while the number of mosquito bites did not impact the day to patency or sterile protection (p=0.2020, 
r=-0.1835; Figure 7D).  Notably, all mice that had greater than 1mg/mL of 2A10 were completely 
protected from sporozoite challenge. 
Evaluation of VIP expression of human IgG over time 
In order to combat malaria, a vaccine must provide protection for an extended period of time.  To 
determine the longevity of the expression of human IgG by AAV transduction, antibody levels in 
transduced mice were monitored over 36 weeks.  The serum antibody concentration plateaus around eight 
weeks post-transduction and was maintained for the duration of the 36-week study (Figure 8).  This 
demonstrates the utility of VIP to stably express protective antibodies for long periods of time, suggesting 
the feasibility of using this technology for effective malaria control. 
Anti-human Fc immune responses 
Viral-vectored gene therapy treatments may induce the development of an immune response 
against the transgene product which could negatively impact the efficacy of the therapy [39-43].  To 
determine if transduced mice were generating a detectable immune response against the AAV-encoded 
mAb transgene, an ELISA was developed to test for the presence of mouse antibodies that recognize the 
human Fc region.  In agreement with previous studies of VIP and AAV-induced tolerance in mice, fewer 
than half of the mice developed a detectable immune response against the human Fc (Figure 9B).  While 
some animals generated antibodies against the transgene, these did not appear to impact human IgG levels 
or protection from sporozoite challenge (Figure 4A and 7C).  However, there was an increase in 
concentration and frequency of anti-transgene antibodies in transduced mice over time (Figure 9A). 
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Although ELISA data suggests that most transduced mice do not develop an immune response 
against the human transgene, it is possible that anti-human Fc antibodies exist but are not being detected 
as they are tied up in immune complexes (IC) that have been deposited in tissue [44].  To further 
investigate potential deleterious effects due to high expression of human IgG, a group of five mice were 
transduced with 2A10-AAV while another group only received media.  At 26 weeks post transduction, 
both groups of mice were euthanized and assessed for any gross pathological differences between the 
transduced and non-transduced mice.  There was no pathological evidence of IC deposition in any tissue, 
with particular attention paid to the kidney glomeruli, suggesting that an immune response against the 
human Fc is minimal.  Additionally, there were no consistent pathological effects attributed to 














Conventional vaccination strategies based upon exposure to an antigen have not resulted in an 
effective malaria vaccine.  The most advanced conventional vaccine candidate, RTS/S, comprised of 
hepatitis B VLPs expressing the carboxy-terminal half of CSP, has resulted in insufficient protection that 
rapidly wanes with time [16, 17].  Even naturally acquired immunity develops slowly and does not yield 
in sterile protection [3].  The only strategy that consistently provides sterile protection is vaccination with 
radiation-attenuated sporozoites, which is not clinically feasible in areas of high malaria burden as it 
requires bites by multiple infected irradiated mosquitoes or at least five intravenous injections with 
irradiated sporozoites [6-8].  Therefore, a different approach needs to be taken in the development of 
vaccines against malaria.   
It has been known for decades that antibodies targeting the repeat region of CSP can prevent 
malaria infection by inhibiting sporozoites from invading liver cells [12, 13].  Even though immunity to 
CSP targets a bottle-neck phase in the malaria life cycle, achieving high enough antibody titers to 
neutralize all sporozoites prior to reaching the liver has been difficult as liver invasion by one parasite 
results in clinical infection.  Dr. David Baltimore’s laboratory at California Institute of Technology 
recently demonstrated a way to express high titer monoclonal human IgG antibodies in vivo by using an 
AAV vector (Figure 1).  This system was capable of protecting humanized mice from an HIV challenge 
and immune-deficient mice from a lethal influenza challenge, demonstrating the utility of this technology 
in protecting against infectious diseases where antibody alone is protective [28, 29].  To test whether this 
approach would work for malaria, we collaborated with the Baltimore laboratory to create and 
characterize AAV2/8 vectors expressing humanized monoclonal CSP antibodies 2A10 or 2C11 [30]. 
These vectors directed mAb expression at ~100-1000 µg/mL of human IgG, as early as one week post 
transduction, in vitro (Figure 2) and in vivo (Figure 3, 5, 7, 8). Expressed mAbs recognized both 
recombinant CSP and Pb-Pf sporozoites (Figure 3B, C) and led to a statistically significant reduction in 
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liver parasite burden following i.v. challenge (Figure 4).  When challenged by infected mosquito bite, a 
more natural route of infection, there was a statistically significant delay to patency in mice, with a subset 
that were completely protected (Figure 5, 7).  The expression of these CSP-specific mAb by AAV vectors 
was sustained out to at least 36 weeks (Figure 8), with less than half of the mice exhibiting a detectable 
anti-transgene immune response (Figure 9).  Detectable antibodies against the human Fc did not affect the 
human IgG antibody levels or ability of mice to be protected from sporozoite challenge.  VIP thus 
demonstrates potential for use as a novel malaria prevention strategy. 
The protection of 2A10-AAV mice from sporozoite challenge was dependent upon antibody 
concentration (Figure 6A, 8C).  All mice with greater than 1mg/mL CSP-specific human IgG were 
completely protected (Figure 8C).  It is unknown if this high concentration is needed to evenly distribute 
antibody throughout the circulatory system or is necessary to allow for multiple antibodies to bind to a 
single sporozoite to inhibit mobility.  Additionally, the antibody threshold needed to consistently provide 
protection in humans may differ.  Human antibodies have a significantly longer serum half-life in humans 
than in mice, which may result in higher steady-state levels than were obtained in this study [45, 46].   
2A10 and 2C11 antibodies are protective mAbs with known sequences that both target the CSP 
NANP repeat and are routinely used by collaborators [30], making them ideal for use in the VIP system.  
An inherent problem in utilizing mAb to one target antigen is the potential for immune escape through 
mutations.  It is unlikely that CSP repeat region escape mutants will emerge, as it would require 
simultaneous mutation of 30 to 50 NANP and NVDP repeats to prevent antibody binding [12, 47, 48].  
While 2A10 is very well characterized and has a high affinity for the CSP tetrapetide repeat, there are 
other CSP mAb with a greater protective capacity that target either the repeat regions or other domains 
(Zavala, unpublished).  By making VIP vectors expressing these antibodies, we could continue to 
optimize this technology and improve protection in mice and Aotus monkeys, with the eventual goal of 
entering clinical trials.  Additionally, AAV vectors could express mAb that target other sporozoite 
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antigens or antigens present in different stages of the parasite.  While this particular study only utilized 
mAb targeting the repeat region of CSP, multiple stages of the parasite could easily be targeted at once 
via different mAb.  There is limitless potential for this technology and multiple approaches to be taken to 
continue to optimize it as a form of malaria control.   
The induction of antibodies from natural exposure to AAV early in life can compromise the use 
of AAV as a gene therapy or VIP vector by preventing efficient transduction.  Approximately 30-60% of 
the population has neutralizing antibodies (nAb) specific for AAV2 and AAV1, the most common human 
serotypes [49].  Due to the prevalence of nAb to human serotypes, AAV8, isolated from rhesus macaques 
[26], was used in VIP vectors since it was anticipated to have a much lower seroprevalence among 
humans. However, in a worldwide epidemiological study of nAb to AAV serotypes in human sera, a 
percentage of the population, ranging from approximately 15-30%, are seroprevalent for anti-AAV8 nAb 
at serum dilutions of >1:20 [49].  The frequency of binding but non-neutralizing antibodies that could aid 
in opsonization of AAV particles is even higher with 38% seropositivity for AAV8 [25].  While there is 
still a significant advantage of using AAV8 over AAV1 or AAV2 in overcoming preexisting immunity in 
humans, it should be noted that there was a higher prevalence for AAV8 nAb in Africa, a target 
population for the VIP-mediated malaria control.  Even very low detectable nAbs could be problematic in 
a large population.   
While the low prevalence of anti-AAV8 nAb may present difficulties in administering VIP for 
malaria control, there are multiple strategies that can be used to overcome preexisting immunity.  The 
epitopes of these nAb for AAV8 have been identified [50], and at least for AAV2, amino acid 
substitutions at epitopes have successfully conferred escape from a majority, but not all, of nAbs [51].  
Another approach is to create a new AAV variant that is resistant to neutralization by preexisting 
antibodies through error-prone PCR in a technique called directed evolution of AAV vectors [52, 53].  
However, it is also possible to minimize contact of the AAV vector to nAb by directly injecting the vector 
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into the target tissue rather than via circulation.  It has been demonstrated that there was minimal impact 
on systemic gene expression from an AAV8 vector that was injected directly into muscle in non-human 
primates with preexisting AAV8 nAbs as high as 1/320 [54].  This has also been demonstrated in AAV1- 
and AAV2-mediated gene therapy clinical trials [41, 43], suggesting that intramuscular administration of 
AAV8-VIP, even in the presence of nAb, will yield in strong transgene expression. 
The use of VIP technology for malaria control depends upon long-term mAb expression.    
Clinical studies using AAV to target immunoprivileged sites such as retinal tissue [55] have shown 
remarkable success although transduction of the liver has induced an adaptive immune response against 
the vector capsid [42].  Studies have demonstrated that activation of T cells against the vector capsid is 
limited to serotypes that have a heparin binding motif and exhibit heparin-binding activity [27].  
Interestingly, serotypes such as AAV8 that lack this activity are better tolerated in vivo since they do not 
induce cytotoxic T lymphocyte responses, making it more likely that long term transduction will be 
achieved.  The route of administration of AAV also appears to impact the longevity of transgene 
expression as intramuscular transduction has been shown to yield in long-lived expression of factor IX, 
which is in contrast to liver transduction [40, 43, 56]. Although we only look at mAb expression out to 36 
weeks, it has been previously demonstrated that expression is stable out to at least 72 weeks [28, 29], 
suggesting that this approach would result in long-term mAb expression necessary for an effective 
malaria control.  
While the lack of a mouse-mediated immune response against the transgene is surprising, this is 
consistent with other AAV literature.  Less than half of the mice developed a detectable antibody 
response against the human Fc region which did not appear to impact transgene expression and there was 
no indication of immune complex deposition upon pathological examination of mouse tissue (Figure 9).  
It is possible that the persistent high expression levels of human IgG antibody induced B cell anergy or 
exhaustion, a phenomenon that has been associated with autoimmune diseases, HIV and TB.   
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AAV vectors have been utilized for many years in both vaccine and gene therapy trials and have 
exhibited an exemplary safety record [22].  In our experiments, adverse events such as pathology from 
high titer human IgG expression were not detected.  However, safety concerns still exist.  A major 
concern centers on the ability of WT AAV to integrate into host DNA.  Many studies have been 
undertaken to determine the frequency and general location of AAV integration events, both in WT 
infections and in gene therapy trials [57-63].  The level of integration, with WT AAV, is much lower than 
that of retroviral vectors [58].  In AAV vectors, like the one used in this study, that lack the Rep genes 
necessary for integration, the frequency of these events is closer to the number of random DNA 
integration events from DNA vaccines.  Most studies found AAV to primarily exist as a circular 
extrachromosomal episome, with integration events being rare but happening more often in liver 
transduction than muscle [58, 59, 61, 62].  To date, no detected AAV integration has been associated with 
an increase in tumor formation or an increase in gene transcription [57, 59, 60].  Recently, the first AAV-
vectored gene therapy has been approved in Europe for treating LPLD [23, 57].  Thus, the safety and 
long-term effects of AAV vectored therapies will continue to be investigated.  More information on the 
use of VIP in humans will become available as Dr. Baltimore’s laboratory is pursuing entering clinical 
trials in HIV infected individuals with their b12-AAV construct.   
Despite decades of research, a malaria vaccine still does not exist and according to the WHO, in 
order to eradicate malaria, a vaccine would need to have 80% efficacy lasting for 4 years or longer.  
Given the urgency of combating malaria and inability of current vaccine candidates to induce effective 
long-lasting immunity, novel methods need to be explored.  Our work demonstrates the feasibility of 
translating existing broadly neutralizing antibodies into a functional immunoprophylaxis in vivo that 
could work as a form of malaria control.  The level of protection that VIP has demonstrated in our initial 
experiments indicates that this strategy could be optimized to combat malaria in endemic regions, with the 









Figure 1: Schematic representation of VIP expression vector. 
(A) The novel CASI promoter combines the cytomegalovirus (CMV) enhancer and chicken β-actin 
promoter followed by a splice donor (SD) and splice acceptor (SA) flanking the ubiquitin (UBC) 
enhancer region. (B) The VIP expression vector for antibody expression indicating the AAV2 inverted 
terminal repeats (ITR), the CASI promoter, an IgG1 heavy chain linked to the light chain separated by a 
self-processing 2A sequence, a woodchuck hepatitis posttranscriptional regulatory element (WPRE) and 
an SV40 polyadenylation signal (SV40pA). Antibody variable regions of the heavy and light chains are 
colored in red (C) Schematic representation of the IgG1 transgene that was optimized for expression in 
vitro.  Highlighted in blue is the human growth hormone (HGH) derived signal sequence (SS) and the 
F2A self-processing peptide (orange), yielding in separate heavy and light chains.  Red lines mark the 










Figure 2: AAV2/8 vectors express high quantity of human IgG antibodies in vitro.  
The functional activity of each VIP vector was tested in vitro by infecting 293T cells with AAV2/8 
vectors expressing monoclonal antibody b12, 2A10 or 2C11.  B12-AAV served as an expression control.  
Supernatant from infected cells was assayed for human IgG 6 days post infection by ELISA.  Creation 
















Figure 3: All vectors express high levels of sustained human IgG antibody in vivo, and VIP-
produced P. falciparum neutralizing antibodies retain ability to recognize CSP.  Quantification of 
human IgG (A) and anti-CSP antibodies (B) by ELISA after intramuscular injection of 1x1011 genome 
copies of the VIP expression vector producing b12, 2A10 or 2C11 in female C57BL/6. The plot shows 
mean and standard error of titers for each mouse, n=10.  Sera from b12 transduced mice did not recognize 
recombinant CSP and thus is not shown in (B).  (C) Immunofluorescence images of transgenic Pb-Pf 
sporozoites incubated with 500ng of human IgG from pooled sera from either b12-, 2A10- or 2C11-






























Figure 4: VIP administration significantly reduces parasite burden in the liver.  
(A) Eight weeks post VIP administration, mice were challenged intravenously with 1.0x104 Pb-Pf 
sporozoites.  Parasite burden was assessed 40-42 hours post challenge on liver homogenates by qRT-PCR 
for P. berghei 18S rRNA copies. The plot shows values for each individual mouse and the geometric 
mean of the group (n=5-10).  Arrows denote mice having a detectable anti-human Fc humoral immune 
response. ***p<0.001. (B) Correlation between liver parasite burden 40-42 hours post challenge and 








Figure 5: VIP can provide sterile protection to mice challenged by infected mosquito bite. 
Concentration of human IgG (A) and anti-CSP (B) antibodies measured by ELISA on serum samples 
either taken 11 weeks after intramuscular injection of media or vector expressing b12, 2A10 or 2C11, or 
taken 3 weeks after the third injection of 1.0x105 to 1.5x105 irradiated Pb-Pf sporozoites. (C) Mice that 
received VIP 11 weeks prior or 3 weeks after the third dose of irradiated Pb-Pf sporozoites were 
challenged with Pb-Pf sporozoites delivered by infected mosquito bite.  The Kaplan Meier survival curve 
depicts percent of mice that were parasite-free, determined by monitoring mice for the presence of blood-















Figure 6: Sterile protection correlates with human IgG concentration in sera prior to challenge in 
2A10-transduced mice.  
Correlation between days to patency and serum human IgG concentration (A, B) or number of mosquito 
bites (C, D) for 2A10- (A, C) and 2C11-transduced (B, D) mice.  Plot shows values for each individual 










Figure 7: Antibody expression and protection are dependent on VIP vector dose.   
(A) 2A10 expression over time as a function of vector dose as determined by total human IgG ELISA on 
serum samples taken after AAV administration. B12-denoted mice received 1x1011 genome copies of 
b12-expressing vector.  Plot shows mean and standard error (n=10). (B) Mice were challenged 11 weeks 
after VIP-administration with Pb-Pf sporozoites by infected mosquito bite.  Survival curve depicts the 
percentage of mice that do not show blood-stage parasites.  ***p<0.005 *p<0.05.  (C, D) Correlation 











transduced mice.  Arrows denote mice with a detectable anti-human Fc antibody response.  Linear 



























Figure 8: Expression of human IgG by VIP is sustained over time in vivo  
Quantification of human IgG by ELISA in sera of mice transduced with b12-, 2A10 or 2C11-expressing 

















Figure 9: Anti-transgene immune response increases over time but does not affect human IgG 
concentration  
(A) Anti-human Fc reciprocal dilution titers for week 2 and week 24 post transduction as determined by 





human IgG concentration in sera.  Plot depicts anti-human Fc antibody levels at the last bleed before 
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